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Chapter 1
Introduction

1.1 Background
Since the 1950’s and especially since the 70’s upon the introduction of megavoltage 
radiotherapy plays a growing and more important role in the treatment of cancer, especially 
in breast, rectal, prostate and lung cancer and lymphoma. With curative intention it can be 
part of the primary treatment, often in combination with surgery and/or chemotherapy or it 
can be used for treatment of recurrence. In palliation, either as primary treatment or in case 
of recurrence or metastases, a short course of radiotherapy often relieves pain or other 
symptoms.1
Of all newly diagnosed cancer patients about 50% are generally assumed to receive 
radiotherapy during the course of their disease.2, 3 This percentage is only an estimation but is 
nevertheless often used in the process of decision making to plan the future capacity of 
radiotherapy equipment and personnel needed. It consists of a mixture of immediate 
radiotherapy (as part of  the primary treatment) and delayed (or secondary) radiotherapy.
In Australia a technique was developed to estimate the ideal proportion of new  cases of 
cancer that should receive radiotherapy at least once during the course of their illness based 
on the best available evidence, which was 52%.4
Population-based studies, however, (which are hardly done in the field of radiotherapy 
use or outcome) give a real insight in the use of radiotherapy. They are also essential to 
explore trends in time. And they might be very suitable to extrapolate the consumption of 
radiotherapy in the future, which will provide a contribution to planning and programming 
the required capacity of  equipment and personnel.5 
Population-based studies of the use of radiotherapy for different tumour types, 
preferably by stage and age, can also illustrate necessary as well as arbitrary changes in 
treatment and provide an impression of  adherence to guidelines. 
Guidelines
In the Netherlands treatment guidelines have been developed for most tumour types 
since the 80’s; first at institutional and regional, then at national, and nowadays more and 
more at international level, increasingly evidence-based. At national level guideline 
development through the Dutch Institute for Healthcare Improvement (CBO) went from 
consensus and expert-based to evidence-based.6
For example, for patients with breast  cancer, radiotherapy is an indispensable part of breast-
conserving treatment.6 About 75% of all patients with stage I or IIa disease are eligible for 
breast-conserving treatment, while only half of these patients receive conserving surgery.7 
Postoperative radiotherapy after mastectomy decreases the risk of loco regional recurrence 
and is associated with improved survival in high-risk breast cancer patients.8-11
In patients with stage III or IV lung cancer and low  performance status, weight loss or 
locally too advanced disease radiotherapy can accomplish a decline in tumour load which 
reduces symptoms.12 
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In recent years, for patients with locally advanced (stage III) lung cancer the standard 
treatment (with curative intent) is a combination of  chemotherapy and radiotherapy.6, 13
The standard treatment for operable rectal cancer stage T3 and/or N1 was postoperative 
radiotherapy. Since the 1980’s the role of preoperative radiotherapy was extensively 
examined,14, 15 based on the more thorough total mesorectal excision (TME) without any 
positive margins, and some departments in the Netherlands started with preoperative 
radiotherapy in the early/mid 90’s.16, 17 Between 1996 and 2001 many Dutch patients with 
rectal cancer were treated within the framework of the Dutch TME-trial, in which 
randomisation occurred between total mesorectal excision with or without RT.18 Since 2001 
the standard treatment for patients with resectable rectal cancer (except for T1 tumours) is a 
short course of  preoperative radiotherapy.6
Treatment options for patients with localised prostate cancer are, besides watchful waiting, 
radical prostatectomy, external beam radiotherapy or brachytherapy, often depending on the 
preference of the urologist.6, 19 Patients with a locally advanced tumour may be treated with 
radical prostatectomy or external beam radiotherapy, both with or without hormonal therapy, 
or hormonal therapy alone.6, 20 
Postoperative radiotherapy was controversial in patients with endometrial cancer stage I21 
(for stage II and III postoperative radiotherapy is standard treatment). From the results of 
the Portec-Trial, studying the value of radiotherapy for patients with stage I endometrial 
cancer,22 guidelines were developed: postoperative radiotherapy is indicated for patients older 
than 60 years with stage Ia and Ib grade 3 or with stage Ic and for patients younger than 60 
years with stage Ic grade 3.6 
Variations in treatment
Despite guidelines, large variations in the management of patients with cancer were seen 
in the USA and Europe between regions, hospitals and surgical units.19, 23-29 These variations 
can be explained partly by differences in management protocols between treatment units or 
hospitals, by preferences of specialists (i.e. due to deficient knowledge of or disagreement 
with guidelines) or by patient characteristics such as age or co-morbid conditions as well as 
individual preferences of patients. In the Netherlands variations between hospitals in referral 
for radiotherapy were never studied before.21
In elderly patients therapy may be less aggressive.30, 31 There might be several reasons for 
older patients why they should not endure radiotherapy, such as the distance to the 
radiotherapy facility and the long duration of the therapy (often 6-7 weeks for curative 
therapy), the fear for more severe side effects and the possibility of social disturbances such 
as disorientation or anxiety. Because elderly patients are often excluded from clinical trials, 
effects are not always well known, or only in healthy elderly. It is therefore more complex to 
choose the optimal treatment for elderly patients. Nevertheless, radiotherapy should not be 
withheld because of  chronological age alone.31-33 
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Serious co-morbidity is present in more than 50 percent of patients aged 60 years or older 
with cancer.34, 35 For patients with serious co-morbidity, the standard oncological treatment 
might be altered because of an increased risk of complications or a limited life expectancy 
for non-oncologic reasons. To study the influence of age and/or co-morbidity on receiving 
radiotherapy, a population-based setting is very convenient. 
Secondary and palliative radiotherapy
Radiotherapy plays an important role in palliation. For example, radiotherapy is the 
treatment of choice for most patients with spinal cord compression;36 it should be initiated as 
soon as possible to optimise the chances for restoration of neurological function. A survey 
among general practitioners in Canada showed that many physicians were unaware of the 
effectiveness of radiotherapy in palliative situations like spinal cord compression, 
haemoptysis, haematuria and brain metastases.37 Research among Dutch general practitioners 
seemed to confirm this.38
In the literature most population-based studies only describe radiotherapy as part of the 
primary treatment. The estimated percentages are a combination of radiotherapy as part of 
the primary treatment and delayed radiotherapy. No reliable impression is given of the 
cumulative proportion of patients receiving delayed or secondary radiotherapy,2 although this 
may contribute substantially to the total radiotherapy consumption. A real insight can be 
given in primary and secondary radiotherapy for patients in a cohort during the time they are 
followed and such data become comparable when this cohort is population-based.
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1.2 Patients and Methods
Eindhoven Cancer Registry
The Eindhoven Cancer Registry (ECR) was started in 1955 as part of a program for 
nation-wide cancer registration in the area of South-Eastern North Brabant. Data on all new 
cancer patients were collected directly from pathology reports and patients’ medical records. 
The registry was started in three hospitals in Eindhoven and gradually expanded into the 
south-east of North Brabant, the northern part of the province of Dutch Limburg (since 
1970) and, following the foundation of the Comprehensive 
Cancer Centre South (Integraal Kankercentrum Zuid, 
IKZ), the middle, north eastern and south-western 
part of North Brabant since 1986 (except the most 
western part) (figure 1). 
In the rest of the Netherlands, other regional 
registries had discontinued their activities, until a 
successful nation wide program was re-
established since 1984. Since 1989 the whole 
Dutch population is covered by nine 
regional cancer registr ies, which 
established the Netherlands Cancer 
Registry.
Figure 1:  The current area of  the 
 Eindhoven Cancer   Registry 
 of  the Comprehensive Cancer 
 Centre South
 
In the Netherlands nine Comprehensive Cancer Centres, covering the entire population, 
are working together to improve the quality of cancer care. They exploit the regional cancer 
registries. In addition to the development of treatment guidelines they play an important role 
in the implementation of and the promotion of adherence to the guidelines. Furthermore 
they coordinate palliative care by providing for education and guidelines.39
The area covered by the population-based Eindhoven Cancer Registry, with 
approximately 2.4 million inhabitants in 2004, (15% of the Dutch population) is now  served 
by 10 general hospitals at 16 locations and two large radiotherapy institutes, one in the 
western (Tilburg) and one in the eastern (Eindhoven) part of the region. The area does not 
contain a university hospital or a specialised cancer hospital. There are 6 pathology 
laboratories, all participating in the nationwide PALGA (Pathologisch-Anatomisch Landelijk 
Geautomatiseerd Archief) network, which also notifies the regional cancer registries. 
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The cancer registry receives lists of newly diagnosed cases on a regular basis from the 
pathology departments. In addition, the medical record departments of the hospitals provide 
lists of outpatients and hospitalised cancer patients. Following this notification, the medical 
records of newly diagnosed patients (and tumours) are collected, and trained registrars from 
the cancer registry abstract the necessary information, such as data on diagnosis, staging, and 
primary treatment, given or planned within 6 months of diagnosis. Data are checked for 
duplicate records.
Patients who live in the catchment area of the Eindhoven Cancer Registry, but are 
diagnosed elsewhere in the Netherlands, are regularly retrieved from all other Dutch Cancer 
Registries since 1989. Before this year it was done directly through manual retrievals at all the 
cancer centres.
Major aims of  the registry are to host and facilitate studies on:
• Public health aspects, e.g. trends and clusters, scenarios.  
• Quality of  care: adherence to guidelines, studies of  side effects and quality of  life. 
• Prognosis: focus on elderly and role of  co-morbidity or social-economic status. 
Generally, the region can be characterised by good access to medical care without 
financial obstacles. The distance to a hospital has always been less than 30 kilometres, and the 
travel time to a radiotherapy department is for most patients less than 30 minutes and for 
some almost one hour if they are not hampered by traffic jams. The population in the area is 
increasingly ageing, with an increasing proportion of elderly women (from less than 5% to 
more than 10%), and since 1965 a decreasing number of  children (figure 2).
            15% 10% 5% 0% 5% 10% 15%          15% 10% 5% 0% 5% 10% 15%          15% 10% 5% 0% 5% 10% 15%
Figure 2: Age-distribution of  the population in the area of  the Eindhoven Cancer Registry
Histological classification and Staging
All tumours were classified based on topography and histology, according to the WHO 
International Classification of  Diseases for Oncology (ICD-0).40 
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Stage of the tumours was categorised according to the TNM-classification International 
Union against Cancer (IUCC).41
Co-morbidity
On demand of various specialists who were increasingly worried about the age and 
treatability of their patients, the registry also recorded co-morbidity at diagnosis since 1993 
according to a slight adaptation of the list of serious diseases drawn up by Charlson and 
colleagues.42 In short, the following important conditions were recorded: chronic obstructive 
pulmonary diseases (COPD), cardiovascular and cerebrovascular diseases, other malignancies 
(excluding basal cell carcinoma of the skin), and diabetes mellitus. Furthermore, 
hypertension, connective tissue disease, rheumatoid arthritis, kidney, bowel and liver diseases, 
dementia, tuberculosis and other chronic infections were also recorded. Chapter 4.1 of this 
thesis contains a table of  the recorded co-morbid conditions.
Radiotherapy
Primary radiotherapy was defined as radiotherapy given or planned within 6 months of 
date of diagnosis. Secondary radiotherapy was defined as radiotherapy given 6 months or 
later after diagnosis, or as radiotherapy given after a previous course of radiation for the same 
tumour (figure 3).
Figure 3:  Flow chart of  the kind of  radiotherapy. PRT = primary radiotherapy, given or planned
 within 6 months of diagnosis; SRT1 = secondary radiotherapy, given after a previous 
 course of radiation for the same tumour; SRT2 = secondary radiotherapy, given 6 
 months or later after diagnosis.
The area of the Eindhoven Cancer Registry is served by two large radiotherapy institutes, 
one in the western region as an independent facility and one in the eastern region as part of a 
large general hospital, each serving only community hospitals. The institutes now  each treat 
about 2500 new (newly diagnosed cancer patients, or patients with a new episode of the 
disease, who were never irradiated before) patients a year and 500 to 800 patients who were 
irradiated before for the same tumour. 
!
Radiotherapy 
(SRT1) 
No 
radiotherapy 
Primary 
treatment 
Secondary 
treatment 
Radiotherapy 
(SRT2) 
No 
radiotherapy 
Patients first diagnosed with 
cancer 
Radiotherapy (PRT) No radiotherapy 
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In both institutes each course of radiation (primary or secondary) is recorded with date of 
onset, patient characteristics and treatment protocol number, indicating the kind of treatment 
given. For the studies in chapter 3.1 and 3.2 data from the radiotherapy institutes were 
combined with data from the Eindhoven Cancer Registry.
1.3 Outline
The objectives of this thesis were to study variation in the use of radiotherapy in a variety 
of  study designs in a large population-based setting:
• To explore trends in referral for primary radiotherapy. 
• To investigate the use of  secondary radiotherapy. 
• To explore variations in referral for radiotherapy in relation to patients’ and doctors’
    characteristics.
In chapter 2.1 an overview  is given of consumption of primary radiotherapy for patients 
with different tumour types between 1988 and 2002. Also the time trends are discussed and 
whether the variation decreased. Variations between hospitals in referral for primary 
radiotherapy are described in chapter 2.2. Chapter 2.3 is a continuation of chapter 2.1; 
referral rates and trends are studied up to 2006 inclusive, and changes are discussed, with 
emphasis on breast and rectal cancer and differences between the two regions. 
The use of secondary radiotherapy for patients with breast and rectal cancer was studied 
in a population-based cohort of breast cancer patients and in a cohort of rectal cancer 
patients. These studies are described in chapter 3.1 and 3.2. These are the first population-
based studies to give insight in the use of  secondary radiotherapy.  
In chapter 4.1 the influence of age and co-morbidity on receiving primary radiotherapy is 
discussed for the following tumour types: breast, rectal, lung and prostate cancer and non-
Hodgkin lymphoma. Chapter 4.2 gives a literature overview  of treatment possibilities of 
rectal cancer since 1980, but as well as of  its real management, especially in relation to age.
The results of a questionnaire among general practitioners about their knowledge of 
palliative radiotherapy are presented in chapter 5.1. Chapter 5.2 describes variations in time 
pattern of  referral for spinal cord compression.
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Chapter 2
Long-term trends

2.1
Referral rates and trends in radiotherapy 
as part of  primary treatment of  cancer
 in South Netherlands, 1988 - 2002
J.C.M. Vulto, W.J. Louwman, P.T. Rodrigus, J.W.W.Coebergh
Radiotherapy and Oncology 2006; 78: 131-137
Abstract
Background and Purpose
To study referral rates and time trends in the use of  primary radiotherapy (RT). 
Methods 
The proportion and number of irradiated patients were calculated in a population-based 
setting among 58,436 cancer patients diagnosed between 1988 and 2002. 
Results
The number of patients receiving RT within 6 months of diagnosis (RT6mo) increased 
by about 3.3% annually, the proportion of all incident cases that received RT6mo remained 
stable (±30%). Only 20% of  elderly patients (75+) received RT6mo.
The proportion of cancer patients that received RT6mo increased markedly between 
1988-92 and 1998-2002 for patients with prostate cancer (15 and 28%, respectively), rectal 
cancer (33 and 43%) and brain tumours (48 and 67%). The absolute number of irradiated 
breast cancer patients increased 30% between 1988 and 2002.  Among patients with rectal 
cancer a shift occurred from postoperative to preoperative RT since 1995. The percentage of 
irradiated patients with stage I endometrial cancer decreased from 47% in 1988-92 to 15% in 
1998-2002. 
Conclusion
The percentage of cancer patients who received primary RT remained stable throughout 
1988-2002, being consistently lower for older patients. The increased number of irradiated 
patients was due mainly to earlier detection and the ageing of the population. To clarify the 
overall percentage of patients irradiated, population-based studies on RT given after 6 
months since diagnosis are warranted.
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Introduction
Of all cancer patients about 50% are generally assumed to receive radiotherapy (RT) 
during the course of the disease.1, 2 These percentages are normally not based on population-
based studies but are nonetheless often used for decisions on the required capacity of RT 
equipment and personnel. The percentage usually consists of primary RT as part of an initial 
treatment and secondary RT in the case of recurrent disease or metastases1, 3 without taking 
into account whether patients had already received primary RT. A population-based study 
from an adjacent RT department in Eindhoven, which belongs to the same comprehensive 
cancer centre, showed that 32% of the cancer patients received primary RT between 1975 
and 1998.4, 5 A study of trends in the use of RT for different tumour types, preferably by 
stage and age, can illustrate necessary as well as arbitrary changes and would provide an 
impression of adherence to guidelines, that are being developed increasingly in the 
Netherlands. We studied the number and proportion of cancer patients who received primary 
RT and analysed trends in the use of  primary RT between 1988 and 2002. 
Methods
The Eindhoven Cancer Registry (ECR) records data on all patients newly diagnosed with 
cancer in the southern part of the Netherlands with a population of approximately 2.3 
million. This population-based registry covers all facilities in the region, which are: six 
regional pathology departments, 15 community hospitals and two large RT departments, one 
of which is located in the mid-western part (Tilburg) as an independent facility and the other 
in Eindhoven. Trained registry personnel actively collect information from the medical 
patients’ records upon notification of newly diagnosed cases by the regional departments of 
pathology, haematology and radiotherapy and the national Registry of Hospital Discharge 
Diagnosis. Patients referred for treatment outside the area (<3%) are completely registered by 
the ECR. Cancer registries in the Netherlands usually cover over 95% of all cases due to the 
infrastructure of and good access to Dutch health care facilities, together with the multiple 
source notification procedures used.6 Recorded are patient characteristics (gender, age, 
concomitant diseases7), tumour characteristics (localisation and morphology (according to the 
International Classification of Diseases for Oncology8), stage at diagnosis (according to the 
Tumour-Node-Metastasis (TNM) system 4th edition9) (which is rather complete, about 10% 
of all patients’ stage is unknown, depending on the site of the primary tumour)), primary 
treatment (given or planned within 6 months of  diagnosis), and date of  death. 
The Dr. B. Verbeeten Institute (BVI) is an independent non-academic facility, which had 
3 linacs, 1 cobalt and 1 orthovolt in 1988, and 1 cobalt and 5 linacs in 2002. The number of 
full-time radiation oncologists increased from 5 in 1988 to 10 in 2002. The BVI provides RT 
for all patients diagnosed in the 8 hospitals in the western part of the Comprehensive Cancer 
Centre, with a growing and ageing population of approximately 1 million people,10 where the 
cancer registry of  the ECR has been complete since 1988.
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We included all patients diagnosed with cancer (excluding carcinoma in situ, superficial 
bladder cancer and non-melanoma skin cancer) between 1988 and 2002 (n=58,436). We 
studied tumour-specific and 15-year age-specific applications of RT that is given within 6 
months of diagnosis (RT6mo). Patients who are planned to receive RT after several courses 
of chemotherapy (so the start of radiotherapy may actually be after 6 months) are also 
included as having received RT6mo. Age and stage-specific trend analyses were performed 
for individual tumour types. For the stage specific analysis NX and MX were coded N0 and 
M0.
The estimated annual percentage change (EAPC) was calculated as an estimate of the 
trend. A regression line was fitted: i.e. y = ax + b, where y = rate and x = calendar year. 
EACP = a / b.11
Results
The total annual number of patients receiving RT6mo increased from 851 in 1988 to 
1439 in 2002 (table 1), an EAPC of 3.3%.11 The percentage of patients receiving RT6mo 
remained stable at about 30%. Thirty to forty percent of new  patients between 30 and 75 
years received RT6mo, and 20% of  the patients older than 75 (table 1). 
Table 1 - Age-specific use and sharea of  radiotherapy given within 6 months of  diagnosis according to period of  
diagnosis in South Netherlands, 1988-2002
1988-1992 1993-1997 1998-2002
No. 
cancer
patients
No. 
irra-
diated
Irra-
diated 
(%)
Share 
(%)
No. 
cancer
patients
No. 
irra-
diated
Irra-
diated 
(%)
Share 
(%)
No. 
cancer
patients
No.
irra-
diated
Irra-
diated 
(%)
Share 
(%)
0-44 1745 648 37.1 12.4 1862 663 35.6 11.2 1934 717 37.1 10.8
45-59 3869 1548 40 29.7 4442 1746 39.3 29.6 5164 1930 37.4 29
60-74 7041 2161 30.7 41.4 8306 2538 30.6 43 9139 2939 32.2 44.1
75+ 4249 859 20.2 16.5 4981 953 19.1 16.2 5704 1073 18.8 16.1
Total 16904 5216 30.9 100 19591 5900 30.1 100 21941 6659 30.3 100
aShare: the proportion of  irradiated patients from one age group relative to all irradiated patients in that specific 
period of  diagnosis  
Tumour-specific application of RT is shown in table 2. Patients with breast cancer (31%) 
and lung cancer (26% in 1988-1992, 19% in 1998-2002) form the largest portion of all 
irradiated patients. 
The proportion of irradiated patients increased among patients with rectal tumours (33 to 
43%), laryngeal tumours (73 to 88%), prostate cancer (15 to 29%), tumours of the central 
nervous system (49 to 67%), and Hodgkin’s disease (39 to 62%). Most other tumour types 
showed a decrease. 
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Table 2 - Cancer-specific use and sharea of  radiotherapy given within 6 months of  diagnosis according to cancer site 
and period of  diagnosis in South Netherlands, 1988-2002
1988-1992 1993-1997 1998-2002
No.
Cancer
patients
No.
irra-
diated
Irra-
diated 
(%)
Share
 (%)
No. 
Cancer
patients
No.
irra-
diated
Irra-
diated 
(%)
Share
 (%)
No. 
Cancer 
patients
No.
irra-
diated
Irra-
diated 
(%)
Share
 (%)
Head and neck
Oral 
cavity/
pharynx
366 169 46.2 3.2 407 194 47.7 3.3 445 245 55.1 3.7
   Larynx 222 162 73 3.1 222 175 78.8 3 233 206 88.4 3.1
Rectum 832 279 33.5 5.3 946 320 33.8 5.4 1058 454 42.9 6.8
Lung 2783 1344 48.3 25.8 2940 1383 47 23.4 3119 1285 41.2 19.3
Breast 2660 1589 59.7 30.5 3138 1833 58.4 31.1 3692 2047 55.4 30.7
Gynaecological
   Cervix 220 123 55.9 2.4 195 85 43.6 1.4 182 90 49.5 1.4
Corpus
uteri
327 164 50.2 3.1 382 146 38.2 2.5 470 109 23.2 1.6
   Ovary 338 55 16.3 1.1 418 10 2.4 0.2 397 2 0.5 0
Urological
   Prostate 1266 192 15.2 3.7 1841 379 20.6 6.4 2240 643 28.7 9.7
   Bladder 352 186 52.8 3.6 377 184 48.8 3.1 448 177 39.5 2.7
   Testis 86 28 32.6 0.5 146 51 34.9 0.9 157 69 43.9 1
Lymphomas
Hodgkin's
disease
103 40 38.8 0.8 107 59 55.1 1 113 70 61.9 1.1
Non-
Hodgkin
575 111 19.3 2.1 745 154 20.7 2.6 741 206 27.8 3.1
CNSb 231 112 48.5 2.1 290 174 60 2.9 295 198 67.1 3
Myeloma 170 41 24.1 0.8 198 51 25.8 0.9 202 59 29.2 0.9
Oeso-
phagus
184 80 43.5 1.5 250 102 40.8 1.7 375 140 37.3 2.1
Soft tissue 242 43 17.8 0.8 251 47 18.7 0.8 273 47 17.2 0.7
Unknown 
primary
824 144 17.5 2.8 892 208 23.3 3.5 1033 192 18.6 2.9
Other sitesc 5123 354 6.9 6.8 5846 345 5.9 5.8 6468 420 6.5 6.3
Total 16904 5216 30.9 100 19591 5900 30.1 100 21941 6659 30.3 100
Excluded carcinoma in situ, superficial bladder cancer and non-melanoma skin cancer
aShare: the proportion of  one irradiated tumour type relative to all tumours in that specific period of  diagnosis 
bCNS=Central Nervous System
cAll other invasive tumours except non-melanoma skin cancer  
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The proportion irradiated patients with non-small cell lung cancer decreased from 48 to 
41% (figure 1), which can be attributed mostly to patients with a non-localised (stage III and 
IV) tumour, 57% of all patients with non-small cell lung cancer. Forty percent of the patients 
with limited small cell lung cancer younger than 70 received RT in 2002 in contrast to 26% in 
1988. 
Figure 1: Number and percentage of patients with lung cancer receiving radiotherapy according to 
 stage and year of  diagnosis in South Netherlands, 1988-2002
 Non-small cell (NSC) localised: T1-2 N0/X M0/X; T1-2/X N1 M0/X
 Non-small cell not localised: T1-2/X N2 M0/X; T3 N0-2/X M0/X; T4 N0-3/X M0/X 
 T1-4/X N3 M0/X; T1-4/X N0-3/X M1
The number of irradiated patients with prostate cancer increased from 29 in 1988 to 171 in 
2002, the proportion from 15 to 32%. The increase was most striking for those with a 
localised tumour (table 3).
The total number of irradiated patients with breast cancer was approximately 30% higher in 
1992 compared with preceding years (figure 2), mainly due to patients between 50 and 69 
years with stage I or II. The percentage of patients aged 70 and older receiving RT was 
approximately 20% lower compared to younger patients, for all stages of  the disease. 
0 
100 
200 
300 
400 
1988 1990 1992 1994 1996 1998 2000 2002 
N
u
m
b
er
 r
ad
io
th
er
ap
y 
Year of  diagnosis 
Lung, number irradiated 
small cell NSC, stage unknown 
NSC, not localised NSC, localised 
0 
20 
40 
60 
80 
1988 1990 1992 1994 1996 1998 2000 2002 
%
 r
ad
io
th
er
ap
y 
Year of  diagnosis 
Lung, % irradiated 
small cell NSC, stage unknown 
NSC, not localised NSC, localised 
30  Chapter 2.1
The number of irradiated patients with rectal cancer showed a slight increase, the 
proportion was stable until 2000 (table 2). From 1997 onwards postoperative RT was partly 
replaced by preoperative RT, and from 2001 it was almost entirely preoperative (figure 3). 
The percentage of irradiated patients with endometrial cancer decreased from 50% in 
1988-1992 to 23% in 1998-2002 (table 2), mainly due to stage I patients. The proportion of 
patients younger than 70 years with bladder cancer who received RT decreased more (55 to 
31%) than the proportion of  older patients (53 to 46%). 
The proportion and the number of irradiated patients with tumours of the central nervous 
system increased (figure 4), mainly because of the increased irradiation of patients older than 
55 years with high grade astrocytoma. 
The proportion irradiated patients with Hodgkin’s disease increased until 1999 to 70%, and 
then decreased to 58% in 2002. The proportion irradiated patients with non-Hodgkin’s disease 
increased from 17% to 27% (table 3, figure 4).
Table 3 - Radiotherapy consumption in prostate cancer according to stage and period of  diagnosis in South 
Netherlands, 1988-2002
1988-1992 1993-1997 1998-2002
No. 
cancer 
patients
No. 
irra-
diated
Irra-
diated 
(%)
No. 
cancer 
patients
No.
irra-
diated
Irra-
diated 
(%)
No. 
cancer 
patients
No.
irra-
diated
Irra-
diated 
(%)
Localiseda 658 124 18.8 1117 267 23.9 1520 488 32.1
Locally 
advancedb
94 24 25.5 193 60 31.1 264 101 38.3
Metastasisedc 359 29 8.1 366 36 9.8 347 41 11.8
Unknown 155 15 9.7 165 16 9.7 109 13 11.9
All stages 1266 192 15.2 1841 379 20.6 2240 643 28.7
a T1-2 N0/X M0/X
b T3-4 N0/X M0/X
c T1-4/X pN1 M0/X; T1-4/X pN0-1 M1
Discussion
The total number of cancer patients increased substantially during 1988-2002,10 as a result 
of a growing and ageing population. The number of patients who received RT6mo in the 
western part of the ECR also increased (3.3% annually), but the proportion remained stable: 
about 30% of cancer patients received radiotherapy. In the eastern part of the ECR a slightly 
higher percentage of 32% was found between 1975 and 1998,5 mainly due to a higher 
proportion irradiated patients with breast and prostate cancer. A report estimating required 
RT equipment assumed that 47% of the cancer patients received RT in 1995 and that this 
would increase to 50% in 2010.12 This report, and also other reports1-3 did not separate 
RT6mo from RT given later during the course of the disease and the numbers were not 
obtained from population-based studies but were rather expert-opinions. 
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Earlier, we estimated that 45% of all patients received irradiation, including 32% RT6mo, 
5% RT for the first time for relapsed disease or metastases, and 40% after an earlier 
irradiation.4 
Figure 2:  Number and percentage of patients with breast  cancer receiving radiotherapy according to 
 year of  diagnosis, age and stage in South Netherlands, 1988-2002
 Stage I: T1 N0 M0/X
 Stage II: T2 N0-1 M0/X; T1 N1 M0/X; T3 N0 M0/X
 Stage III: T1-2 N2 M0/X; T3 N1-2 M0/X; T4 N0-3/X M0/X; T1-4 N3 M0/X
 Stage IV: T1-4/X N0-3/X M1
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In Australia, the proportion of cancer patients who receive RT at some point of their 
illness was calculated to be 52%.13 
Elderly patients (>75) received less RT, the proportion was 10-20% lower than among 
younger patients (table 1). Other authors concluded that use of adjuvant RT decreases more 
with age than can be explained by an age-associated decline in functional status observed in 
the general population.14 The general attitude of doctors is influenced by the belief that 
tolerance to treatment might be compromised in older patients or that the course of cancer 
might be less aggressive in this age group.15
The BVI participates extensively in trials that compare different radiation doses or fields, 
sometimes in combination with chemotherapy. Because randomisation takes place after 
referral, these trials barely influence the percentage of patients irradiated. However, two trials 
focused on the additional value of RT: the TME-rectum trial and the Portec-study 
(endometrial cancer) (described later).16, 17 
The introduction of better diagnostic possibilities improved the selection for surgical 
resection among patients with localised non-small cell lung cancer, also for older patients.18 For 
non-localised tumours a combination of chemotherapy and RT replaced the RT alone.19 The 
decreased percentage of irradiated patients accompanied an increased use of chemotherapy.18 
We found an increase in the percentage of irradiated patients with small cell lung cancer, 
especially patients younger than 70 years with limited disease. The real level of RT may be 
underestimated because of a time delay: patients with small cell lung cancer receive 
chemotherapy followed by consolidation RT,20 often later than 6 months after diagnosis. In 
the early years these patients were not always registered as having received RT. The overall 
percentage of patients with lung cancer receiving primary RT6mo (45.4%) corresponds with 
that estimated by an evidence-based approach (45.9% ± 4.3%), although it differed by stage, 
probably due to different indications for RT in North America.21 
The total number of patients with prostate cancer increased markedly because of the 
growing number of older men in the population, and because the wide-spread use of the 
PSA-test since 1994.22 The treatment of localised prostate cancer largely depends on the 
preference of the urologist.23 Although alternative treatments are available, such as radical 
prostatectomy or watchful waiting, a large increase was observed in the proportion irradiated 
patients with a localised tumour.24 The percentage of 30% irradiated patients in the last 
period corresponds with the evidence-based estimate of 32.2% ± 3.8% from the model by 
Foroudi and colleagues.25 In North America, where incidence rates are much higher, the share 
of  irradiated patients is also higher than in our study.10, 26
The absolute number of patients with breast cancer increased because of the introduction 
of mass screening in 1991. Also the number of patients who received breast-conserving 
therapy including RT increased.27 The slight decrease in percentage irradiated patients 
younger than 70 years with stage I and II in the nineties indicates that fewer patients with a 
relatively small tumour received breast-conserving therapy.27-29 This will have the same result 
in terms of disease-free survival and survival as mastectomy.30, 31 Referring specialists 
apparently had different ideas about the best therapy.32 
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Also in other countries treatment of small breast tumours was (too) often amputation, or 
breast-conserving surgery without RT.33, 34 Patients aged 70 years and older were less often 
treated according to therapy guidelines.14, 35, 36 The overall percentage of 54-60% irradiated 
patients is similar to the evidence-based result of  57.3% ± 4.7% in initial treatment.37
The standard treatment for patients with rectal cancer was surgery followed by RT until a 
reduction was seen in the local recurrence rate for patients who received preoperative 
RT.38, 39 From 1996 to 1999 most patients received preoperative RT within the framework of 
the TME trial (total mesorectal resection with or without preoperative RT).16 The proportion 
irradiated patients remained stable because of the high participation in this trial. In 2002 the 
percentage of patients receiving RT had increased from 40% to 65%, almost all preoperative 
(figure 3). An evidence-based estimation from 2003 showed that 69.6% ± 0.9% of rectal 
cancer cases would require RT in their initial treatment. These numbers are based on the 
North American management of rectal carcinoma, which consists of postoperative RT in 
most centres.40 We found a much lower percentage of  postoperative irradiated patients (35%).
Figure 3:  Treatment (%) of rectal cancer according to year of diagnosis in South Netherlands, 
 1988-2002 
 1=preoperative radiotherapy, 2=postoperative radiotherapy, 3=only surgery, 
 4=only radiotherapy (patients with other or unknown therapy were excluded)
The BVI actively participated in the Portec-Trial that studied the value of radiotherapy 
for patients with stage I endometrial carcinoma.  Postoperative RT was controversial for this 
tumour.41 Patients were randomised to receive pelvic RT or no further treatment after total 
abdominal hysterectomy. Consequently the percentage irradiated patients with stage I 
decreased. An even further decrease was seen after 1999, especially for patients younger than 
60, but also for older patients, according to the guidelines which were developed from the 
results of the Portec-Trial,17 but also because more patients had undergone lymph node 
dissection.42 The optimal RT utilisation at some point of the illness in Australia was 34% if 
pelvic lymph node dissection was widely practised, otherwise 58%.43 
Until the early nineties patients with bladder cancer received often RT before a cystectomy. 
Since then, more patients were operated, but without RT.
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For patients with a high-grade astrocytoma the median survival increases after postoperative 
RT.44 There is no consensus on the treatment strategy for patients with a low-grade glioma. 
Postoperative RT appears to improve the progression-free survival, but not overall survival.45
Patients with Hodgkin’s disease received RT alone or in combination with chemotherapy.46 
The low  percentage of patients irradiated found at the end of the eighties and early nineties 
(figure 4) is probably a registration artefact: RT given in combination therapy after 
chemotherapy was not always coded as a primary treatment in the early years of the cancer 
registry. The proportion of irradiated patients we found in the period 1998-2002 (70%) was 
comparable to that from an evidence-based estimation in Australia (75%).47 
Figure 4:  Percentage of patients who received radiotherapy: Central Nervous  System and Hodgkin’s 
 disease according to year of diagnosis and age; non-Hodgkin’s lymphoma according to 
 year of  diagnosis and stage in South Netherlands, 1988-2002
Since 1997 patients with a low-grade non-Hodgkin’s lymphoma receive a fraction of 4 Gray at 
the affected localisation.48 The increase in the proportion of irradiated patients with an 
intermediate/high grade non-Hodgkin’s lymphoma is probably a registration artefact as well, 
as is explained above.49 According to an evidence-based estimation in 2004 the proportion of 
patients in Australia that should receive RT at some point in their treatment, was calculated 
64%, which was much higher than our findings of  only RT6mo (28%).47 
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Conclusion
Although the number of cancer patients receiving RT6mo increased markedly in the last 
15 years, the overall percentage, which was lower for the elderly, remained stable, despite an 
increase in the number of linacs and staff as well as screening campaigns. Changing 
indications often based on results of  randomised clinical trials went in both directions. 
To clarify the overall percentage of patients irradiated, population-based studies on 
secondary RT should also be performed.
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 1988-1999
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Abstract 
We assessed whether referral for primary radiotherapy varied according to hospital size in 
a region with 1 million inhabitants served by community hospitals. We studied 20,178 patients 
diagnosed with breast, non-small cell lung, prostate, rectal, or endometrial cancer between 
1988 and 1999. We used logistic regression analysis, adjusted for age, stage and period of 
diagnosis. Medium-sized and small hospitals referred breast cancer patients more often 
(OR=2.2, 95%CI=2.0-2.5, OR=1.2, 95%CI=1.1-1.4, respectively) and patients with prostate 
cancer less often (OR=0.7 (0.5-0.8) and 0.7 (0.6-0.9), respectively). Referral rates for patients 
with non-small cell lung and rectal cancer showed minor differences according to hospital 
size, referral for endometrial cancer was somewhat higher for patients from medium-sized 
hospitals (OR=1.5 (1.0-2.1)). Time trends in variation were shown, but differences according 
to hospital size only decreased over time for rectal cancer. Despite multidisciplinary oncology 
meetings and treatment guidelines there were large variations in rates of referral for 
radiotherapy.
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Introduction
Of all cancer patients 50-60% are assumed to receive radiotherapy (RT).1-3 These 
numbers are often used in decision-making, for example to calculate required capacity of RT 
equipment. According to a population-based study from the Eastern part of the Eindhoven 
Cancer Registry (ECR) approximately 30% of all cancer patients received primary RT 
between 1975 and 1998.4, 5 We found the same percentages for the western part of the ECR 
(data not shown). Little is known about the inter-hospital variation in referral patterns. Our 
regional radiotherapy department operates in a region covered by the Comprehensive Cancer 
Centre South, which promotes adherence to (and sometimes development of) guidelines. The 
area includes a population-based cancer registry and is served by community hospitals only. 
This allows us to study the variation in rates of referral for a regional radiotherapy 
department in a population-based setting.
Methods
The ECR records data on all patients newly diagnosed with cancer in the southern part of 
the Netherlands; it covers a population of approximately 2.3 million. This population-based 
registry includes six pathology departments, 15 community hospitals (no university hospital) 
and two RT departments, one of which is located in the western part (Tilburg) as an 
independent facility. Data on patient characteristics (age, gender, concomitant diseases), 
tumour characteristics (localisation, morphology, stage at diagnosis) and treatment (planned 
within 6 months of diagnosis) is recorded by trained registry personnel, usually between 6 
and 18 months after diagnosis. Despite the lack of access to death certificates, the 
infrastructure of and good access to Dutch health care facilities, together with the multiple 
source notification procedures used, cancer registries in the Netherlands typically cover over 
95% of cases.6 The Dr. B. Verbeeten Institute (BVI) offers RT in the western part of the 
region. Within the referral area the number of referring hospitals decreased due to mergers 
from 9 to 7 between 1988 and 1999, but the original locations (units of patient care) were 
retained. A subdivision was made into large (more than 500 beds, n=2), medium-sized 
(350-500 beds, n=3) and small hospitals (less than 350 beds, n=4). Physicians’ training 
facilities were present in both large and some of the medium-sized hospitals. Treatment 
guidelines for most tumour types were available. In all hospitals cancer patients were 
presented on multidisciplinary oncology meetings, in the presence of a radiation oncologist 
to discuss treatment policy. We included all patients with cancer of the breast, prostate, rectal 
and endometrial and non-small cell lung cancer diagnosed between 1988 and 1999 
(n=20,178). We studied both the individual hospital and the hospital size. In stage-specific7 
analysis of breast cancer NX and MX were coded N0 and M0, respectively. Differences in 
distribution were tested with the chi-square test. Logistic regression analysis was used to 
estimate the effect of hospital size on the referral for RT, adjusted for age, stage and period 
of  diagnosis.
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Results  
Forty-five percent of patients in the study received primary RT (i.e. within 6 months of 
diagnosis). The lowest percentage (42%) of cancer patients was referred for RT in the large 
hospitals (medium: 43%, small: 51%, p<0.0001). Variation in stage existed between the 
hospitals for most tumour types. Regardless of hospital size, referral for RT was lower for 
patients aged 70+ compared to those below  70, except for non-small cell lung cancer (table 
1). This was also demonstrated by the multivariate analysis (table 2). The largest effect was 
observed for breast cancer patients, the odds for receiving RT were 0.3 for patients aged 70+ 
compared to those diagnosed before age 70 (95%CI=0.3-0.4).
Table 1 - Total number of  cancer patients and referral rates (%) for primary radiotherapy according 
to hospital sizea and age in South Netherlands, 1988-1999
Tumour type Age Hospital size
Large Medium Small
Breast cancer
No. patients 2211 3023 2336
% irradiated < 70 57 63 75
≥ 70 35 35 50
NSCLCb
No. patients 2830 2456 549
% irradiated < 70 45 48 45
≥ 70 44 45 48
Prostate cancer
No. patients 1260 1583 902
% irradiated < 70 32 28 25
≥ 70 21 15 18
Rectal cancer
No. patients 616 869 658
% irradiated < 70 40 44 46
≥ 70 25 23 28
Endometrial cancer
No. patients 286 341 258
% irradiated < 70 38 43 45
≥ 70 33 37 49
Total
No. patients 7203 8272 4703
% irradiated < 70 47 51 60
≥ 70 34 30 35
alarge = >500 beds, n=2; medium = 350-500 beds, n=3; small = <350 beds, n=4; bNSCLC = non-
small cell lung cancer 
Patients with breast cancer from large hospitals were referred for RT less often (42%, 
medium-sized 43% and small 50%, p<0.0001) (table 1). When adjusted for age, stage and 
period of diagnosis, the chance to receive RT was higher for patients referred by specialists in 
the medium-sized (OR=2.2, 95%CI=2.0-2.5) and the small hospitals (OR=1.2, 1.1-1.4). 
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Especially patients with stage I and II breast cancer from the small hospitals received RT 
more often (70-80% compared to 50-60% from the medium-sized and large hospitals, 
p<0.0001).
Specialists in the large and medium-sized hospitals referred most of the patients with non-
small cell lung cancer for RT. The referral of non-small cell lung cancer patients decreased from 
50% in 1988 to 36% in 1999 with only small variations according to hospital size or 
individual hospital. 
Table 2 - Chance to receive primary radiotherapy for different tumour types according to hospital sizea adjusted for 
age, stageb and period of  diagnosis in South Netherlands, 1988-1999
Breast cancer NSC lung cancerc Prostate cancer Rectal cancer Endometrial cancer
ORd 95%CIe OR 95%CI OR 95%CI OR 95%CI OR 95%CI
Hospital type
Large* 1 1 1 1 1
Medium 
sized
2.2 2.0-2.5 0.9 0.7-1.1 0.7 0.5-0.8 1.2 0.9-1.6 1.5 1.0-2.1
Small 1.2 1.1-1.4 1.2 1.0-1.3 0.7 0.6-0.9 0.9 0.7-1.2 1.1 0.8-1.6
Age
<70* 1 1 1 1 1
≥70 0.3 0.3-0.4 1 0.9-1.2 0.6 0.5-0.7 0.4 0.3-0.5 0.9 0.7-1.2
Stage
I* 1 1 1 1 1
II 1 0.9-1.1 3 2.6-3.4 1.3 1.1-1.6 4.4 3.3-5.8 3.2 1.9-5.5
III 1.8 1.5-2.1 1.6 1.2-2.1 8.7 6.5-11.8 4.2 2.4-7.3
IV 0.2 0.1-0.2 0.1 0.0-0.1 1.2 0.8-1.7 0.5 0.2-1.3
Unknown 0.3 0.2-0.4 1.5 1.3-1.8 0.5 0.3-0.7 4.8 3.4-6.9 0.5 0.2-1.5
Period of  
diagnosis
1988-1991* 1 1 1 1 1
1992-1995 1 0.9-1.1 1 0.9-1.2 1 0.8-1.3 1 0.7-1.2 0.7 0.5-1.0
1996-1999 0.8 0.7-0.9 0.6 0.5-0.7 1.3 1.0-1.6 0.9 0.7-1.2 0.5 0.4-0.7
alarge=>500 beds, n=2, medium sized=350-500 beds, n=3, small=<350 beds, n=4
bNSC lung cancer: I=localised, II=non-localised; cNCS = non-small cell; dOR = Odds ratio
eCI=Confidence Interval; *reference category
Specialists in the large hospitals referred 25% of patients with prostate cancer for RT 
(medium 19% and small 20%, p<0.0001). The chance of RT after adjustment was 
significantly lower for patients from small and medium-sized hospitals (OR=0.7, 95%CI= 
0.5-0.8, OR=0.7, 95%CI=0.6-0.9, respectively). 
For rectal cancer the referral rates for RT were approximately 35% regardless of hospital 
size.
Patients with endometrial cancer were referred more often by specialists in the medium-sized 
or small hospitals (41% and 47%, respectively), compared to the large hospitals (36%, 
p=0.06). According to multivariate analysis the chance that patients from medium-sized 
hospitals would receive RT was significantly higher (OR=1.5, 95%CI=1.0-2.1) (table 2). 
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The variation in referral between individual hospitals was large for patients with breast 
cancer (mean 58%, range 44-71%), prostate cancer (mean 22%, range 12-33%), rectal cancer 
(mean 36%, range 28-48%) and endometrial cancer (mean 42%, range 29-63%). For non-
small cell lung cancer the referral rate ranged from 32-49% (mean 46%), with an outlier 
(65%) for 1 small hospital with only a few patients (figure 1).
The time trend in variation according to hospital size is shown in figure 2. The referral 
rates converged for rectal cancer. The differences remained stable for patients with breast, 
non-small cell lung and endometrial cancer, and the variations became larger for prostate 
cancer.
Figure 1:  Referral for primary radiotherapy (%) according to tumour type and hospital in South 
 Netherlands, 1988-1999 (NSCLC = non-small cell lung cancer)
 1,2: large hospitals; 3,4,5: medium-sized hospitals; 6,7,8,9: small hospitals
Discussion
The rate of referral for primary RT in the study region (the western part of the ECR) was 
30% between 1988 and 1999 for all cancer patients (data not shown), and 45% for the 5 
tumour types studied, which is very similar to that found for the eastern part of the ECR.4, 5 
We found variations in referral rates for RT between the different hospitals. Variations in 
referral rates might be explained by the preference of specialists with regard to treatment 
chosen, sometimes despite treatment guidelines. Some variation can be explained by the 
choice of the patient. Although a variation in stage was seen for most tumour types between 
the hospitals, this cannot explain the variation in referral rates for RT because we corrected 
for this in the multivariate analysis (table 2). 
The slight increase in rates of referral for RT for breast  cancer in 1992-1994 can be 
explained by the introduction of mass screening in 1992. For most small breast cancers 
conservative surgery with RT was established as the standard treatment because it gave the 
same results in terms of  disease-free survival and overall survival as mastectomy.8-10
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Figure 2: Time trends for variation in referral for primary radiotherapy (%) according to tumour type 
 and hospital size in South Netherlands, 1988-1999
Nevertheless we found a large difference in the referral rates for RT (which is an 
important indicator of the percentage of patients undergoing conservative surgery11), 
between hospitals. The small hospitals, with the lowest caseload, had the highest percentage 
referrals. In these hospitals a larger proportion of patients was presented at the 
multidisciplinary oncology meetings. Probably because of the fact that less expertise on 
cancer treatment was available these meetings had more influence on the treatment policy in 
these hospitals. Other authors found the opposite: according to Moritz and colleagues 
surgeons with a higher caseload had a lower mastectomy rate,12 and Nattinger and colleagues 
noted that larger hospitals were more likely to perform breast-conserving surgery compared 
to smaller hospitals.13 
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In our region the choice between conservative treatment and mastectomy in the larger 
hospitals was influenced markedly by the personal experience and practice of the individual 
surgeon, and to a lesser extent by multidisciplinary recommendations.
The decreasing rate of referral for RT for patients with non-small cell lung cancer was seen in 
all hospitals, probably as a result of  increased use of  chemotherapy.14 
Since 1994 the PSA-test has been used for detection of prostate cancer. More patients with 
a localised tumour were referred for RT from that time.15 The large variation in referral rates 
may be related to the preference of the urologist for different treatment modalities. This 
variation in the management of localised prostate cancer (prostatectomy, RT or watchful 
waiting) exists world-wide.16-19
From 1996 most patients with rectal cancer were treated with preoperative instead of 
postoperative RT within the framework of the TME trial (Total Mesorectal Resection with or 
without preoperative RT).20 Before 1994 referral rates converged, then they diverged to lower 
referral rates for the large and higher referral rates for the small hospitals. Since 1996 the 
referral rates have converged again.
Variation in referral of patients with endometrial cancer stage I, similar variations were also 
found in the south-eastern part of the Netherlands,21 can be explained by the lack of 
conclusive evidence for postoperative RT, which was therefore applied depending on the 
individual gynaecologists and the individual oncology meetings. When the results of the 
Portec trial22 became available in 1997, the decreasing trend was interrupted for patients aged 
70+, but differences according to hospital sizes remained.
For each of the investigated tumours we found variations in the rates of referral for RT 
according to hospital size. However, we did not find that the highest referral rates were 
always from one particular hospital size. For one tumour the small hospitals referred most 
patients, for another tumour large hospitals referred the most.  After a change in treatment 
policy the same trend in referral for RT was found for all three hospital sizes, but for most 
tumour types the variations in referral rates remained.
Conclusion
Despite the existence of guidelines and multidisciplinary oncology meetings during which 
the treatment policy for cancer patients is discussed, large variations, with a slight 
convergence in later years, were found for the referral rates for RT.
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Abstract
Purpose
To explore still existing variations in use of primary radiotherapy (RT) in a region with 
two RT departments with adjacent referral areas.
Methods and Materials
We calculated the proportion of all 147,588 newly diagnosed cancer patients between 
1988 and 2006 in the south of the Netherlands receiving primary radiotherapy, according to 
referral to the RT departments.
Results
The number of newly diagnosed patients receiving primary RT increased from 1668 in 
1988 to 2971 in 2006, the proportion remaining more or less stable (±30%). Only 20% of 
elderly patients (75+) received primary RT, slightly more in the eastern area.
Over time, more irradiation was administered to patients with prostate and rectal cancer, 
less to patients with lung and bladder cancer or Hodgkin’s lymphoma and recently more to 
patients with cervix or endometrial cancer. The proportion remained more or less unchanged 
for patients with most other tumour types and became slightly higher in the eastern region. 
Patients with breast or rectal cancer from the eastern part of the region were significantly 
more likely to receive primary RT (OR=1.4, 95%CI=1.4-1.5, OR=1.4, 95%CI=1.3-1.6, 
respectively).
Conclusions
During 1988-2006 the number of irradiated patients increased substantially, while the 
proportion remained stable. Large variations were found in referral rates for RT, especially in 
later years, between the eastern and the western parts of the region, each with their own RT 
departments and referring hospitals. 
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Introduction
Of all patients with cancer about 50% are generally assumed to receive radiotherapy (RT) 
during the  course of their disease.1 This percentage is, in a way, experts’ opinion but is 
nonetheless often used for decisions on the current and future required capacity of RT 
equipment and personnel. It usually consists of primary RT as part of an initial treatment 
and secondary RT for recurrent disease or metastases,1, 2 irrespective of whether patients had 
already received primary RT. Population-based studies from our region showed that a 
constant percentage (about 30%) of all cancer patients received primary RT.3-5 Furthermore, 
67% of all patients with breast cancer and 45% of all patients with rectal cancer received RT 
(primary or secondary) in the first 5 years after diagnosis.6, 7  
Between 1988 and 1999 referral for primary RT per hospital varied substantially in our 
region,8 as well as in other parts of the Netherlands and in the USA, especially for patients 
with breast cancer.9, 10 Feedback among referring specialists during 2004-05 led to many 
discussions, encouraging us to continue our earlier studies on variations in the use of primary 
RT for different tumour types. This can serve as a means to detect improved adherence to 
guidelines, increasingly available at a national level in the Netherlands. 
We estimated the proportion of all cancer patients who received primary RT and analysed 
more in-depth trends and variations in the use of primary RT for patients with primary 
breast and rectal cancer newly diagnosed between 1988 and 2006. 
Methods and Materials
Data were derived from the Eindhoven Cancer Registry (ECR), which contains data on all 
patients newly diagnosed with cancer since 1955. The registry covers a large part of South 
Netherlands with approximately 2.4 million inhabitants in 2004. The medical infrastructure 
consists of six Pathology Departments, 10 general hospitals (there were 20 hospitals 25 years 
ago) and two large RT departments, one in the west as an independent facility (Tilburg) 
(currently with 7 megavoltage units) and one in the east (Eindhoven) as part of a large 
general hospital (now  with 6 units). Most patients live within a travelling range of 30 minutes 
to one hour from the RT department. Trained registry personnel from the ECR actively 
collect data from the hospital charts after notification of newly diagnosed cases by the 
regional Pathology and Haematology Laboratories and Radiotherapy Departments as well as 
the national Registry of Hospital Discharge Diagnoses. Patients referred for treatment 
outside the area (<3%) are completely registered in the ECR, but often a few years later. 
Cancer registries in the Netherlands usually comprise over 95% of all cases due to the 
infrastructure of and good access to Dutch health care facilities, together with the multiple 
notification procedures used.11 Recorded are patient characteristics (gender, age, concomitant 
diseases12), tumour characteristics (localisation and morphology (according to the 
International Classification of Diseases for Oncology13), stage at diagnosis (according to the 
Tumour-Node-Metastasis (TNM) system14) (unknown for only 10% of all patients, 
depending on the site of  the primary tumour)) and primary treatment. 
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The cancer registries are part of the Comprehensive Cancer Centres which have a largely 
coordinating role, enhancing communication among the various regional tumour study 
groups by publishing studies of  adherence to guidelines.
We included all patients (n=147,588) diagnosed with cancer between 1988 and 2006 
(excluding carcinoma in situ, superficial bladder and non-melanoma skin cancer). We studied 
tumour-specific and 15-year age-specific use of primary radiotherapy (RT) given within 6 
months of diagnosis for the total group of patients, and for the western and eastern regions 
separately. Patients who were scheduled to receive RT after several courses of chemotherapy 
(sometimes after 6 months) are also included in the analyses. RT given within 6 months for 
metastases, if  present at diagnosis, was not included, in contrast to previous studies.4, 5
For breast and rectal cancer patients we studied in more detail primary RT according to 
stage (only for breast cancer) and age and also separately for the populations from the eastern 
and the western regions. The changes in time of the percentage irradiated patients with 
breast and rectal carcinoma per individual hospital were also evaluated.
For stage classification of breast cancer the pathological TNM was used after breast-
conserving surgery, breast amputation or other surgery; otherwise the clinical TNM was used, 
NX and MX being coded N0 and M0. 
We used logistic regression analysis to estimate the chance of receiving RT in the western 
or the eastern region for breast or rectal cancer, adjusting for univariately significant 
determinants including age, gender (rectal cancer), stage (breast cancer), period of diagnosis, 
co-morbidity at diagnosis12 and socio-economic status.15 
Results
Total group 
The annual number of newly diagnosed cancer patients increased by 73% from 5479 in 
1988 to 9469 in 2006, the number of irradiated patients increased from 1668 to 2971, an 
absolute increase of 78%. During this period the annual percentage of patients receiving 
primary RT fluctuated between 30 and 32%, remaining at 30% in the western and becoming 
35% in the eastern region in the period 2003-2006 (table 1). Patients older than 75 years were 
irradiated less often in both regions, although this also varied from about 18% in the western 
to 21% in 1988-1992 and 23% in 2003-2006 in the eastern region (table 1). 
Tumour-specific application of primary RT is shown in table 2. The irradiated proportion 
of all newly diagnosed patients increased between 1988 and 2006 for patients with prostate 
or rectal cancer, but decreased for patients with lung or bladder cancer or with Hodgkin’s 
lymphoma. After a decrease in the nineties an increase in the percentage irradiated patients 
with cervix or endometrial cancer was seen in more recent years. With most other tumour 
types it remained more or less unchanged, being slightly higher in the eastern region. 
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Table 1 - Percentage irradiated patients with cancer according to period 
of  diagnosis, age and region in South Netherlands, 1988-2006
Period of  
diagnosis
Age of  
diagnosis 
(years) Region
West East
1988-1992 0-44 37.8 38.9
45-59 38.1 38.3
60-74 29.5 32.4
≥75 19.9 20.9
Total 30.1 31.6
1993-1997 0-44 36.1 34.9
45-59 37.8 37.5
60-74 28.9 31.9
≥75 18.7 20.8
Total 29.2 30.8
1998-2002 0-44 34.8 35
45-59 33.4 38.3
60-74 29.7 34
≥75 17.4 22.4
Total 28.1 32.3
2003-2006 0-44 36.6 39.3
45-59 35.5 41.8
60-74 32.3 37.3
≥75 18.2 23.6
Total 29.8 35
Breast cancer 
The annual number of irradiated patients with breast cancer increased by more than 
100% between 1988 (n=496) and 2006 (n=1005), while the total number of breast cancer 
patients simultaneously increased by 91%.
The percentages irradiated patients fluctuated annually between 57 and 62% for both the 
western and the eastern region until 1995 and then diverged to 69% in the eastern and 54% 
in the western region (figure 1). During the latter period a lower proportion of patients 
underwent breast-conserving surgery and a higher proportion mastectomy in the western 
than in the eastern region, while fewer mastectomy patients received RT in the western 
region. In 2006 the percentages of both surgical procedures seemed to converge to almost 
the same percentage in both regions, but this could not be seen yet in the percentages RT.
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Figure 1: Radiotherapy for patients with breast cancer in South Netherlands, 1988-2006: according to 
 catchment area (West and East)
Similar percentages of patients with stage I breast cancer were irradiated in the eastern 
and western regions in the late eighties and early nineties. In the western region the 
percentage decreased between 1994 and 1999 from 70 to 53%, followed by an increase to 
65% in the last 4 years. In the eastern region a slight increase to 81% was seen over time 
(figure 2). The percentage irradiated patients with stage II disease in the eastern region 
fluctuated between 60 and 70% until 2000, and then stabilised at 60%. In the western region, 
however, a decrease was seen from 60 to less than 50% irradiated patients (figure 2). For 
patients with stage III disease no clear trend was found in either region, with again a higher 
percentage of  patients being irradiated in the eastern than in the western region.
Figure 2:  Radiotherapy for patients with breast cancer stage I and II in South Netherlands, 1988-2006: 
 according to catchment area (West and East)
Differences between percentages irradiated patients in the two regions according to age 
are shown in figure 3. They are of course derived from the individual hospitals which refer 
patients for RT. The percentage irradiated patients from some hospitals was stable 
throughout time (no 1,2,3,5,10), for other hospitals it increased (6,9) or decreased (4,7,8) 
(figure 4).
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The logistic regression analysis showed that patients with breast cancer from the eastern 
region were significantly more likely to receive RT than patients from the western region 
(OR=1.4, 95%CI=1.4-1.5). 
Figure 3:  Radiotherapy for patients with breast cancer in South Netherlands, 1988-2006: according to 
 catchment area (West and East) and age
Rectal cancer
The percentage patients with rectal cancer who received RT increased in 2003-2006 35% 
compared to the previous period, whereas the proportion receiving postoperative RT 
decreased from 1995 when preoperative RT was introduced. This implied short-course 
radiotherapy for resectable rectal cancer and long-course for locally advanced tumours, 
starting first in the eastern region: in 2004 50% of all patients with rectal cancer received 
preoperative RT and 25% underwent surgery without RT (figure 5). After 2004 a slight 
decrease was seen in the total percentage undergoing primary RT for rectal cancer (figure 6), 
due to a decrease in postoperative RT in the western region and a decrease in preoperative 
RT in both regions.
Patients with rectal cancer from the eastern region were significantly more likely to receive 
primary RT than patients from the western region (OR=1.4, 95%CI=1.3-1.6). This difference 
in RT (figure 6) was found for every age, the percentage irradiated patients older than 75 
years being 10 to 15% lower than at middle age. The inter-hospital variation in RT use was 
large and did not converge in later years; nevertheless for every hospital an increase was seen 
over time (figure 4).
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Discussion
Total group
Although the total number of cancer patients and the number of irradiated patients both 
increased substantially during 1988-2006,16 the percentage of patients who received RT 
within the framework of their primary treatment remained stable at about 30%. This stable 
percentage is made up of a rising percentage irradiated patients with prostate and rectal 
cancer and a decreasing percentage with lung and bladder cancer as well as Hodgkin’s 
lymphoma. Despite the development of clear guidelines for the treatment of cancer patients 
which are easily accessible on the internet,17 the percentage irradiated patients between the 
two regions we studied diverged over time. In the western region it increased gradually or 
remained stable for all ages, in the eastern region it increased for all ages. We found a lower 
referral rate for elderly patients in the western region; however there are no clear differences 
in geographical and socio-economical background.
Figure 4:  Radiotherapy for patients from community hospitals in South Netherlands, 1988-2006: 1,2,3,4 
 are hospitals in the western, 5,6,7,8,9,10 in the eastern region
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We analysed patients with breast and rectal cancer in more detail, because breast cancer 
forms the largest group of patients in a RT department and national guidelines have been 
available for several years.17 For rectal cancer too RT is an important part of the treatment, 
with significant changes in the nineties. For both of these tumour groups surgery is usually 
the primary treatment with RT postoperative or preceding surgery as for early stage rectal 
cancer. We found the largest differences between the eastern and the western region for 
patients with these tumours. A difference in referral policy between the eastern and western 
region might be the greater emphasis on clinical surgical research on rectal carcinoma and the 
intensive collaboration with the national trial organisation in the eastern region.18 
In this study we defined primary RT as radiotherapy given within 6 months of diagnosis 
within the framework of the primary treatment. RT given within 6 months of diagnosis for 
metastases was not defined as primary RT. In earlier studies from our region covering parts 
of the same periods, this distinction was not made. Therefore, in the former, the percentages 
irradiated patients were 1-2 percent higher in both the western and the eastern region.4, 5
In our view the new guidelines for endometrial cancer, which were implemented in 2004 
and which specified postoperative RT for stage I after a hysterectomy (RT for patients older 
than 60 years with stage Ia and Ib grade 3 or with stage Ic and for patients younger than 60 
years with stage Ic grade 3)17 might have increased the percentage irradiated patients with 
endometrial cancer in our last study-period in both regions, after a decrease caused mainly by 
the then ongoing PORTEC-trial evaluating the value of postoperative RT for patients with 
stage I endometrial cancer5, 19, 20 and despite the negative side effects on quality of life among 
long term survivors.21 For cervix cancer new  guidelines promoted chemo-radiation for 
patients with stage IIb-IVa.17, 22, 23
The increasing percentage irradiated patients with prostate cancer through the years was 
the result of an increase in RT for elderly patients and also of an increase in patients both 
with localised and locally advanced tumours, while the portion of locally advanced tumours 
rose, especially in the last study-period. However for localised prostate cancer the treatment 
options, being radical surgery, external RT or brachytherapy, or watchful waiting,17 are 
generally dependent on the patient’s or doctor’s preferences.24, 25 We think that the 
encouraging results of several trials evaluating adjuvant hormonal treatment for patients with 
locally advanced tumours boosted referral for combined RT-hormonal treatment as well.26-28 
The preference of urologists in the eastern region for RT might explain the higher RT rates 
there.
Breast cancer
The introduction of mass screening for breast cancer between 1991 and 1996 led to a 
substantial increase in the absolute number of breast cancer patients. However, no increase 
was found in the percentage irradiated patients, probably because the percentage undergoing 
breast-conserving surgery (which gives, in combination with RT, the same results in terms of 
disease-free survival and survival as mastectomy29-32) in the age group eligible for screening 
(50-70 years, later up to 75) remained largely the same.33 
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We can explicate the divergence in referral rates for RT between the two regions since 
1995 mainly from the differences in percentage breast-conserving surgery as follows: 
especially the percentage patients with stage I disease who underwent breast-conserving 
surgery  increased during our whole study period in the eastern region, whereas it remained 
stable in the western region with a small increase in the last period. In both regions almost all 
of these patients received RT. For patients with stage II disease the percentage undergoing 
breast-conserving surgery has increased in both regions since 1995 (from 43 to 54 % in the 
eastern and 36 to 42% in the western region), but the percentage irradiated patients in this 
subgroup decreased (from 96 to 94% in the eastern and 96 to 89% in the western region). 
These decreases mainly explain the decrease in the total percentage RT for patients with stage 
II disease (figure 2). 
Patients older than 75 years received RT less often, in the western region even less than in 
the eastern region. However, in elderly patients too, breast cancer does not behave as an 
indolent disease and RT after breast-conserving surgery should not be omitted.34 Replacing 
RT by hormonal treatment is less safe and is subject to (other) side effects as well.35, 36 Even 
after mastectomy RT might remain indicated for those with high-risk breast cancer.37-39 
The differences in RT for breast cancer between the two regions reflected, in our opinion, 
the referral policy of the surgeons from the hospitals in the regions. For 5 hospitals the 
referral rates were more or less stable, with prominent low  rates especially in the western 
region. A decreasing referral rate was seen in 3 and an increasing in 2 hospitals; this might be 
related to changes in the surgical staff. Variations in surgical treatment have also been found 
for other Dutch regions.9, 40 Surgeons’ characteristics, such as gender, degree or location of 
training, appear to be associated with breast conserving-surgery and the referral for RT.10, 41, 42
Figure 5:  Time trend of  primary treatment (%) of  rectal cancer in South Netherlands, 1988-2006
 (RT=radiotherapy, S=Surgery, postop=postoperative,  preop=preoperative)
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Rectal cancer
The large increase in percentage irradiated patients with rectal cancer in the period 
2003-2006 can be clarified by the implementation of a short course of preoperative RT in 
both RT departments in the region as standard treatment for patients with clinically 
resectable rectal cancer. 
Both departments participated in the Dutch TME-study between 1996 and 2000,43 but 
the RT department in the eastern region had already introduced preoperative RT in 1994, 
while the department in the western region only started preoperative RT as standard 
treatment after publication of the results of the TME-study.43 The surgeons and radiation 
oncologists in the eastern region have demonstrated a high scientific interest in rectal cancer.44-47 
Figure 6:  Radiotherapy for patients with rectal cancer in South Netherlands, 1988-2006: according to 
 catchment area (West and East)
In our opinion the slight decrease in percentage RT after 2004 might be the result of 
publications regarding late side effects of  short-course preoperative RT.48, 49 
The percentage irradiated elderly patients in our region remained low  after the 
implementation of preoperative RT. Less RT for elderly patients was described also in other 
recent population-based studies.50 Although in the TME-study patients aged 75 years and 
older showed a better reduction of the local recurrence rate with preoperative RT compared 
to younger patients, distant metastasis free survival, cancer free survival and 5-years survival 
did not improve. Postoperative complications were a major problem in the elderly, especially 
in the first 6 months after surgery, compared with younger patients.18, 46 Delayed surgery after 
a short course of preoperative RT might be an option, especially for elderly patients to 
decrease the combined risks of surgery and RT while still depending on their important role 
in the prevention of  local recurrences.
We did not include stage of rectal cancer in this study, because preoperative stage was 
often unknown, and postoperative stage might have become lower, especially after a long 
course of  preoperative irradiation.51, 52 
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Conclusion
Although the absolute number of irradiated patients with cancer increased substantially 
during 1988-2006, the proportion of referred patients remained stable in the south of the 
Netherlands. 
Between the eastern and the western parts of the region, each with their own RT 
departments and referring hospitals, substantial variations were found in referral rates for RT, 
especially in later years. The question is whether this divergence might have been larger if 
there had not been guidelines and multidisciplinary oncology meetings. 
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Abstract
We studied the use of radiotherapy (RT) (especially secondary RT) in a cohort of 6561 
patients in South Netherlands with invasive breast cancer diagnosed between 1996-2000 
(median follow  up: 66 months, range 0-107 months). Radiation within 6 months of diagnosis 
was considered primary RT (PRT). RT given 6 months or later after diagnosis or after PRT 
was considered secondary RT (SRT). Of all patients, 67% received RT, 3554 only PRT, 323 
only SRT and 503 both. The cumulative use of SRT at 100 months was 17%. The 826 
patients receiving SRT underwent 1846 courses 0-105 months (median 36) after diagnosis; 
the retreat-rate was 35%. Elderly patients received SRT significantly less often (ORage 
50-69=0.7, 95%CI=0.6-0.8, ORage ≥70=0.4, 95%CI=0.3-0.5). The following factors increased 
the chance for SRT: patients from the eastern region (OR=1.3, 95%CI=1.1-1.6); patients 
who received PRT (OR=1.3, 95%CI=1.0-1.5) and patients who underwent mastectomy 
including axillary node dissection as well as unresected patients (OR=1.9, 95%CI=1.5-2.4, 
OR=2.6, 95%CI=1.7-3.9, respectively).
Thirteen percent of all patients with breast cancer received SRT, with a large variation in 
age and between the 2 RT departments in the region. 
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Introduction
The incidence of breast cancer in the south of the Netherlands amounted to 120 per 
100,000 women in 2000. Radiotherapy (RT) is an essential part of breast cancer treatment, 
either as part of the primary treatment within the framework of breast-conserving treatment 
or mastectomy,1-3 or for palliation of recurrent or metastatic breast cancer. 4, 5 Therefore 
patients with breast cancer constitute a large proportion of the patients treated in a RT 
department.
Of all cancer patients about 50% are likely to receive radiotherapy during the course of 
their disease.6, 7 This percentage is not derived from population-based studies but is 
nevertheless often used in the process of decision-making for estimation of the future 
capacity of RT equipment and personnel needed. The overall percentage usually consists of a 
mixture of primary RT (PRT) as part of the initial treatment and secondary RT (SRT) in the 
case of recurrent disease or metastases without taking into account whether patients had 
already received primary RT.6, 8 In a population-based study of patients treated with RT as 
part of their primary treatment we found that 30% of all cancer patients received PRT.9, 10 
For patients diagnosed with breast cancer in 1998-2002 this amounted to 55%.9 SRT has 
been studied in our region for all cancer patients diagnosed between 1975 and 1989: 5% of 
previously non-irradiated patients received RT for recurrent disease or metastases, and about 
40% of all irradiated patients had RT again.11 Recent studies used an evidence-based 
approach to determine the use of RT as part of primary treatment and for treatment of 
recurrences or metastases. They estimated that 66% to 83% of all breast cancer patients 
received RT during the course of  their illness.12, 13 
Since we had already performed several studies on the use of primary RT we wanted to 
estimate the percentage of patients receiving RT during their illness, which can also be 
relevant for planning purposes. We determined, in a population-based setting in a region with 
2 large RT departments, the proportion of patients with breast cancer who received RT as 
part of their primary treatment and as SRT. We explored the influence of patient and tumour 
characteristics on SRT and variations in referral for SRT.
Methods
We studied a cohort of patients with a first invasive breast cancer, diagnosed between 1st 
January 1996 and 31st December 2000 and followed until 1st January 2005. Data were derived 
from the population-based Eindhoven Cancer Registry (ECR), which has recorded data on all 
patients newly diagnosed with cancer since 1955. The registry covers a large part of South 
Netherlands with approximately 2.4 million inhabitants in 2004. The medical infrastructure 
consists of six Pathology departments, hospital medical records offices in 10 general 
hospitals and two large RT departments (one in the western (Tilburg) and one in the eastern 
(Eindhoven) part of the region). Patients never have to travel more than one hour to a RT 
department. 
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Table 1 - Characteristics of  patients with breast cancer diagnosed between 1996 and 2000 (n=6561) receiving 
primary radiotherapy in South Netherlands
Patient characteristics Primary radiotherapy
No (n=2504) (%) Yes (n=4057) (%) Total (n=6561) (%)
Age at diagnosis
≤ 49 years 554 (22) 1142 (28) 1696 (26)
50 t/m 69 1002 (40) 2059 (51) 3061 (47)
≥70 years 948 (38) 856 (21) 1804 (28)
Number of  concomitant diseases
None 1188 (47) 2441 (60) 3629 (55)
One 580 (23) 889 (22) 1469 (22)
2+ 387 (16) 372 (9) 759 (12)
Unknown 349 (14) 355 (9) 704 (11)
Socio-economic status
Low 687 (28) 977 (24) 1664 (25)
Middle 927 (37) 1669 (41) 2596 (40)
High 660 (26) 1249 (31) 1909 (29)
Institutiona 195 (8) 131 (3) 326 (5)
Unknown 35 (1) 31 (1) 66 (1)
Stage at diagnosis 
I 897 (36) 1713 (42) 2610 (40)
II 1135 (45) 1815 (45) 2950 (45)
III 133 (5) 390 (10) 523 (8)
IV 176 (7) 105 (3) 281 (4)
Unknown 163 (7) 34 (1) 197 (3)
Second breast tumour
No 2377 (95) 3847 (95) 6224 (95)
Yes 127 (5) 210 (5) 337 (5)
Vital status 1-1-2005
Alive 1664(66) 3068 (76) 4732 (72)
Deceased 840 (34) 989(24) 1829 (28)
Surgeryb (western region)
BCS + AC 432 (3) 1227 (67) 1269 (39)
BCS 62 (4) 32 (2) 94 (3)
MRM + AC 1074 (76) 510 (28) 1584 (49)
MRM 63 (4) 25 (1) 88 (3)
No surgery 176 (12) 41 (2) 217 (7)
Surgery (eastern region)
BCS + AC 53 (5) 1632 (73) 1685 (51)
BCS 51 (5) 35 (2) 86 (3)
MRM + AC 840 (77) 502 (23) 1342(41)
MRM 28 (3) 18 (1) 46 (1)
No surgery 115 (11) 35 (2) 150 (5)
Radiotherapy Department
Western region 1417 (57) 1835 (45) 3252 (50)
Eastern region 1087(43) 2222 (55) 3309 (50)
Secondary Radiotherapy
No 2181 (87) 3554 (88) 5735 (87)
Yes 323 (13) 503 (12) 826 (13)
a institution: patients living in an institution (i.e. nursing home)
b BCS=Breast-conserving surgery, AC=axillary clearance, MRM=modified radical mastectomy
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Trained registry personnel from the ECR actively collects data on diagnosis, staging, co-
morbidity and primary treatment, given or planned within 6 months of diagnosis, from the 
hospital charts after notification of newly diagnosed cases by the regional Departments of 
Pathology, Haematology and Radiotherapy as well as the national Registry of Hospital 
Discharge Diagnoses. An indicator of socio-economic status (SES) was developed by 
Statistics Netherlands based on individual fiscal data (economic value of the home and 
household income) and provided at aggregated levels for each postal code (average of 17 
households). Socio-economic status was categorised 1 (low) to 3 (high), with a separate class 
for postal codes with a care-providing institution (such as a nursing home).
Cancer registries in the Netherlands usually cover over 95% of all cases, due to the 
infrastructure of and good access to Dutch health care facilities, together with the multiple 
source notification procedures used.14 In both RT Departments each course of RT is 
recorded with date of onset, patient characteristics and treatment protocol number indicating 
the kind of radiation treatment given. Data on all patients with breast cancer who received 
RT between 1st January 1996 and 1st January 2005 at the two RT Departments were 
combined with the above-mentioned data from the ECR.
Figure 1:  Flow chart of the study-population: breast cancer patients diagnosed between 1996 and 2000 
 in South Netherlands (PTR=primary radiotherapy, SRT=secondary radiotherapy)
Between 1996 and 2000, a total of 7224 patients were first diagnosed with breast cancer, 
including sarcomas (n=55) and unknown morphology (n=38). Patients with carcinoma in situ 
(n=663) were excluded. We only considered RT given for the first tumour. Eventually we 
included 6561 patients with invasive breast cancer in our analysis (figure 1).
Radiation given or planned within 6 months of  diagnosis was considered PRT.15
!
In situ 
N=663 
(excluded) 
Radiotherapy (PRT) 
N=4057 
No radiotherapy 
N=2504 
Radiotherapy 
(SRT) 
N=503 
No radiotherapy 
N=3554 
Primary 
treatment 
Secondary 
treatment 
Patients with breast cancer, first diagnosed 
between 1996 and 2000 
N=7224 
Primary tumour 1996-
2000 
N=6561 
Radiotherapy 
(SRT) 
N=323 
No radiotherapy 
N=2181 
Cohort of  patients with breast cancer   77
This includes patients irradiated within 6 months of diagnosis only for metastases as 
planned primary treatment (n=64). We also included patients who were irradiated as part of 
primary treatment later than 6 months after diagnosis (in case of prolonged chemotherapy) 
(n=86). 
Table 2 - Odds of  receiving secondary radiotherapy for patients with breast cancer diagnosed 
between 1996 and 2000 (n=6561) in South  Netherlands, each variable adjusted for all others
Odds-ratio 95%CI p-value
Age at diagnosis
≤49 years 1
50 t/m 69 0.7 0.6-0.8 <0.0001
≥70 years 0.4 0.3-0.5 <0.0001
Number of  concomitant diseases
None 1
One 0.9 0.8-1.1 0.5
2+ 0.8 0.6-1.1 0.1
Unknown 1 0.7-1.2 0.7
Socio-economic status
Low 1
Middle 1 0.9-1.3 0.7
High 1.1 0.9-1.4 0.4
Institutiona 0.8 0.5-1.3 0.4
Unknown 1.4 0.7-2.9 0.4
Stage at diagnosis
I 1
II 2.2 1.8-2.7 <0.0001
III 2.9 2.1-3.9 <0.0001
IV 8 5.5-11.5 <0.0001
Unknown 0.9 0.5-1.7 0.8
Radiotherapy department
Western region 1
Eastern region 1.3 1.1-1.6 0.0003
Primary radiotherapy
No 1
Yes 1.3 1.0-1.5 0.02
Second breast tumour
No 1
Yes 1 0.7-1.5 0.8
Surgeryb
BCS + AC 1
BCS 1.6 0.9-2.8 0.09
MRM + AC 1.9 1.5-2.4 <0.0001
MRM 1.7 1.0-3.0 0.07
No surgery 2.6 1.7-3.9 <0.0001
a institution: patients living in an institution (i.e. nursing home)
b BCS=Breast-conserving surgery, AC=axillary clearance, MRM=modified radical mastectomy
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RT given 6 months or later after diagnosis (other than the above) or RT given after a 
previous course of radiation for breast cancer (even within 6 months) was considered as 
delayed or SRT. Patients first irradiated for metastases within 6 months of diagnosis, but for 
whom this irradiation was not planned as primary treatment, were also considered to have 
received SRT (n=57).
When data from the RT institutes were compared with data from the ECR we found that 
PRT was not registered in the ECR in 136 cases (2% of the total cohort). We included them 
in our analysis as part of the PRT group. RT registered in the ECR for 2 patients who were 
treated later than 6 months (25 and 51 months) after diagnosis was considered to be SRT.
Twenty-one patients were treated with a combination of  hyperthermia and external RT for 
recurrent breast cancer, all administered in the RT department at the Western region, which is 
a top level reference department for superficial hyperthermia.16 Eleven of  these patients 
received previous PRT at the same department, and 9 in the other; 1 had previous SRT for 
recurrent breast cancer in the same institute.
The retreat-rate is defined as the number of radiation courses given after the first course 
divided by the number of all first courses either as PRT or as SRT (=number of patients 
irradiated).
Table 3 - Number of  secondary radiation courses (range:0*-105 months after primary diagnosis) 
per patient in a cohort of  breast cancer patients diagnosed between 1996-2000 (n=6561) in South 
Netherlands
Number of  secondary 
radiotherapy courses
Number of  patients 
(%)
Total number of
secondary
radiotherapy courses
Cumulative number 
of  secondary
radiotherapy courses
1 438 (53) 438 438
2 166 (20) 332 770
3 76 (9.2) 228 998
4 47 (5.7) 188 1186
5 44 (5.3) 220 1406
6 14 (1.7) 84 1490
7 13 (1.6) 91 1581
8 11 (1.3) 88 1669
9 5 (0.6) 45 1714
10 4 (0.5) 40 1754
11 6 (0.7) 66 1820
12 0 (0) 0 1820
13 2 (0.2) 26 1846
Total 826 (100) 1846 1846
*0 months after diagnosis: patients first irradiated for metastases within 6 months of
diagnosis, but for whom this irradiation was not planned as primary treatment
Cohort of  patients with breast cancer   79
Characteristics of patients who did or did not receive PRT are listed in table 1. For 
surgery we distinguished between patients from the western and the eastern region. 
We used logistic regression analysis to estimate the chance of receiving SRT adjusting for 
age, number of concomitant conditions, socio-economic status, stage, second breast tumour, 
RT institute, primary surgical treatment and prior PRT.  We assessed the number of patients 
receiving SRT, and the number and type of secondary radiation treatments (for recurrent or 
for metastasised disease) they received.
The cumulative use of any RT (PRT or SRT) over time was calculated according to the 
Life Table Method,17 starting on the date of diagnosis and ending on the date of start of RT, 
or censored on the date of death or 1st January 2005 whichever occurred first. In total 1543 
patients were censored on 1st January 2005. The cumulative use of SRT was calculated by 
means of the same method: follow-up for patients who received PRT (n=4057) started on 
the last day of primary RT (according to the definition, these patients were at risk for SRT 
after having received PRT); follow-up for patients who received no PRT (n=2385, 119 
patients died within 6 months of diagnosis) started 6 months after diagnosis (by definition 
patients without PRT were at risk for SRT 6 months after diagnosis). Follow-up of both 
groups ended on the date of initiating SRT, date of death or 1st January 2005, whichever 
occurred first. These 2 groups were compared by means of  the log-rank test.
Results
In our cohort of 6561 patients with breast cancer diagnosed between 1996 and 2000, 
(median follow-up 66 months, range 0-107 months), 4380 (67%) patients received RT 
between 1st January 1996 and 1st January 2005: 3554 (54%) only PRT, 323 (5%) only SRT and 
503 (8%) both (figure 1). Five hundred and three patients who received PRT and 120 patients 
who received only SRT were irradiated twice or more. The retreat rate was 35% (1523/4380). 
The patient characteristics are listed in table 1. About half of all patients underwent breast-
conserving surgery and half mastectomy. In the eastern region a higher percentage received 
breast-conserving surgery and was referred for PRT. Five percent of the patients (n=337) 
developed a second breast tumour between 1st January 1996 and 1st January 2005, 146 (43%) 
of whom received PRT for the second tumour. Six patients developed a second tumour in 
the ipsilateral breast, but with other morphology or at another sub localisation, 331 in the 
contralateral breast. For 105 patients the second tumour was diagnosed within 1 month of 
the first, for 82 of these patients on the same day. In this study we only considered RT given 
for the first tumour (n=57). The odds for receiving SRT are shown in table 2. Patients aged 
50 years or older received SRT significantly less often (OR=0.7, 95%CI=0.6-0.8 and OR=0.4, 
95%CI=0.3-0.5 for patients 50-69 years and 70 years or older, respectively). Patients with an 
initial tumour stage higher than stage I received SRT significantly more often (stage II: 
OR=2.2, 95%CI=1.8-2.7, stage III: OR=2.9, 95%CI=2.1-3.9, stage IV: OR=8, 
95%CI=5.5-11.6). Patients from the eastern region were referred more often for SRT 
(OR=1.3, 95%CI=1.1-1.6). Patients who received PRT had a slightly higher chance of 
receiving SRT (OR=1.3, 95%CI=1.0-1.5). 
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Patients who underwent mastectomy including axillary node dissection and patients who 
did not undergo surgery had SRT significantly more often (OR=1.9, 95%CI=1.5-2.4, 
OR=2.6, 95%CI=1.7-3.9, respectively).
Figure 2:  Cumulative use of radiotherapy (primary or secondary)  in a cohort of breast  cancer patients 
 (n=6561) diagnosed between 1996 and 2000 in South Netherlands
Of 826 patients receiving SRT, 138 (17%) had the first course of SRT for a recurrence 
and 688 for metastases; they underwent 1846 courses in total, with a range of 0-101 months 
(median 36 months) after primary diagnosis: 174 courses for relapsed breast tumours and 
1672 courses for metastases. Seventy-four percent of these patients had more than one 
secondary treatment (median=3) (table 3).
Figure 2 shows the cumulative use of RT, either PRT or SRT. Of all patients at risk, 4035 
(61%) had RT within the first 6 months of diagnosis. After 101 months 4380 patients had 
received RT, or 67% of the patients at risk. In figure 3 the cumulative use of SRT is shown 
separately for patients who did or did not receive previous PRT. 
The total cumulative use of SRT was 17% 100 months after start of follow-up. The 
cumulative chance to have SRT was slightly higher for patients who did not receive prior PRT 
(p=0.2).
 
Patients at risk 
            6.561    2.273    2.091    1.935    1.796    1.328    913     546     256 
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Figure 3:  Cumulative use of secondary radiotherapy for patients who did  or did not receive primary 
 radiotherapy in a cohort of breast cancer patients (n=6561) diagnosed between 1996 and 
 2000 in South Netherlands (PTR=primary radiotherapy, SRT=secondary radiotherapy)
Discussion
We studied the percentage of patients with breast cancer in a cohort diagnosed between 
1st January 1996 and 31st December 2000 in our region who received either primary or 
secondary RT. With a median follow-up of 66 months, 67% of all breast cancer patients 
received RT at some point in the course of their illness. This is similar to an evidence-based 
estimation for optimal RT utilisation in Canada, while an evidence-based study in Australia 
calculated a higher level.12, 13 However, reported actual RT utilisation rates were much lower 
(25-50%),18, 19 except in the state of New South Wales, Australia (71%) which was the only 
study that included patients who had their first RT late during the course of  their disease.20
We found that patients older than 50 years of age had a significantly lower chance of 
receiving SRT than younger patients. Manders and colleagues described the clinical 
management of women with metastatic breast cancer, demonstrating that patients aged 70 
years or older were less likely to receive both chemotherapy or RT.21 Elderly patients were 
also treated less often with primary irradiation, sometimes related to co-morbidity.22, 23
Socio-economic status did not affect the chance to receive SRT in our cohort (table 2), 
while in the USA large treatment disparities were found.24 
 
Patients at risk 
No  PRT:    2.385   2.182   2.007   1.858  1.571   1.123   381    381    115 
     PRT:    4.057   3.819   3.598   3.409  2.977   2.160  1.449   859    350 
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However, socio-economic disparities in the Netherlands are relatively small and medical 
insurance covers cancer treatment for 99% of  the population.25
The chance to receive RT for an invasive carcinoma may have been influenced by a 
previous carcinoma in situ (CIS). According to the national guidelines duct carcinoma in situ 
(DCIS) should be treated with breast-conserving surgery, including RT, or alternatively with a 
simple mastectomy on indication.26 Currently 49% of patients with DCIS are irradiated but 
in 1996 this was only 20%.27 After breast-conserving therapy, including irradiation for a 
previous DCIS, no standard RT is possible for a new  invasive tumour in the same breast. As a 
result patients with an invasive carcinoma after earlier treatment for DCIS are more likely to 
undergo a mastectomy without irradiation. DCIS forms 8% (in 1996) to 10% (in 2003) of all 
new breast tumours.28 
In our cohort 337 (5%) patients developed a second breast tumour between 1st January 
1996 and 1st January 2005. This percentage was also found in another population-based study.29 
Because we only considered RT given for the first tumour, we excluded these second 
tumours, 43% of which received PRT, from our cohort. If these patients received SRT, we 
distinguished for which tumour on the basis of data from the RT departments. Only SRT for 
the first tumour was included in our study. A second breast tumour did not influence the 
chance of  receiving SRT for the first tumour.
When a local recurrence occurs after mastectomy (66% of patients primarily undergoing 
a mastectomy received no PRT), the recurrent tumour can often be treated with SRT. Patients 
with a recurrence after breast conserving-treatment (97% of whom received PRT) are usually 
not suited for RT for their recurrence. Therefore a mastectomy will commonly be the first 
treatment of choice. Some of these patients are eligible for regional lymph node irradiation. 
Superficially located recurrent breast cancer in a previously irradiated area can be treated with 
RT in an adapted fractionation schedule combined with hyperthermia as radiosensitizer.16 
In the eastern region a higher percentage of patients were treated with breast-conserving 
surgery, which leads to a higher percentage of patients receiving PRT in that region. This can 
be explained by variations in surgical management, which are larger in the western region 
than in the eastern region.30, 31 This variation in referral for radiotherapy was observed not 
only for PRT but also for SRT.
Patients with a higher stage, usually treated with mastectomy including axillary node 
dissection, have a higher risk for metastases amenable to RT. Patients who did not have any 
surgery at all had a significantly higher chance of receiving SRT, probably because almost 
50% of them had a stage IV tumour at diagnosis, thus a higher risk for symptomatic 
metastases amenable to RT. Eventually, skeletal metastases occur in 20-40% of patients with 
breast cancer.32, 33 RT relieves pain in most cases, is effective in spinal cord compression and 
can prevent a pathological fracture in the case of lytic lesions of the bone cortex.34-36 It also 
improves quality of life and may prolong median survival for most patients with symptomatic 
brain metastases which occur in 10-20% of  women with metastatic breast cancer.37
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The cumulative use for SRT was slightly higher for patients who did not receive prior 
PRT (figure 3), but after adjustment, the chance of receiving SRT was 30% higher for 
patients with prior PRT in comparison with patients without prior PRT (OR=1.3, table 2). 
This can partly be explained by the differences in stage distribution and variations in surgical 
procedures. 
A potential drawback of our study is the median follow-up time for our cohort (66 
months, range 0-107), which is not very long for a population of breast cancer patients. 
However, we were unable to study an earlier cohort, because data were incomplete before 
1996. Although the development of loco-regional recurrences after 5 years is not 
uncommon,38 the majority of recurrences and distant relapses occur in the first 5 years.39-41 
Generally, breast cancer often behaves as a chronic disease for many patients, resulting in 
prolonged survival with metastases.41, 42 Patients with metastasised disease may be referred 
for the first SRT many years after the first appearance of the disease and can be treated with 
irradiation on different locations until their death. Only 28% of patients in our cohort had 
died on 1st January 2005. So, whereas the majority of SRT for recurrent breast cancer will 
occur within our study period, illustrated by the levelling off of the total referral rate (PRT 
and SRT) after the first year of follow-up (figure 2), the cumulative use of SRT (17% at 100 
months after the start of follow-up) will undoubtedly continue to increase slowly over 
subsequent years.
Conclusions
The required capacity for RT for breast cancer is likely to be higher than the cumulative 
rates calculated now, requirements also need to be based on RT for DCIS (now 10% of all 
breast cancers, 50% of whom receive RT), and the RT for second primary breast cancer. 
Furthermore, there was a relatively low  rate of breast-conserving surgery (and thus PRT) 
attributable to several referring specialists30, 31 and there was also some under-treatment of 
elderly patients.22, 23 This approach to the investigation of radiotherapy consumption 
stimulates discussion on optimal treatment and clinical justification of treatment variations. 
Therefore continued monitoring and discussion with referring specialists is highly warranted. 
84  Chapter 3.1
References
1. Whelan TJ, Julian J, Wright J, Jadad AR, Levine ML. Does locoregional radiation therapy 
improve survival in breast cancer? A meta-analysis. J Clin Oncol 2000;18:1220-1229.
2. Vinh-Hung V, Verschraegen C. Breast-conserving surgery with or without radiotherapy: 
pooled-analysis for risks of ipsilateral breast tumor recurrence and mortality. J Natl Cancer Inst 
2004;96:115-121.
3. Favourable and unfavourable effects on long-term survival of radiotherapy for early breast 
cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative 
Group. Lancet 2000;355:1757-1770.
4. van der Sangen MJ, Coebergh JW, Roumen RM, Rutten HJ, Vreugdenhil G, Voogd AC. 
Detection, treatment, and outcome of isolated supraclavicular recurrence in 42 patients with 
invasive breast carcinoma. Cancer 2003;98:11-17.
5. McQuay HJ, Carroll D, Moore RA. Radiotherapy for painful bone metastases: a systematic 
review. Clin Oncol (R Coll Radiol) 1997;9:150-154.
6. van Daal WA, Bos MA. Infrastructure for radiotherapy in The Netherlands: development 
from 1970 to 2010. Int J Radiat Oncol Biol Phys 1997;37:411-415.
7. Porter A, Aref A, Chodounsky Z, Elzawawy A, Manatrakul N, Ngoma T, et al. A global 
strategy for radiotherapy: a WHO consultation. Clin Oncol (R Coll Radiol) 1999;11:368-370.
8. Moller TR, Brorsson B, Ceberg J, Frodin JE, Lindholm C, Nylen U, et al. A prospective 
survey of  radiotherapy practice 2001 in Sweden. Acta Oncol 2003;42:387-410.
9. Vulto A, Louwman M, Rodrigus P, Coebergh JW. Referral rates and trends in radiotherapy as 
part of primary treatment of cancer in South Netherlands, 1988-2002. Radiother Oncol 
2006;78:131-137.
10. Lybeert ML, Louwman M, Coebergh JW. Stable overall referral rates of primary radiotherapy 
for newly diagnosed cancer patients in the ageing population of South-Eastern Netherlands, 
1975-1998. Radiother Oncol 2004;73:101-108.
11. de Jong B, Crommelin M, van der Heijden LH, Coebergh JW. Patterns of radiotherapy for 
cancer patients in south-eastern Netherlands, 1975-1989. Radiother Oncol 1994;31:213-221.
12. Foroudi F, Tyldesley S, Walker H, Mackillop WJ. An evidence-based estimate of appropriate 
radiotherapy utilization rate for breast cancer. Int J Radiat Oncol Biol Phys 2002;53:1240-1253.
13. Delaney G, Barton M, Jacob S. Estimation of an optimal radiotherapy utilization rate for 
breast carcinoma: a review of  the evidence. Cancer 2003;98:1977-1986.
14. Schouten LJ, Hoppener P, van den Brandt PA, Knottnerus JA, Jager JJ. Completeness of 
cancer registration in Limburg, The Netherlands. Int J Epidemiol 1993;22:369-376.
15. Vulto JC, Louwman WJ, Lybeert  ML, Poortmans PM, Rutten HJ, Brenninkmeijer SJ, et al. A 
population-based study of radiotherapy in a cohort of patients with rectal cancer diagnosed 
between 1996 and 2000. Eur J Surg Oncol 2007;33:993-997.
16. Vernon CC, Hand JW, Field SB, Machin D, Whaley JB, van der Zee J, et al. Radiotherapy with 
or without hyperthermia in the treatment of superficial localized breast cancer: results from 
five randomized controlled trials. International Collaborative Hyperthermia Group. Int J 
Radiat Oncol Biol Phys 1996;35:731-744.
17. Cutler SJ, Ederer F. Maximum utilization of the life table method in analyzing survival. J 
Chronic Dis 1958;8:699-712.
18. Hill DJ, White VM, Giles GG, Collins JP, Kitchen PR. Changes in the investigation and 
management of primary operable breast cancer in Victoria. Med J Aust 1994;161:110-111, 
114, 118 passim.
19. Luke C, Chapman P, Priest K, Roder D. Use of radiotherapy in the primary treatment of 
cancer in South Australia. Australas Radiol 2003;47:161-167.
20. NSW radiotherapy management information system report 2000. Sydney: New South Wales 
Health Department, 2001. Statewise Services Development Branch 2001.
21. Manders K, van de Poll-Franse LV, Creemers GJ, Vreugdenhil G, van der Sangen MJ, 
Nieuwenhuijzen GA, et  al. Clinical management of women with metastatic breast cancer: a 
descriptive study according to age group. BMC Cancer 2006;6:179.
Cohort of  patients with breast cancer   85
22. Vulto AJ, Lemmens VE, Louwman MW, Janssen-Heijnen ML, Poortmans PH, Lybeert ML, 
et al. The influence of age and comorbidity on receiving radiotherapy as part of primary 
treatment for cancer in South Netherlands, 1995 to 2002. Cancer 2006;106:2734-2742.
23. Louwman WJ, Janssen-Heijnen ML, Houterman S, Voogd AC, van der Sangen MJ, 
Nieuwenhuijzen GA, et al. Less extensive treatment and inferior prognosis for breast cancer 
patient with comorbidity: a population-based study. Eur J Cancer 2005;41:779-785.
24. Voti L, Richardson LC, Reis I, Fleming LE, Mackinnon J, Coebergh JW. The effect of race/
ethnicity and insurance in the administration of standard therapy for local breast  cancer in 
Florida. Breast Cancer Res Treat 2006;95:89-95.
25. MinisterieVWS www.minvws.nl/dossiers/>zorgverzekering/onverzekerden/default.asp 2007.
26. Oncoline www.oncoline.nl. 2006.
27. Bijker N, Meijnen P, Peterse JL, Bogaerts J, Van Hoorebeeck I, Julien JP, et al. Breast-
conserving treatment with or without radiotherapy in ductal carcinoma-in-situ: ten-year 
results of European Organisation for Research and Treatment of Cancer randomized phase 
III trial 10853--a study by the EORTC Breast Cancer Cooperative Group and EORTC 
Radiotherapy Group. J Clin Oncol 2006;24:3381-3387.
28. IKCnet www.ikcnet.nl. 2006.
29. Gao X, Fisher SG, Emami B. Risk of second primary cancer in the contralateral breast in 
women treated for early-stage breast  cancer: a population-based study. Int J Radiat Oncol Biol 
Phys 2003;56:1038-1045.
30. Vulto JC, Louwman WJ, Poortmans PM, Coebergh JW. Hospital variation in referral for 
primary radiotherapy in South Netherlands, 1988-1999. Eur J Cancer 2005;41:2722-2727.
31. Siesling S, van de Poll-Franse LV, Jobsen JJ, Repelaer van Driel OJ, Voogd AC. [Trends and 
variation in breast conserving surgery in the southeast  and east of the Netherlands over the 
period 1990-2002]. Ned Tijdschr Geneeskd 2005;149:1941-1946.
32. Coleman RE, Rubens RD. The clinical course of bone metastases from breast cancer. Br J 
Cancer 1987;55:61-66.
33. Tubiana-Hulin M. Incidence, prevalence and distribution of bone metastases. Bone  1991;12 
Suppl 1:S9-10.
34. Nielsen OS, Munro AJ, Tannock IF. Bone metastases: pathophysiology and management 
policy. J Clin Oncol 1991;9:509-524.
35. van der Linden YM, Steenland E, van Houwelingen HC, Post WJ, Oei B, Marijnen CA, et al. 
Patients with a favourable prognosis are equally palliated with single and multiple fraction 
radiotherapy: results on survival in the Dutch Bone Metastasis Study. Radiother Oncol 
2006;78:245-253.
36. Rades D, Veninga T, Stalpers LJ, Schulte R, Hoskin PJ, Poortmans P, et  al. Prognostic factors 
predicting functional outcomes, recurrence-free survival, and  overall survival after 
radiotherapy for metastatic spinal cord compression in breast cancer patients. Int J Radiat 
Oncol Biol Phys 2006;64:182-188.
37. Lin NU, Bellon JR, Winer EP. CNS metastases in breast cancer. J Clin Oncol 
2004;22:3608-3617.
38. van der Sangen MJ, van de Poll-Franse LV, Roumen RM, Rutten HJ, Coebergh JW, 
Vreugdenhil G, et al. The prognosis of patients with local recurrence more than five years 
after breast conservation therapy for invasive breast carcinoma. Eur J Surg Oncol 
2006;32:34-38.
39. van Tienhoven G, Voogd AC, Peterse JL, Nielsen M, Andersen KW, Mignolet F, et al. 
Prognosis after treatment for loco-regional recurrence after mastectomy or breast conserving 
therapy in  two randomised trials (EORTC 10801 and DBCG-82TM). EORTC Breast Cancer 
Cooperative Group and the Danish Breast Cancer Cooperative Group. Eur J Cancer 
1999;35:32-38.
40. Holzel D, Engel J, Schmidt M, Sauer H. [A model for primary and secondary metastasis in 
breast cancer and the clinical consequences]. Strahlenther Onkol 2001;177:10-24.
41. Chung CT, Carlson RW. Goals and objectives in the management of metastatic breast cancer. 
Oncologist 2003;8:514-520.
86  Chapter 3.1
42. Solomayer EF, Diel IJ, Meyberg GC, Gollan C, Bastert G. Metastatic breast cancer: clinical 
course, prognosis and therapy related to the first site of metastasis. Breast Cancer Res Treat 
2000;59:271-278.
Cohort of  patients with breast cancer   87

3.2
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Abstract
Aims
To study, in a population-based setting, the use of delayed radiotherapy (RT) in a cohort 
of  2008 unselected rectal cancer patients diagnosed between 1996-2000.
Patients and Methods 
Radiation within 6 months of diagnosis was considered part of the primary treatment 
(PRT). RT given 6 months or later after diagnosis or after PRT was considered as delayed or 
secondary RT (SRT). Number, percentage and cumulative proportion of patients receiving 
SRT were calculated. The odds for receiving SRT (total and for recurrent rectal cancer only) 
were studied by logistic regression analysis, taking into account age, gender, co-morbidity, 
socio-economic status, stage, prior PRT and RT department (2 departments, each serving 
general hospitals only).
Results
Forty-six percent of all newly diagnosed patients received RT. Ten percent (n=203) 
received at least once SRT, either after PRT or as first RT, of which 96 patients for a relapsed 
rectal tumour (31 after PRT on the rectal tumour, 65 as a first radiation treatment). In a 
multivariate analysis of patients with rectal recurrence secondary pelvic irradiation was less 
often given after primary irradiation (OR=0.7, 95%CI=0.4-1.1). Patients with a stage III 
significantly more often received SRT on a recurrence (OR=2.5, 95%CI=1.4-4.5). Generally, 
patients in the eastern department received more often PRT and less often SRT for 
recurrence (OR=0.5, 95%CI=0.3-0.8).
Conclusions
 Five percent of all patients with rectal cancer received SRT on a recurrent tumour, with a 
large variation between the two RT departments in the region.
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Introduction
The incidence of rectal cancer in the Netherlands was 26 per 100,000 for men and 13 per 
100,000 for women in 2002. Radiotherapy (RT), pre- and postoperative or for palliation, plays 
an important role, especially since the results of the Total Mesorectal Excision study were 
published.1, 2 Of all newly diagnosed cancer patients about 50% are generally assumed to 
receive radiotherapy during the course of their disease.3, 4 Although not derived from 
population-based studies this percentage is nevertheless often used in the process of 
decision-making on required capacity of RT equipment and personnel. The overall 
percentage usually consists of a mixture of immediate or primary RT (PRT) as part of the 
initial treatment and delayed or secondary RT (SRT) in the case of recurrent disease or 
metastasis3, 5 without taking into account whether patients had already received primary RT. 
In a population-based study of patients treated with RT as part of their primary treatment 
about 30% of all cancer patients had received PRT,6, 7 being 43% for patients diagnosed with 
rectal cancer in 1998-2002.6 In our region SRT had already been studied for the total group 
of cancer patients, of whom 40% received RT for the first time as part of the primary 
treatment or for recurrent disease or metastases in 1986 and 1987.8
Recent studies used an evidence-based approach to determine the use of RT as part of 
primary treatment and as part of the treatment of recurrence or metastases. Of all rectal 
cancer patients 61-72% were estimated to receive RT during the course of their illness.9, 10 
Having performed several studies on the use of primary RT we wanted to estimate the 
percentage of patients receiving RT during their illness, which can also be relevant to 
planning purposes.
We studied a region of 2.4 million people with 2 large RT departments and determined 
the proportion of patients with rectal cancer receiving RT as part of their primary treatment 
and as secondary RT. We also explored the influence of  covariates on SRT.
Patients and Methods
Study population
We studied, in a population-based setting, a cohort of patients with rectal cancer, 
diagnosed between 1st January 1996 and 31st December 2000 and followed until 1st January 
2005.  Data were derived from the population-based Eindhoven Cancer Registry (ECR), 
which has recorded data on all patients newly diagnosed with cancer since 1955. The registry 
covers a large part of South Netherlands with approximately 2.4 million inhabitants in 2004. 
It is supported by six Pathology Departments, hospital medical records offices in 10 general 
hospitals and two large RT departments (one in the western (Tilburg) and one in the eastern 
(Eindhoven) part of  the region so that patients never have to travel for more than one hour). 
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Trained registry personnel actively collects data on diagnosis, staging, co-morbidity and 
primary treatment, given or planned within 6 months of diagnosis, from the hospital charts 
after notification of newly diagnosed cases by the regional departments of Pathology, 
Haematology and Radiotherapy as well as the national Registry of Hospital Discharge 
Diagnoses. Socio-economic status (SES) was defined as either low, medium or high based on 
fiscal data on income and the value of the house determined for each postal code in 
residential areas (average: 17 households). Cancer registries in the Netherlands usually cover 
over 95% of all cases, thanks to the infrastructure of and good access to Dutch health care 
facilities, together with the multiple source notification procedures used.11 
Between 1996 and 2000, a total of 2043 patients were diagnosed with invasive rectal 
cancer. Patients with unknown morphology (n=28), malignant melanoma of the rectum 
(n=3), leiomyosarcoma (n=2), or a cytological diagnosis only (n=1) were excluded. We also 
excluded a patient diagnosed with rectal cancer at autopsy, leaving 2008 patients for analysis.
Radiotherapy
In both RT departments, each serving only community hospitals, each course of radiation 
(primary or secondary) is recorded with date of onset, patient characteristics and treatment 
protocol number indicating the kind of radiation treatment given. Data on all patients with 
rectal cancer who received RT between 1st January 1996 and 1st January 2005 at the two RT 
departments were combined with the above-mentioned data from the ECR. 
Radiation given within 6 months of diagnosis was considered as PRT. RT given 6 months 
or later after diagnosis or RT given after a previous course of radiation for rectal cancer was 
considered as delayed or SRT (RT for a recurrent rectal tumour or for metastases). When 
data from the RT institutes were compared with data from the ECR we found that PRT was 
not registered in the ECR in 14 cases. We considered them as part of the PRT group. PRT 
was registered in the ECR for 4 patients who were treated later than 6 months after diagnosis; 
they were considered as part of  the SRT group. 
The RT department in the eastern part of the region is a highest level reference 
department, especially for recurrent tumours. Here intraoperative electron beam radiation 
therapy (IORT) could be given as a supplement to external preoperative RT for fixated or 
locally recurrent rectal cancer.12 The medical records of patients who were registered with the 
treatment protocol for IORT (n=83) were checked. Nineteen of these cases received only 
external RT; IORT was not given because metastases were detected during surgery, the rectal 
tumour appeared to be inoperable, or an area of risk could not be indicated because the 
tumour had been removed completely. In all other cases we considered the combined therapy, 
including IORT, as one treatment (n=43 for primary and n=21 (one patients 2 times) for 
secondary treatment), also when external beam RT was given in the other RT Department 
(n=15). 
The retreat-rate is defined as the number of radiation courses given after the first course 
divided by the number of  all first courses.
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Table 1 - Patient characteristics and multivariate analysis of  patients with rectal cancer diagnosed 
between 1996 and 2000 receiving secondary radiotherapy (RT) in South Netherlands
Patient characteristics Secondary RT Multivariatea
No (n=1805) Yes (n=203) ORb (95%CIc)
Gender
Male 1061 124 1
Female 744 79 0.9 (0.7-1.3)
Age at diagnosis
70 years or younger 979 137 1
70+ years 826 66 0.7 (0.5-0.9)
Number of  concomitant diseases
None 767 106 1
One 516 50 0.8 (0.6-1.2)
2+ 363 33 0.8 (0.5-1.2)
Unknown 159 14 0.7 (0.4-1.4)
Socio-economic status
Low 492 57 1
Middle 672 82 1.0 (0.7-1.4)
High 516 58 0.9 (0.6-1.3)
Institutiond 105 5 0.5 (0.2-1.1)
Unknown 20 1 0.4 (0.1-3.2)
Stage
I 512 28 1
II 446 44 1.8 (1.1-3.0)
III 361 74 3.7 (2.3-5.8)
IV 292 40 2.5 (1.5-4.1)
Unknown 194 17 1.8 (0.9-3.3)
PRTe 
Western region: no 554 56 1
Western region: yes 274 36 1.0 (0.7-1.6)
Eastern region: no 533 53 1.0 (0.6-1.6)
Eastern region: yes 444 58 0.9 (0.6-1.4)
Vital status 1-1-2005
Deceased 937 178
Alive 868 25
aMultivariate analysis: each variable is adjusted for all others, except for vital status
bOR=Odds Ratio
c95%CI=95% Confidence Interval
dInstitution: patients living in an institution (i.e. nursing home)
ePRT=primary radiotherapy
Statistical analysis
Differences in the distribution of determinants of SRT between patients who did or did 
not receive SRT were tested with the chi-square test. We used logistic regression analysis to 
estimate the chance of receiving SRT (for recurrence and metastases, and for recurrence 
alone) adjusting for age, gender, number of concomitant conditions, socio-economic status, 
stage, prior PRT and RT department. 
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We assessed the number of patients receiving SRT, and the number and type of 
secondary treatments (for recurrent or for metastasised disease) these patients received.
The cumulative risk of receiving any RT (PRT or SRT) over time was calculated 
according to the Life Table Method,13 starting on the date of diagnosis and ending on the 
date of start of RT, date of death or 1st January 2005 (median time of follow  up 49 months, 
range 0-107 months), whichever occurred first. The cumulative risk of receiving SRT was 
calculated by means of the same method as follows: follow-up for patients who received PRT 
(n=812) started on the last day of primary RT (according to the definition these patients were 
at risk for SRT after having received PRT); follow-up for patients who received no PRT 
(n=1196, of whom 201 patients died within 6 months after diagnosis) started 6 months after 
diagnosis (by definition  patients without PRT were at risk for SRT 6 months after diagnosis). 
Follow-up of both groups ended on the date of initiating SRT, date of death or 1st January 
2005, whichever occurred first. These 2 groups were compared by means of  the log-rank test.
Table 2 - Patients receiving secondary radiotherapy (SRT) in a cohort of  rectal cancer 
patients diagnosed between 1996 and 2000 according to stage (except stage unknown), 
kind of  SRT and region
Stage SRT Western 
region
Eastern 
region
I and II SRT for LRa after PRTb on primary tumour 6 6
SRT for LR without PRT on primary tumour 22 7
SRT for metastases 13 18
no SRT 456 502
III SRT for LR after PRT on primary tumour 7 5
SRT for LR without PRT on primary tumour 11 10
SRT for metastases 14 27
no SRT 153 208
IV SRT for LR after PRT on primary tumour 3 1
SRT for LR without PRT on primary tumour 8 2
SRT for metastases 5 21
no SRT 120 172
aLR=Local relapse
bPRT=Primary Radiotherapy
Results
In our cohort of 2008 rectal cancer patients diagnosed between 1st January 1996 and 31st 
December 2000, 921 patients received RT (63 of whom underwent IORT, 1 patients 2 times) 
between 1996 and 2005 (median follow-up: 49 months); 718 only PRT, 109 only SRT and 94 
both (table 1). In the eastern region 46% of all patients received PRT, in the western region 
34%. Six percent of all patients received RT twice or more (94 patients who had received 
PRT and 23 patients who had received SRT only). The retreat-rate was 20% (187/921). 
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Secondary radiotherapy
Patients who received SRT were significantly younger and had a higher tumour stage 
(table 1). 
The 203 patients receiving SRT underwent 300 courses, with a range of 1-96 months 
(median 24 months) after primary diagnosis: 197 courses for metastases and 103 courses for 
relapsed rectal tumours in 96 patients (90 patients with 1, 5 with 2 and 1 with 3 SRT courses). 
Thirty-one of these 96 patients received SRT for local recurrence after prior PRT on the 
rectal tumour, 65 patients received SRT for local recurrence as a first radiation treatment, 
with a large difference per RT department (table 2). In a multivariate analysis in which only 
patients with SRT on the rectal recurrence were entered as the dependent variable, the Odds 
for secondary pelvic irradiation after primary irradiation were 0.7 (95%CI=0.4-1.1); patients 
with stage III tumours were more likely to receive SRT for a recurrence (OR=2.5, 
95%CI=1.4-4.5) and patients in the eastern department significantly less often received SRT 
for local relapse (OR=0.5, 95%CI=0.3-0.8).
Figure 1: Cumulative use of secondary radiotherapy for patients who received either primary 
 radiotherapy or not in  a  cohort of rectal cancer patients diagnosed between 1996 and 2000 in 
 South Netherlands. (PTR=primary radiotherapy, SRT=secondary radiotherapy)
 
Patients at risk 
No PRT:     995    803   701    626   526    369    230   123    43 
    PRT:     812    615   517    455   392    280    200   117    58 
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Cumulative use of  radiotherapy
After 106 months of follow up the cumulative use of RT, either PRT or SRT was 50%. 
In figure 1 the cumulative use of SRT is shown separately for patients who either received 
previous PRT or not. The cumulative risk for SRT was 16% at 92 months after start of 
follow  up i.e. after 6 months after diagnosis or after end of primary RT. No significant 
difference was seen between these 2 groups.
Discussion
To our knowledge this is the first population-based study performed to calculate the total 
use of  radiotherapy in rectal cancer.
We studied the percentage of patients receiving RT as part of their primary treatment 
(which has been studied extensively in our region6, 7), but especially RT as a secondary 
treatment in a cohort of rectal cancer patients diagnosed between 1996 and 2000, followed 
until 1st January 2005. In this cohort, 46% of all rectal cancer patients received RT at some 
point in the course of their illness, which percentage is much lower than the evidence-based 
estimations from the U.S., Canada and Australia, but it is higher than the actual use of RT in 
the U.S., Australia and the United Kingdom.9, 10
Secondary radiotherapy
Ten percent of all patients in our cohort received SRT, either after previous PRT or more 
than 6 months after diagnosis without prior PRT. Six percent of the patients received RT two 
or more times. Acquaintance with RT (as part of the primary treatment) did not significantly 
influence the total use of SRT or SRT for a recurrent rectal tumour (table 1). Thirty-four 
percent of  all SRT courses were given on a recurrent rectal tumour.
After conventional surgery the local failure rate among patients with rectal cancer 
amounted to 25-30% without and 10-15% with RT, mostly delivered postoperative.14 The 
local recurrence rate after total mesorectal excision (TME), which was applied increasingly 
during the study period, is 5-15% without and 2-4% with preoperative RT.14, 15 A loco-
regional recurrence of a rectal tumour often leads to major clinical problems including pain, 
fistulae and bleeding. Even after previous RT a relapsed rectal tumour can be irradiated, 
sometimes in combination with resection and IORT, with a long-term local control rate of 
60-70% after 3 years.12, 16-18 We considered the combination of external beam irradiation and 
IORT as one single treatment because it was previously planned as such,12 and thus affects 
the planning capacity because IORT equipment must be ready for use in the operating room. 
Twenty-three percent (n=19) of the planned intraoperative treatments could not be 
performed. 
In the RT department in the eastern part of the region a higher proportion of patients 
had received PRT because it already started with preoperative RT of 5 x 5 Gray during 
1994.19 
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In the other department postoperative RT was largely given for tumours from stage T3 
and/or N1 on, and 5 x 5 Gray was exclusively given to patients treated within the framework 
of the Dutch TME-trial between 1996 and 2000, in which randomisation occurred between 
total mesorectal excision with or without RT.1 The cancer registry-based cohort did not 
contain follow-up data regarding recurrent rectal cancer or metastases. The higher percentage 
of patients irradiated for a recurrent rectal tumour in the western region (table 2), which also 
remained after adjusting, may indicate a higher percentage of relapses which might result 
from the lower use of primary preoperative irradiation in the western region (24% against 
77% in the eastern region). Patients with stage III cancer were more likely to undergo SRT 
for recurrent rectal cancer after adjusting for PRT and region, which indicates a higher 
relapse percentage for patients with a stage III tumour.
Sixty-six percent of all SRT courses were given to patients with metastases. Skeletal 
metastases occur in 6-16% of patients with rectal cancer,20-22 mainly in combination with 
lung, liver or brain metastases. RT relieves pain in the vast majority of patients with skeletal 
metastases, but also often relieves symptoms and may prolong median survival for patients 
with brain metastases.23, 24 
Cumulative use of  radiotherapy
The cumulative risk of receiving RT (PRT or SRT) for our whole cohort amounted to 
50% up to 106 months after date of diagnosis. It is not likely that many patients will still be 
irradiated later. The chance to receive SRT more than 4-5 years after date of diagnosis 
remains small (figure 1). The cumulative risk to receive SRT is almost the same for patients 
with or without PRT. Patients who were known in a RT department were not referred earlier 
or more often than patients who had not been irradiated before.
According to data of the ECR, 65% of all patients with rectal cancer received PRT in 
2004. Following the introduction of preoperative RT (5 x 5 Gray) and TME in the whole 
region in 2001, the rate of locally recurrent rectal cancer is expected to decline, although the 
rate of distant metastases is not likely to be affected by this change of treatment. We estimate 
that a total of approximately 69% of all patients with rectal cancer will receive RT with 
similar indications at some point in the course of their illness, which is comparable with the 
evidence-based estimations mentioned before.9, 10 However, the tendency towards a long 
preoperative chemoradiation regimen of 30 x 1.8 Gray instead of 5 x 5 Gray for patients with 
a tethered tumour located in the lower part of the rectum,25, 26 might lower the local 
recurrence rate further and so decline the need to irradiate on local recurrences. The 
percentage irradiated patients may be affected by this, but the number of radiation sessions 
per patient is likely to increase, which has an impact on the RT capacity. Thus the treatment 
of rectal cancer will remain a dynamic process, influenced by new  evidence, and potential 
changes in clinical view of  the oncological community.
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Conclusion
The cumulative use of RT in our population-based cohort of rectal cancer was 50% and 
varied with time and per RT department. The use of SRT on recurrent rectal tumours 
depended on the difference in primary treatment (i.e. the degree of pre- or postoperative RT) 
between the 2 RT departments in the region. In the department in the eastern region patients 
more often received PRT and less often SRT.
Given that cancer treatment is a dynamic process, population-based studies serve to 
determine the actual use of RT, in order to extrapolate and estimate the future capacity 
needed for radiotherapy. This study may have contributed to a better comprehension of the 
total use of  RT but especially the use of  delayed RT for patients with rectal cancer.
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Chapter 4
Co-morbidity and age

4.1
Influence of  age and co-morbidity on receiving 
radiotherapy as part of  primary treatment of  
cancer in South Netherlands, 1995-2002
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Abstract 
Background
To study the influence of age and co-morbidity on receiving radiotherapy (RT) in primary 
treatment of  cancer.
Methods
In a population-based setting we calculated the proportion of irradiated patients within 6 
months of diagnosis of lung, rectal, breast and prostate cancer and non-Hodgkin’s 
lymphoma (N=33,369) according to age and co-morbidity between 1995 and 2002. We used 
logistic regression analysis to adjust for age, co-morbidity, gender, and stage.
Results 
Patients with localised non-small cell lung cancer (NSCLC) aged 65 years or older or with 
co-morbid conditions received RT alone significantly more often compared to younger 
patients (65-79 years: Odds Ratio (OR)=3.4, 80+: OR=12) or those without co-morbidity (1 
co-morbid condition: OR=2.1, 2+: OR=2.4). This also applied for patients with non-
localised NSCLC aged 65-79 years compared to younger patients (OR=1.4). RT was 
administered significantly less often to elderly with resected rectal cancer (65-79 years: 
OR=0.7, 80+: OR=0.4), with breast cancer after conserving surgery aged 80+ (OR=0.1), and 
with cT1-cT3 N0 M0 prostate cancer aged 80+ (OR=0.1) than to younger patients. Breast 
cancer patients undergoing breast-conserving surgery received significantly less often RT in 
the presence of co-morbidity (1 co-morbid condition: OR=0.6, 2+: OR=0.4). Older patients 
with aggressive non-Hodgkin’s lymphoma received RT as only treatment significantly more 
often compared to younger patients (OR=3.4).
Conclusion
Co-morbidity and age did have influence on receiving RT, although for most tumour 
types age appeared to be a stronger predicting factor. Under-treatment was found for patients 
with breast cancer or rectal cancer. 
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Introduction
Serious co-morbidity is present in more than 50% of cancer patients aged 60 years and 
older.1, 2 The highest prevalence is found for patients with lung, kidney, stomach, bladder and 
prostate cancer (between 50 and 60%). For patients with serious co-morbidity, the standard 
oncological treatment might be altered because of an increased risk of complications or a 
limited life expectancy due to non-oncological reasons. Also, for elderly patients therapy is 
often less aggressive due to fragility or alleged increased toxicity.3 Because elderly patients are 
less easily comparable due to an often unique combination of diseases, it is not clear when a 
modification of treatment would be justified. This is also reflected by the fact that in general 
elderly patients are excluded from clinical trials. It is therefore more complex to choose the 
optimal treatment for elderly patients or for patients with co-morbid conditions. Several 
authors have reported that older patients receive radiotherapy (RT) less often.4-6 Adjuvant RT 
after surgery might be withheld. On the other hand, RT is sometimes a good alternative for 
surgery or chemotherapy (CT), e.g. in the case of  localised prostate cancer. 
We studied the influence of age and co-morbidity on receiving RT in the primary 
treatment of  cancer in South Netherlands in the period 1995-2002.
Table 1 - Classification of  co-morbidity, according to an adapted version of  the
Charlson Co-morbidity Score (1987)9
Previous malignancies (except basal skin carcinoma and carcinoma in situ 
of  the cervix)
Chronic Obstructive Pulmonary Diseases (COPD)
Cardiovascular diseases (myocardial infarction, cardiac 
decompensation, angina pectoris, intermittent claudication,
abdominal aneurysm, peripheral arterial disease)
Cerebrovascular diseases (cerebrovascular accident, hemiplegia)
Hypertension
Diabetes mellitus 
Digestive tract diseases (gastric diseases, Crohn’s disease, ulcerative 
colitis, liver cirrhosis, hepatitis)
Other (connective tissue diseases, severe rheumatoid arthritis, kidney 
diseases, dementia, tuberculosis, chronic infections) 
Methods 
The Eindhoven Cancer Registry, which covers a large part of South Netherlands with 
approximately 2.4 million inhabitants, records data on all patients newly diagnosed with 
cancer since 1955. This population-based registry is supported by six pathology departments, 
hospital medical records offices in 10 general hospitals and two large, but accessible, RT 
departments to which the distance for patients is less than one hour of  travel.
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Registration takes place via the hospital charts 6 to 18 months after diagnosis by trained 
registrars. Recorded are patient characteristics (such as age, gender), tumour characteristics 
(e.g. localisation, morphology (according to the International Classification of Diseases for 
Oncology7) and stage (according to the Tumour-Node-Metastasis (TNM) system 5th 
edition8)) and primary treatment (planned within 6 months of diagnosis). Since 1993 serious 
co-morbidity with prognostic impact has also been recorded via the medical records for all 
patients according to a slightly modified version of the Charlson co-morbidity index.9 Within 
the framework of the cancer registry it was not feasible to register severity of co-morbidity. 
However we only recorded serious co-morbid conditions with possible prognostic impact, 
except for hypertension (table 1). Despite the lack of access to death certificates, the 
infrastructure of and good access to Dutch health care facilities, together with the 
notification procedures used, have resulted in cancer registries with a completeness exceeding 
95%.10
Our study population consisted of 33,369 newly diagnosed cancer patients aged 50 years 
or older with lung (N=8946), colorectal (N=8540, of which 3058 with rectal cancer), breast 
(N=8097), or prostate cancer (N=6326) or non-Hodgkin’s lymphoma (NHL) (N=1460) 
diagnosed between 1995 and 2002, all tumours amenable to RT. 
The prevalence of co-morbidity, according to age and tumour type, was based on data 
from the Cancer Registry. Completeness and accuracy of the data on co-morbidity were 
validated in random samples of different tumour sites (internal reports). Co-morbidity was 
scored correctly in 80-90% of patients. However, there was some under-registration, mainly 
of cardiovascular diseases. Therefore, the real effects of co-morbidity are possibly stronger 
than those presented in this study. For each tumour type the proportion that received RT 
(including adjuvant RT) and the proportion receiving other therapies such as surgery, CT, 
hormonal therapy, ‘other treatments’ and no therapy, were computed according to age and 
the number of co-morbid conditions (0, 1 and 2 or more). ‘Other treatments’ included: 
treatment for metastases (if applicable), hormonal only (breast), immune therapy, therapy not 
otherwise specified, laser therapy, photodynamic therapy (lung), RT alone (rectal), high-dose 
CT before stem cell therapy (breast, NHL), bone marrow  transplantation (breast, NHL), 
peripheral stem cell therapy (breast, NHL), transurethral tumour resection (prostate) or 
splenectomy (NHL). Patients with lung cancer were divided into patients with non-small cell 
lung cancer (NSCLC) stage I (T1-T2 N0/X M0/X) and II (T1-2 N1 M0/X or T3 N0/X 
M0/X), NSCLC stage III (T1-2 N2 M0/X, T3 N1-2 M0/X, any T N3 M0/X or T4 any N 
M0/X) and limited (confined to one hemithorax, including hilar ipsilateral and contralateral 
mediastinal and supraclavicular lymph nodes) small cell lung cancer (SCLC). Patients with 
NSCLC stage IV (any T any N M1) and extensive (any disease beyond limited) SCLC were 
excluded. Patients with NHL were subdivided into indolent versus aggressive lymphoma 
according to the REAL classification by recoding the registry data, which were originally 
recorded according to the Working Formulation.11 Age groups were 50-64, 65-79 and 80 
years or older for rectal, lung, breast and prostate cancer, and 50-69 and 70 years or older for 
NHL because of  the small numbers of  patients. 
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Differences between age groups were tested with the chi-square test. Logistic regression 
analysis to determine the independent effects of age, co-morbidity, gender, stage and grade 
(for breast and prostate cancer) on receiving RT or RT and CT was applied to subgroups of 
the following tumour types: lung cancer (stage I  and II NSCLC combined, stage III NSCLC 
and limited SCLC), rectal cancer (stage I-III (any T any N M0), resected), breast cancer (after 
breast-conserving surgery), prostate cancer (cT1-cT3 N0 M0) and aggressive and indolent 
NHL.
Figure 1:  Primary treatment of lung cancer in South Netherlands, 1995-2002, according to age and 
 concomitant diseases. RT = radiotherapy, CT = chemotherapy, S = surgery
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Results
The prevalence of co-morbidity increased with age (p<0.0001). The lowest prevalence 
was found for patients with breast cancer, the highest for patients with lung cancer 
(p<0.0001) (table 2).
Figure 2:  Primary treatment of rectal (stage I-III), breast and prostate cancer in South Netherlands, 
 1995-2002, according to age and concomitant diseases. RT = radiotherapy, ST = systemic 
 therapy, S = surgery
A higher proportion of elderly patients (65+) with lung cancer received RT as single 
therapy (figure 1). For patients with stage I and II NSCLC aged 80 years or older RT was the 
most frequently used treatment modality, in contrast to surgery for younger patients. 
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Eighty-four percent of the patients with other/no therapy did not get oncological 
treatment. Younger patients with stage III  NSCLC received CT with or without RT more 
often, while patients aged 80 years or older received only RT or other/no therapy. Of all 
patients with other/no therapy 67% received no treatment. Patients aged 80 or older with 
limited SCLC received RT alone more often instead of a combination of CT and RT. Ninety-
six percent in the category other/no therapy were not treated. The logistic regression analysis 
showed that higher age (65+) was an independent factor for RT as a single therapy for each 
tumour type, except for patients aged 80 years or older with NSCLC stage III (table 3).
In contrast, elderly patients with rectal cancer stage I-III, breast cancer or prostate cancer 
received RT less often (figure 2). Although 60% of the patients with rectal cancer aged 80 or 
older underwent surgery, adjuvant RT was often withheld. Fifty-four percent of the patients 
with other/no treatment were not treated. Patients with stage I-III rectal cancer received pre- 
or postoperative RT less often if  they were 65 years or older (table 3). 
Elderly patients with breast cancer underwent surgery less often than younger patients, and 
after surgery older patients received RT less often. Twenty percent of all patients with other/
no therapy were not treated, 80% received mostly hormonal therapy (figure 2). After breast-
conserving surgery patients aged 80 or older received RT significantly less often (Odds Ratio 
= 0.1, 95% Confidence Interval = 0.1-0.2) (table 3). 
Patients aged 80 years or older with prostate cancer seldom received RT. Most patients in 
this group received hormonal or other/no (of  which 88% no treatment) therapy (table 3).
Patients aged 70 or older with aggressive NHL received RT more often as a single therapy 
compared to those younger than 70 years, but received CT combined with RT less often 
(table 3). Sixty-one percent of the patients with other/no therapy were not treated (figure 3). 
No difference was seen between patients younger than 70 years and those aged 70 or older 
with indolent NHL who received only RT (figure 3) or CT combined with RT (table 3). 
Seventy-nine percent of  the patients with other/no therapy received no treatment.
Patients with stage I and II NSCLC suffering from concomitant diseases received RT as 
single therapy significantly more often (table 3). 
The number of co-morbid conditions did not significantly influence the proportion 
receiving RT among patients with resected rectal cancer stage I-III. 
For patients with breast  cancer treated with breast-conserving surgery the chance of 
receiving adjuvant RT was significantly lower when 1 or more concomitant diseases were 
present (table 3).
According to regression analysis the chance of receiving RT for patients with cT1-cT3 
N0 M0 prostate cancer was not significantly different for patients with or without concomitant 
diseases. 
Patients with aggressive NHL with concomitant diseases received RT in combination with 
CT less often (table 3). 
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Table 3. - Chance to receive primary radiotherapy according to age and concomitant diseases in South Netherlands, 
1995-2002
Tumour type Age
(years)
OR* 95%CI p-value Number of
concomitant 
diseases
OR¶ 95%CI p-value
NSCLC, stage I and II, only 50-64 1 0 1
RT 65-79 3.4 2.3-4.8 <0.0001 1 2.1 1.4-3.0 0.0003
≥80 12 7.4-19.7 <0.0001 2+ 2.4 1.6-3.5 <0.0001
NSCLC, stage III, only RT 50-64 1 0 1
65-79 1.4 1.1-1.7 0.003 1 1.2 1.0-1.5 0.07
≥80 1.1 0.7-1.6 0.8 2+ 1.2 1.0-1.5 0.11
Limited SCLC, RT after CT 50-64 1 0 1
65-79 0.7 0.5-1.1 0.08 1+ 0.9 0.6-1.3 0.7
≥80 0.4 0.1-1.7 0.4
Limited SCLC, only RT 50-64 1 0 1
65-79 6 1.4-28.7 0.02 1+ 1.1 0.4-3.4 0.6
≥80 17 3.0-118.6 0.002
Rectal cancer stage I-III, 50-64 1 0 1
RT after surgery 65-79 0.7 0.5-0.8 0.0004 1 1 0.8-1.3 0.9
≥80 0.4 0.3-0.6 <0.0001 2+ 0.9 0.7-1.1 0.2
Breast cancer, RT after 50-64 1 0 1
breast-conserving surgery 65-79 0.9 0.6-1.3 0.5 1 0.6 0.4-0.8 0.0002
≥80 0.1 0.1-0.2 <0.0001 2+ 0.4 0.3-0.7 <0.0001
Prostate cancer 50-64 1 0 1
cT1-cT3, N0, M0, only RT 65-79 1.1 0.9-1.3 0.3 1 1.1 0.9-1.2 0.5
≥80 0.1 0.1-0.2 <0.0001 2+ 1.1 0.9-1.3 0.4
Non-Hodgkin's lymphoma <70 1 0 1
aggressive, only RT ≥70 3.4 1.3-5.9 <0.0001 1+ 0.9 0.8-1.1 0.3
Non-Hodgkin's lymphoma <70 1 0 1
aggressive, CT and RT ≥70 0.5 0.4-0.8 0.002 1+ 0.6 0.5-0.8 0.02
Non-Hodgkin's lymphoma <70 1 0 1
indolent, only RT ≥70 1.1 0.6-2.0 0.9 1+ 0.8 0.7-1.0 0.08
Non-Hodgkin's lymphoma <70 1 0 1
indolent, CT and RT ≥70 0.6 0.3-2.0 0.3 1+ 1.9 0.9-4.3 0.2
OR=odds ratio, 95%CI=95% confidence interval, NSCLC=non-small cell lung cancer, SCLC=small cell lung 
cancer RT=radiotherapy, CT=chemotherapy, cT1-cT3=clinical tumour classification
*adjusted for co-morbidity, gender and stage
¶adjusted for age, gender and stage
Discussion
In this study we found that older age was a stronger factor for receiving RT than the 
presence of co-morbid conditions. With increasing age and/or the presence of concomitant 
diseases RT substituted other more aggressive therapies (lung cancer and NHL), but adjuvant 
RT was withheld more often from older patients with tumours for which surgery is 
recommended (rectal and breast cancer). 
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The higher prevalence of co-morbidity among older cancer patients was not unexpected 
(table 2) and might even be underestimated due to an ascertainment bias. In general, younger 
patients underwent surgery or CT more often. Therefore, the prevalence of co-morbidity 
scored by the treating physician might be higher among younger patients, due to the 
screening examinations required before surgical or systemic treatment.2, 12 
Co-morbid conditions may complicate radiation treatment due to a higher range of late 
toxicity.13 Because of the higher frequency of co-morbidity among the elderly, being old 
tends to be confused with being chronically ill. Also the general attitude of doctors is likely to 
be influenced by the belief that tolerance for treatment might be compromised among older 
patients or that the course of cancer might be less aggressive.14 However RT can be highly 
effective for many cancer types and is well tolerated by even very old patients (80+).15-17 On 
the other hand: for elderly patients there may be several other reasons why they should not 
endure RT, such as the distance to the RT department and the sometimes protracted RT 
course. Frailty, functional disability, social support, psychological or economical factors and 
the patient’s or family preference can also influence treatment decisions.18 So maybe it is not 
abnormal for older patients to receive therapies other than the standard therapy.
Older patients with NSCLC stage I and II are often high risk operative candidates 
because of poor cardiac or pulmonary condition. For such patients RT with a curative intent 
can and should be offered as an alternative to surgery.19, 20 Our study is in agreement with this 
treatment policy. A high proportion of elderly patients with NSCLC stage III received no or 
only supportive treatment,21 although even high-dose radiation therapy is well tolerated by 
the elderly.22-24 Elderly patients and patients with co-morbid conditions usually received RT as 
a single therapy, while younger patients underwent CT, either with or without RT, more often. 
In a retrospective study from Canada it was also found that older patients and patients with 
increased co-morbidity with limited SCLC were less likely to receive a combination of CT and 
RT.25
Resection of the tumour is the recommended curative treatment for rectal cancer. 
Randomised trials show  an improvement in local control with postoperative or preoperative 
RT.26, 27 Also for older patients treatment decisions should be based on the available data.28 In 
our study older patients were treated with a combination of surgery and RT less often, as in 
other population-based studies.29-32 We found no influence of co-morbidity on the use of 
adjuvant RT for patients with a resected rectal tumour, stage I-III. On the other hand, some 
studies described a slight negative influence,29-31 but the populations studied were not the 
same with regard to stage. In an in-depth study of 455 randomly selected rectal cancer 
patients stage I-III from our study population, a higher complication rate was found for 
patients aged 70 years and older, patients with co-morbidity and patients treated with the 
combination of  surgery and RT.33
The low  percentage of RT among older breast cancer patients or patients with co-morbid 
conditions can partly be explained by withholding adjuvant RT after breast-conserving 
surgery, as reported elsewhere.34-37
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However, the local failure rate increases with time of follow  up for (also elderly) patients 
who have undergone a lumpectomy or segmental resection only, in contrast to those who 
were also irradiated.38, 39
Figure 3: Primary treatment of non-Hodgkin’s lymphoma in South Netherlands, 1995-2002, according 
 to age and concomitant diseases. RT = radiotherapy, CT = chemotherapy
A retrospective analysis of elderly women treated with breast-conserving surgery from 
Pennsylvania (USA) showed that breast carcinomas were not indolent and should be treated 
optimally.40 In 2 randomised prospective trials in older patients RT plus tamoxifen 
significantly reduced the risk of  locoregional recurrence, compared to tamoxifen alone.41, 42 
Another explanation for the low  proportion of RT may be more mastectomies without 
RT among elderly patients, in discordance with the guidelines.12, 43, 44 Women in British 
Columbia (Canada) of 70 years or older had a similar or higher chance of recurrence after 
mastectomy without RT compared to younger women.45 In our study we also found a rather 
high proportion of other treatments or even no therapy for elderly patients. A case control 
study by the Geneva cancer registry reported that nearly 50% of women aged 80 years or 
older received suboptimal treatment.46 A higher RT-related complication rate was not found 
for elderly patients in a descriptive study from Texas (USA).47 On the contrary, complications 
following RT were more prevalent among patients younger than 70 years in a randomly 
sampled selection of  527 patients from our study population.12 
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Other authors also found that older patients with prostate cancer received RT less often.48 
Potentially curative therapy (surgery or RT) might lead to significant gains in health outcomes 
for men up to at least 75 or 80 years with moderately or poorly differentiated localised 
prostate cancer.49 
U.S. national surveys of prostate cancer showed similar treatment outcomes after RT for 
patients aged younger than 70 and those aged 70 or older.50 In a prospective study from 
Mississippi (USA) it was found that patients undergoing radical prostatectomy had 
significantly less co-morbidity than those undergoing RT.51 We found no significant influence 
of  co-morbidity on the chance to receive RT. 
A combination of (reduced dose) chemotherapy and involved field radiation therapy for 
stage I and II aggressive NHL was found to be safe, highly effective and potentially curative 
for the elderly,52-54 with or without concomitant diseases.55 In our study elderly patients 
received RT alone more often, very likely due to the fact that RT offers a good alternative for 
these patients.56
The treatment of patients with early stage indolent follicular lymphoma is local RT, for 
patients with advanced stage CT or watchful waiting (low-burden disease).57 We found no 
influence of  co-morbidity or age (table 3). 
Older age appeared in our study to be a stronger factor affecting the receipt of RT than 
the presence of co-morbidity. For elderly patients or patients with co-morbid conditions RT 
was substituted for more aggressive, surgical or systemic, therapy (lung cancer and NHL). 
Adjuvant RT was often withheld before or after surgery (rectal and breast cancer), which may 
lead to higher recurrence rates for which the time to develop seems long enough with an 
average life expectancy of 15 respectively 8.5 years for a 70 or 80 year old Dutch woman and 
12, respectively 6.5 years for a man of  the same age according to Statistics Netherlands.58 
So, in principle, adjuvant radiotherapy should still be offered to elderly patients with 
breast or rectal cancer, unless the benefits become too small by short life-expectancy or 
serious complications can be expected. This pertains to patients after breast-conserving 
surgery,59 after mastectomy with high grade disease and in resectable rectal cancer patients 
stage II and III.27, 28 
Although for men aged 80+ with prostate cancer a ‘wait and see’ policy seems 
appropriate for asymptomatic and low-risk tumours, other patients should receive curative 
radiotherapy or hormonal therapy.
Older patients with NSCLC stage I or II should also receive surgery, after careful 
selection, whereby curative RT can be an alternative60 in case of a high surgical risk. Patients 
with NSCLC stage III with a good performance score can be treated optimally by a 
combination of CT and RT. RT alone is an alternative for patients who are at a high risk of 
CT-related complications. The rule should thus be to follow guidelines and standards unless.  
To learn more about treatment outcome and complications in older patients or patients 
with serious co-morbid conditions, prospective studies are needed, and the reason for 
exclusion should be reported as well. 
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The potential harm of withholding RT from these patients with respect to recurrences, 
survival or quality of  life can also be studied in existing databases.
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4.2
Should radiotherapy be avoided or delivered 
differently in elderly patients 
with rectal cancer?
H. Martijn, J.C.M. Vulto
European Journal of  Cancer 2007; 43: 2301-2306
Abstract
Purpose is to give an overview  of treatment possibilities of rectal cancer over time, but 
also of the real management of rectal cancer especially in relation to age. From literature 
search representative randomised studies on patients with resectable rectal cancer, comparing 
only surgery, post- and preoperative radiotherapy with or without chemotherapy, are 
reviewed. We also reviewed the literature regarding radiotherapy for rectal cancer described in 
population-based studies.
The overview of the trials showed that preoperative radiotherapy improves local control 
in relation to no or postoperative radiotherapy. Adding chemotherapy did not significantly 
improve survival. No relations were seen between age and complications. All population-
based studies showed that increasing age is associated with less (neo)adjuvant treatment.
To avoid local recurrence, the best possible treatment, being preoperative RT, should be 
given to all patients with resectable rectal cancer, irrespective of  age.
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Introduction
In literature there is no clear definition of ‘elderly’ patients. It is however important to 
realize that 80% of all patients with rectal cancer is over the age of 60 years, 50% over the 
age of 70 years and 20% over the age of 80 years. The only treatment modality in rectal 
cancer for cure is radical (pathological negative tumour margins) surgery. The aim of 
(neo)adjuvant treatment is the reduction of local recurrences and the improvement of 
survival. A number of trials assessed the use of either pre- or postoperative radiotherapy 
(RT). Preoperative RT has the advantage of intact anatomy (vasculature) and good 
oxygenation of the tumour cells. Well oxygenated tumour cells are more susceptible for 
irradiation than relative hypoxic cells. Depending on whether a short (e.g. 5 x 5 Gray (Gy)) or 
long irradiation course is given, devitalisation or downsizing/downstaging of the tumour can 
occur. Disadvantages of preoperative RT are that all tumours are irradiated and thus over-
treatment may occur for low-staged tumours. Furthermore in case of a long course of 
preoperative irradiation exact pathological staging is not possible anymore. 
The main advantage of postoperative RT is the selection of patients who may benefit of 
adjuvant treatment on the basis of pathological tumour staging, thus avoiding over-treatment. 
Disadvantages of postoperative RT are the relative hypoxia in the operated area making 
tumour cells less susceptible for irradiation and the small bowel that will be in the irradiation 
fields causing acute and late toxicity.
Although survival is the most important endpoint of any cancer treatment, especially in 
rectal cancer the avoidance of a local recurrence, causing a very negative impact on the 
quality of life, is of utmost importance. Meta-analyses1, 2 show  that postoperative RT has no 
impact on survival while preoperative RT is reported to have a significant, be it modest, 
positive effect. Both post- and preoperative RT reduce the local recurrence rate significantly, 
preoperative RT being more effective than postoperative RT. We give an overview of the 
treatment possibilities of rectal cancer over time. However, since population-based studies 
provide insight in the real management of patients with rectal cancer especially in relation to 
age, this issue will be addressed separately. 
Methods
In preparation of the national Dutch guidelines for peri-operative RT for rectal cancer, an 
extensive literature research was performed in (inter)national guideline databases, websites of 
oncology societies, Medline, Embase etc., for reviews, controlled randomised trials etc. in 
order to establish the role of peri-operative RT with or without chemotherapy (CT) for 
today’s clinical practice. From these results a representative number of reviews and trials over 
the last two decades is shown to highlight the evolution to the present status of peri-
operative RT. 
We also reviewed the literature regarding RT for rectal cancer described in population-
based studies. For this a computerised search of the literature was performed in Pubmed with 
the terms population-based, radiotherapy and rectal neoplasm. 
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The reference lists of all identified publications were checked to retrieve other relevant 
publications, which were not identified by means of the computerised search. With the above 
mentioned search we identified 22 publications, of which hard copies were obtained. Studies 
were included if they described, in a population-based setting, RT use or RT use in 
combination with CT in relation to age. We limited our search to English, German and 
Dutch language studies. 
Results
The selected trials are described hereafter in chronological order and are summarised in 
table 1. Four of  these trials used no age-limitation during the randomisation. 
Two Scandinavian studies, the Stockholm study3 and SRCT study,4-6 comparing surgery 
versus surgery and a short course of preoperative RT (5 x 5 Gy in 1 week), showed a 
significant reduction of the local recurrence rates in favour of the irradiated patients. Due to 
the large irradiation fields (up to L2) and the irradiation techniques (2 opposing fields) there 
was an 8% postoperative mortality rate in the irradiated group in the Stockholm trial. This 
mortality excess disappeared when irradiation was limited to the small pelvis and multiple 
field technique was used as in the SRCT trial. Cancer specific survival was significantly 
improved in both trials. Perineal wound healing problems were seen significantly more in the 
irradiated group especially when the perineum was included in the irradiation fields and an 
abdominal perineal resection had been performed. Another Scandinavian  study,7, 8 the only 
one in the world until now  comparing a short course of preoperative RT with postoperative 
RT, showed a significant reduction in local recurrence rate in favour of the preoperative short 
course; survival was not significantly different. The patients in the preoperative irradiated 
group had significantly more perineal wound healing problems (acute toxicity). Small bowel 
obstructions as well as grade 3 toxicity occurred more often in the postoperative irradiated 
group (late toxicity). Noteworthy was the fact that 50% of the patients could not start their 
postoperative treatment within 6 weeks of  operation. 
In 1991 Krook and colleagues9 published the results of a study comparing postoperative 
RT alone with postoperative RT and CT. Local recurrence and distant metastases rates were 
significantly reduced in the combined modality arm; survival was significantly improved in 
the combined modality arm. Toxicity was comparable between both arms. The Dutch TME 
trial10-15 comparing total mesorectal excision (TME) versus a short course of preoperative RT 
(5 x 5 Gy in 1 week) followed by TME within one week, showed a significantly lower 5-year 
local recurrence rate for the irradiation arm. Survival was the same. Perineal wound healing 
disturbances (acute toxicity) and bowel dysfunction (late toxicity) were seen significantly more 
in the irradiated group. Sauer and colleagues16 published in 2004 the results of a German 
study comparing preoperative CT-RT versus postoperative CT-RT. The local recurrence rate 
was lower for patients treated preoperative with CT-RT; survival was the same. Both acute 
and late toxicity were significantly increased in the postoperative treated group. 
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Furthermore ± 50% of the patients treated postoperative did not receive full course 
irradiation or CT. The EORTC 22921 study,17 comparing long course preoperative RT versus 
preoperative CT-RT versus preoperative RT followed by postoperative CT versus 
preoperative CT-RT followed by postoperative CT, described a significant difference in local 
recurrence rates in favour of the CT-arms; survival was the same. Similar results were 
reported from the French FFCD 9203 study18 comparing preoperative RT versus 
preoperative CT-RT, both arms followed by adjuvant CT. Bujko and colleagues reported in a 
randomised trial comparing preoperative short-course RT with preoperative conventionally 
fractionated CT-RT no differences in survival, local control nor late toxicity.19
In contrast with clinical studies, population-based studies are the best way to assess the 
management of a disease in daily practice. We found 10 population-based studies (described 
below, summarised in table 2), all published after 1999, describing the management of 
patients with rectal cancer in relation to age. Most studies examined the relationship between 
patient characteristics, among which age, and the use of adjuvant (pre- or postoperative) RT 
or RT and CT. However this was not always the only endpoint.
Paszat and colleagues described the use of surgery for rectal cancer and the subsequent 
risk of permanent colostomy. Patients older than 80 years were less often irradiated after 
resection without colostomy in relation to younger patients.20 Schrag and colleagues 
examined the relationship between patient characteristics and the use of RT with and without 
CT among patients aged 65 years or older with stage II and III rectal cancer. The chance to 
receive RT (mostly postoperative) or RT combined with CT was significantly lower for 
patients older than 69 years of age.21 Schroen and colleagues identified patient, hospital and 
surgeon characteristics associated with variation in treatment. The compliance for RT in stage 
II  and III was 73% for patients younger than 60 years of age and only 25% for patients aged 
75 years or older. After adjusting, patients aged 60 years or younger received 9.5 times more 
often a combination of surgery, RT and chemotherapy for stage II and III rectal cancer than 
patients aged 76 or older.22 Dharma-Wardene and colleagues also found that elderly patients 
(≥75 yr) received multimodality therapy less often than younger patients; they also described 
a risk of death 2.35 higher for patients aged 75 or older receiving surgery only with respect to 
elderly patients undergoing surgery plus multimodality therapy.23 In the study of Neugut and 
colleagues an increasing age was associated with a decreased probability of adjuvant 
treatment with RT and CT. Combined RT and CT was associated with improved survival for 
stage III rectal cancer.24 Ayanian and colleagues found a significantly lower chance to receive 
RT for patients older than 75 years of age. The lack of clinical efficacy was cited by 
physicians as the most common reason for not administering radiation therapy to patients 
with rectal cancer, followed by patient refusal and co-morbidity.25 Phelip and colleagues 
described a shift from postoperative RT in 1990 into preoperative RT in 1995, when 72% of 
all irradiated patients received preoperative RT. Patients aged 75 or older were given adjuvant 
RT half  as often as younger patients, and major geographical differences were observed.26, 27
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Table 2 - Population-based studies describing radiotherapy or radiotherapy and chemotherapy for resectable rectal 
cancer in relation to age
Author 
Study 
period
Purpose No. of  
patients
Stage and 
age 
inclusion
Percentage RT Multivariate analyses
Paszat 
et al20
1982-1994
To describe the use of  surgery and RT 
for newly diagnosed rectal cancer 
patients and the subsequent risk of  
permanent colostomy
18695 All stages,  
all ages
1982: 5%,    
1994: 22%
Odds for RT after 
resection without 
colostomy: (ref=60-69) 
70-79=0.6, ≥80=0.2    
(all sign)
Schrag 
et al21
1992-1996
To examine the relationship between 
patient characteristics and the use of  
RT with and without CT among 
patients aged 65 and older with stage II 
and III rectal cancer
1670 II and III,  
>65 years
Total: 57%; 
65-69: 73%, 
70-74: 66%, 
75-79: 52%, 
80-84: 39%,  
≥85: 21%"
Odds for RT: (ref=65-69) 
70-74=0.7,       
75-79=0.4,       
80-84=0.2,          
≥85=0.1 (all sign)
Schroen 
et al22
1994-1996
To assess the use of  surgical procedures 
and adjuvant therapy in the initial 
treatment of  rectal cancer and to 
indentify patient, hospital and surgeon 
characteristics associated with variation 
in treatment
637 All stages,  
all ages
Total: 37%.  
stage I: 14%, 
stage II: 53%, 
stage III: 63%, 
stage IV: 30%
Odds for S, RT, CT in 
stage II and III: 
(ref=≥76) 70-75=4.2, 
60-69=4, <59=9.5        
(all sign)
Dharma-
Wardene 
et al23
1991-1998
To describe relationship between age 
and treatment, to compare risk of  death 
in elderly (≥75 years) receiving optimal 
(S + RT +CT) regimen with those who 
received surgery only, and to compare 
5-year survival for each treatment group
1979, 
random 
sub-
sample 
of  259
All stages,  
all ages
Total: 59% Univariate: elderly (≥75) 
less often multimodality 
treatment (p=0.0001)
Neugut 
et al24
1992-1996
To investigate the use of  treatment with 
CT and RT among patients over 65 
years with surgically resected stage II or 
III rectal cancer
1807 II and III,  
>65 years
Total: 48%. 
65-69: 66%; 
70-74: 55%; 
75-79: 47%; 
80-84: 34%;  
≥85: 17%
Odds for RT+CT: 
(ref=65-69) stage II: 
75-79=0.4, 80-84=0.3, 
≥85=0.07. Stage III: 
70-74=0.4, 75-79=0.25, 
80-84=0.1, ≥85=0.04 (all 
sign,  p-trend=<0.01)
Ayanian 
et al25
1996-1997
To estimate underreporting of  adjuvant 
therapies in routinely collected registry 
data, assess rates of  adjuvant therapy 
and factors associated with use, and 
ascertain why eligible patients were not 
treated
1956 II and III,  
>18 years
<55: 82%,  
55-64: 76%, 
65-74: 68%, 
75-84: 47%,  
≥85: 14%
Odds for RT: (ref=65-74) 
75-84=0.3, ≥85=0.1. 
Odds for RT+CT: 
<55=2.7, 75-84=0.3, 
≥85=0.1 (all sign)
Phelip 
et al27
1995
To determine whether diagnostic and 
therapeutic management practices for 
rectal cancer vary in different 
geographic regions
683 All stages,  
all ages
Total: 47% Odds for RT: (ref=<75) 
≥75=0.47 (sign)
Phelip 
et al26
1990 and 
1995
To evaluate how the results of  a 
consensus conference (1994) were 
taken into account
1990: 
402, 
1995: 
543
All stages,  
all ages
1990: 42%,  
1995: 47%
Odds for preop RT: 
(ref=<75) ≥75=0.67 
(sign)
Baxter 
et al28
1976-2000
To evaluate US trends in adjuvant RT 
over 25-year, timing of  RT and factors 
affecting RT
45000 All stages,  
>18 years
Total: 32%; 
1976: 12%,  
2000: 42%
Odds for RT in stage II 
and III: (ref=>70) 
65-70=3, ≤60=5 (all sign)
Vulto 
et al29
1995-2002
To study the influence of  age (and co-
morbidity) on primary RT
3058 I-III,          
>50 years
Odds for RT: (ref=50-64) 
65-79=0.7, ≥80=0.4    
(all sign)
RT = radiotherapy, CT = chemotherapy, S = surgery, ref  = reference category, sign = significant
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In the USA an increase was seen in adjuvant RT from 1976 to 2000, with a shift into 
preoperative RT from 1996; patients who underwent RT were younger than those who did 
not undergo RT, also in multivariate models.28 Also in our own region we found a 
significantly lower use of  RT for elderly patients.29
Discussion
All population-based studies showed that increasing age is associated with less 
(neo)adjuvant treatment. Also other authors described this phenomenon.30-32
The fear that elderly patients do not tolerate radical pelvic RT as well as young patients is 
not substantiated in the study by Pignon and colleagues;33 they conclude that age per se is not 
a limiting factor. Also doctors’ or patients’ preference, co-morbidity or frailty, socio-economic 
factors or fear for toxicity may play a role. Shahir and colleagues described an almost 2 fold 
higher complication risk within one year after diagnosis for patients who underwent surgery 
and RT, and for patients aged 70 years or older, but no association was made between age 
and RT.34
Increased postoperative mortality, mainly among elderly patients, was described in two 
studies, in which a short course of preoperative RT was given in large irradiated pelvic fields.2, 3, 35 
All other randomised studies we described, used other RT techniques with smaller tissue 
volumes. In these studies no relations were seen between age and complications, so it is 
tempting to believe that a large irradiated volume may be deleterious in the older age group.
At this moment staging (by imaging), preoperative treatment and TME-surgery are 
cornerstones in the treatment of rectal cancer. The choice however between a short 
preoperative RT course or a long preoperative CT-RT course is made difficult by lack of 
exact definitions of ‘early’, ‘mobile’, ‘resectable’ and ‘locally advanced’ rectal cancer. Due to 
the overlap of tumour stages between these groups there is a risk of under- or over-
treatment. We consider T4 tumours and tumours with a margin less than 2 mm to the 
perirectal fascia on MRI as ‘locally advanced’. In recent years, the value of MRI for reliable 
prediction of the circumferential resection margin has been established. In single institution 
studies it was demonstrated that it allows accurate assessment of the circumferential resection 
margin and by that the choice for optimal therapy. A recent publication of the Mercury study 
confirmed the reliability of MRI in a multicenter setting. Therefore, MRI should now  be 
considered as standard of care in the preoperative work-up for rectal cancer patients.36 N2 
tumours can be considered as ‘locally advanced’ also, but the problem is the clinical 
determination of the N2 status. The issue of sphincter-saving surgery after long preoperative 
chemo-radiotherapy has not been solved yet. 
Given the lack of improvement of survival in trials using long course preoperative CT-
RT the question remains whether CT should be added to reduce the local recurrence rate 
considering the results of the short course preoperative RT trials. We believe that, when no 
downsizing/-staging is needed, 5 x 5 Gy followed by TME within one week of completion of 
RT is the treatment of  choice. 
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If the tumour is located more than 10 cm. above the anal verge omission of RT may be 
considered. In case of locally advanced tumours a long course of preoperative CT-RT 
followed by operation approximately 6 weeks later (in order to achieve downsizing/-staging) 
is necessary. Depending on the patient’s status a short course of preoperative RT like 13 x 3 
Gy with operation 6-8 weeks later (Lyon R90-01 trial)37 or even 5 x 5 Gy followed by surgery 
after more than 4 weeks can be considered (Bujko19 or ongoing Stockholm-III trial). As 
pointed out by Rutten and colleagues in this EJC issue38 future studies may focus on delayed 
TME surgery after a short course of preoperative RT, in order to reduce the hazard of 
double trauma by RT and surgery. For more locally advanced tumours the role of local 
excision after preoperative treatment or even chemo-radiotherapy alone and omitting surgery 
in order to reduce the risk of  surgical trauma, may be explored.38, 39
Conclusion
Preoperative (chemo)-radiotherapy improves local control in rectal cancer. No differences 
were seen in toxicity between young and elderly patients when modern RT techniques with 
small tissue volumes are used. To avoid local recurrence, the best possible treatment should 
be given to all patients with resectable rectal cancer, irrespective of age: a short preoperative 
RT course for patients with a primary resectable tumour, a long course of preoperative CT-
RT for patients with locally advanced tumours. Exceptions should be made only for patients 
who are unable to fulfil the combination treatment because of  patients’ condition. 
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Chapter 5
Palliative radiotherapy

5.1
General practitioners and referral for palliative 
radiotherapy: a population-based survey
J.C.M. Vulto, J.M.P. van Bommel, P.M.P. Poortmans, 
M.L.M. Lybeert, W.J. Louwman, J.W.W. Coebergh
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Abstract
Because of the suspicion that the referral rate for palliative radiotherapy (RT) is too low, 
we sent a questionnaire to all general practitioners (GP) to evaluate the knowledge of 
palliative RT among GP’s in the south of the Netherlands. Four hundred and ninety-eight of 
the 1100 questionnaires were analysed. Forty-six percent of the respondents had cared for 
patients referred for palliative RT in the last 2 years. Knowledge about the effects of palliative 
RT on bone metastases and spinal cord compression was good but moderate to poor about 
other palliative indications. Determinants of the actual referral for palliative RT were mainly 
patient-related. GP’s considered their own knowledge to be poor with only 10% reporting 
previous RT education. It is absolutely necessary to inform GP’s about the possibility of 
short series of palliative irradiation in order to improve their information for symptomatic 
cancer patients about all possibilities for palliative treatment.
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Introduction
In the Netherlands general practitioners (GP) provide primary care for an average of 
2350 inhabitants. In general, for more complex and specialised care, GP’s refer their patients 
to second line specialists, who, if necessary, refer to 3rd line specialists such as radiation 
oncologists.
GP’s increasingly provide day-to-day home-bound care for cancer patients who need 
palliation.1 The number of such patients has increased substantially over the last decades 
because of the growing incidence of cancer in the ageing population in the Netherlands2 and 
the trend that people prefer to spend the last phase of their life in their own environment. 
Radiotherapy (RT), especially a short series, is an essential and established modality within 
palliative care, for example for localised symptoms including painful bone metastases, spinal 
cord compression, brain metastases or airway obstruction due to a vena cava superior 
syndrome.3, 4 Samant and colleagues (Ontario-Canada) evaluated the knowledge of GP’s 
about the indications for palliative RT and factors that affect patient referral by means of a 
survey.5 Many GP’s appeared to be unaware of the effectiveness of RT for a variety of 
common palliative situations, and RT referral could be correlated with knowledge about 
indications for palliative RT. 
Earlier studies6, 7 of the pattern of care showed a marked variation in secondary or 
delayed RT for breast and rectal cancer, suggesting differences in the referral of such patients 
with metastases or recurrence, while the higher referral for patients with spinal cord 
compression on Fridays8 illustrated deficiencies in clinical awareness also among GP’s. We 
thus thought it worthwhile to evaluate knowledge of palliative RT and factors which 
influence referral for palliative RT among general practitioners.
Methods
We developed a questionnaire, based on the Canadian survey.5 Because GP’s are often the 
medical care-takers in the last 3 months of the life of cancer patients, we concentrated only 
on palliative RT given in this terminal phase. The questionnaire included the following 
sections: respondent characteristics, number of patients in the palliative-terminal phase and 
number of patients referred for palliative RT, factors influencing referral for palliative RT, 
perception of the effectiveness of palliative and symptomatic RT, former education and 
willingness to learn more about palliative RT. The questionnaire was tested on GP’s attending 
a peer group course on palliative care.9 After a few  adaptations the survey consisted of 23 
questions. The completion time was less than 15 minutes. 
In January 2007 the survey was sent to all GP’s (n=1140) within the area of the 
Comprehensive Cancer Centre South and a small adjacent region in the west, together 
covering about 2.6 million inhabitants. This region is supported by general hospitals only and 
two large radiotherapy departments, one in the western and one in the eastern part of the 
region; most patients live within 30 minutes distance and never have to travel more than one 
hour for RT. 
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Some patients might be referred to a RT Department outside the region, closer to their 
home. The completed surveys were collected and analysed. Forty questionnaires could not be 
delivered because the physician’s address was no longer applicable. The survey response was 
503 out of 1100, but 2 surveys arrived after the results had been processed, yielding a 
response rate of 45.5%. Three questionnaires were not valid because only one or no items 
were filled in. So we had 498 (45.2%) surveys for our analyses. If we assume that in each GP 
Health Centre 2 or 3 GP’s work and only 1 GP returned the survey, then, assuming that all 
GP’s follow the same policy, we could re-calculate the response rate to be between 58.2 and 
71.2%. 
Table 1 - Profile of  the responding general practitioners
Respondents 
(n=498)
All GP’sb in the 
Netherlandsa 
number % %
Gender
Male 375 75.3 65
Female 122 24.5 35
Not reported 1 0.2
Year of  graduation as GPb
1970-79 145 29.1 17
1980-89 184 36.9 36
1990-94 66 13.3 11
1995-99 61 12.2 14
2000-2006 41 8.2 22
Not reported 1 0.2
Type of  practice
Solo 153 30.7 20
Association 190 38.2 30
Health Centre 143 28.7 50
HIDHAc 9 1.8
Not reported 3 0.6
Working days per week
3 days or less 111 22.3 25
4 days 120 24.1 *
Fulltime 265 53.2 *75
Unknown 2 0.4
Distance to RTd Department
< 30 minutes 196 39.4
30 to 60 minutes 281 56.4
> 60 minutes 21 4.2
aNIVEL=Netherlands Institute for health services research10 
bGP= General Practitioner
cHIDHA=GP employed by an independently working GP
dRT= Radiotherapy
*Considered full time by NIVEL  
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Results
The characteristics of the responding GP’s are shown in table 1. The office of ninety-five 
percent of all physicians was located less than one hour from an RT Department, 77% said 
their patients were treated in one of the 2 RT Departments in the region, 23% in RT 
Departments in adjacent regions (Rotterdam, Utrecht, Nijmegen, Heerlen-Maastricht). 
Almost all GP’s who completed the survey (96%) considered themselves to be the most 
important care-giver of terminal patients who received palliation. Most physicians (57%) 
indicated caring for 1-5 terminal patients per year and 31% for 5-10. Forty-seven percent said 
they had ever referred patients directly for palliative RT, 36% of whom more than once in 
the last two years. Fifty percent of the responding physicians referred patients after 
consulting a second-line specialist. 
Figure 1: Proportional distribution of determinants that have a negative influence on the decision by 
 general practitioners to refer a  patient  in the palliative-terminal phase for palliative 
 radiotherapy
The most important negative factors affecting referral for palliative RT were general 
condition, presumed discomfort and wish of the patient. RT-dependent factors, such as 
accessibility of a radiation oncologist, were found to have little influence (figure 1). For one-
third of the respondents, life expectancy did not seem important for referral for palliative RT, 
whereas 42% considered a minimum life expectancy of  6 weeks to be essential.
Most responding physicians considered RT effective for painful bone metastases, spinal 
cord compression, painful local disease, brain metastases and airway obstruction. 
The potential effectiveness for managing haemoptysis and haematuria was not as well 
recognised (figure 2).
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REFERRAL-RELATED 
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Assumption of  lengthening life 
Uncertainty about the benefits 
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PATIENT-RELATED 
Old age of  a patient 
Symptoms of  a patient 
Discomfort for a patient 
Poor functional status of  a patient 
Wish of  a patient 
not important moderate important very important 
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About 40% of the respondents assessed their own knowledge of RT as modest, including 
their knowledge about the application and benefit of short series of palliative RT. Knowledge 
about possible side effects and their management was reported by 56% and 43%, respectively. 
Time since graduation as GP did not seem to affect these figures. However, only 4% of the 
physicians who graduated in the seventies had received education in palliative care, in contrast 
to 78% of those who graduated after 2000. All together, only 10% of all GP’s received 
education in palliative RT, either during their training for GP or post-academically. Ninety-
five percent of  all responding physicians would consider attending courses in palliative RT.
Figure 2: Cancer-related symptoms and appraisal by general practitioners of the effectiveness 
 of  palliative radiotherapy
Discussion
In the south of the Netherlands almost all of the responding general practitioners 
appeared to be actively involved in the care of cancer patients in the terminal phase of their 
disease. 
The profile of the responding GP’s was roughly comparable with the profile of all Dutch 
GP’s, as registered by NIVEL (Netherlands Institute for health services research)10 (table 1), 
with some overrepresentation of older, male physicians working alone and under-
representation of young physicians.11 Some under-representation of GP’s working in a health 
centre seems likely since often only one GP per centre responded.  
Earlier studies reported the presence of five to six terminal cancer patients in a median 
GP practice; 31% of the GP’s in this survey indicated that they cared for a somewhat higher 
number of patients in need of palliation. Furthermore, almost all of them considered 
themselves to be the most important care-giver, while earlier studies reported GP’s to be the 
most important care-giver for only two patients out of  five to six terminal patients.12, 13
According to the radiation oncologist most patients are referred by specialists such as 
surgeons and oncologists, whereas 47% of the responding GP’s indicated that at some time 
they had referred patients directly for palliative RT. 
0% 20% 40% 60% 80% 100% 
Painful bone metastases 
Spinal cord compression 
Painful local process 
Brain metastases 
Airway obstruction 
Haemoptysis 
Haematuria 
effective not effective don't know 
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We assume that the responding GP’s meant that the patients were referred indirectly for 
palliative RT, by specialists to whom the GP referred. Furthermore, while GP’s only have 
about 5 terminal patients per year, they might have a different experience with referral 
patterns than radiation oncologists who see many patients. Moreover there might have been 
some ‘socially desirable’ answers.
Patient-related characteristics such as discomfort and poor condition (but not age) 
affected the decision to refer for palliative RT. Most important, GP’s indicated that they 
reacted to the wish of the patient, partly because they were not sufficiently aware of the 
possibilities of palliative RT to relieve symptoms. This might be a consequence of the low 
percentage who received education in palliative RT. 
Despite the rather low appraisal of their own knowledge about palliative RT, the 
responding GP’s seem well-informed about the effectiveness of symptomatic RT for painful 
bone metastases.14 Furthermore, knowledge about the treatment of spinal cord compression 
seems to be sufficient, which is very important for the chances of restoration of neurological 
function.8, 15 
Almost half of our respondents mentioned a minimal life expectancy of six weeks as a 
parameter for referral for palliative RT, which is in agreement with the average time to 
response after a single fraction for painful bone metastasis, being about three weeks;16 
however 30% indicated that life expectancy was not a criterion.
Conclusion
Most of the respondents considered their own knowledge about (palliative) RT and 
potential side effects as modest, which might have led to fewer referrals for palliative RT for 
cancer patients. Special education in palliative RT and (treatment of) side effects, desired by 
almost all responding GP’s, might give them more insight into the possibilities of palliative 
RT for haematuria, haemoptysis, airway obstruction, brain metastases, painful local processes 
and spinal cord compression as well as more tools to inform the patients properly.
A (desired) side-effect of the questionnaire is likely to be an increased awareness of the 
possibilities of palliative RT among (responding and non-responding) GP‘s and therefore 
more appropriate referral.
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Always on a Friday? 
Time pattern of  referral for 
spinal cord compression
P.M.P. Poortmans, J.C.M. Vulto, E. Raaijmakers
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Abstract
For patients with spinal cord compression, radiotherapy should be initiated as soon as 
possible to optimise the chances for restoration of neurological function. The speed of 
referral in the region of our radiotherapy institution with 9 general hospitals was analysed 
based on a tumour and treatment related registry. From January 1987 to December 1997, 443 
patients were treated. All patients were seen and treated on the day of referral. Significantly 
more referrals took place on Friday, 30%, compared to 12% on Monday, 17% on Tuesday, 
15% on Wednesday, 20% on Thursday, 5% on Saturday and 1% on Sunday (p<0.002). This 
difference was the same for patients who were formerly treated in our institution (n=242) or 
not (n=201). No significant difference was found between different categories of patients 
(p=0.28). These data are discussed with referring physicians to encourage speed of diagnosis 
and referral.
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Introduction
Metastatic disease to the bone often affects the vertebral bodies, with the most affected 
sub-site the lumbar spine while the most common site for spinal cord compression secondary 
to metastatic disease is the thoracic spine.1-3 The underlying primary cancers most frequently 
reported are breast, lung, and prostate.
Pain is the most common presenting symptom of vertebral metastases. Most patients 
presenting with metastatic spinal cord compression have endured back pain for weeks. 
Radicular pain in the arms, in the legs, or across the chest is an important prodromal 
symptom.4 Myelopathy, radiculopathy, or cauda equina syndrome are all possible. A particular 
important sign is loss of proprioception and sphincter function. This is a harbinger of 
serious neurologic damage and is much less likely to recover following any form of 
treatment. Sensory levels, if present, may be numerous segments lower than the level of the 
compression. Paraplegia usually means cord infarction which is irreversible.
The differential diagnosis includes benign neoplasms, herniated intervertebral discs and 
infectious syndromes. Some of the early signs and symptoms can also be caused by other 
metastatic locations such as brain metastases or by tumoural compression of peripheral 
nerves. Especially when a patient with myelopathy or neuropathy does not have associated 
back pain that preceded the neurologic dysfunction, a cause other than metastasis to the 
epidural space must be considered.
Table 1 - Primary tumour sites of  'old' patients, already known at our department and 
'new' patients who come for the first time at our department
 'Old' patients  'New' patients
n % n %
Breast 84 35 14 7
Lung 49 20 33 16
Prostate 48 20 46 23
Renal 10 4 15 8
Stomach/colorectal 10 4 11 6
Unknown primary 7 3 51 25
Myeloma 3 1 12 6
Other 31 13 19 9
Total 242 100 201 100
MRI is the most informative study for the evaluation of the patient with suspected 
metastasis involving the epidural space. The extent of vertebral bony metastasis and the 
number of epidural compressions can be evaluated in one single study.5 MRI demonstrates 
more than one epidural tumour in 20% of the referred patients. Patients who cannot 
undergo a MRI should be offered a myelography, if  necessary complemented with a CT scan.
The standard of practice in past years was to perform an emergency posterior operative 
procedure, followed by postoperative irradiation. 
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Retrospective studies, confirmed by a randomised trial of radiation versus laminectomy 
and posterior decompression of the spinal cord, demonstrated that radiation therapy without 
surgery is as successful as surgery plus irradiation in ambulatory patients and in paretic 
patients who respond to steroids.6-10 An operative procedure including decompression of the 
spinal cord, tumour debulking and stabilisation of the affected vertebrae, can be considered 
for fracture dislocation, since patients with spinal instability, retropulsed bone fragments, or 
complete collapse of the vertebral body with myelopathy rarely benefit from irradiation 
alone. A surgical intervention should be considered also if no histologic diagnosis of cancer 
has been made, in case of rapid progression and serious neurological deficiency, in 
radioresistant tumours and in an earlier irradiated anatomical location.
After diagnosis, a starting dose of 10 to 20 mg of dexamethasone or an equivalent dose 
of another steroid, followed by 12 to 16 mg in 3 to 4 times a day, relieves pain and improves 
neurologic symptoms in most patients.11 Especially if the neurologic deficit has improved 
with steroid therapy, patients are likely to benefit from irradiation. Patients are maintained on 
steroids, and dose tapering occurs gradually after the completion of irradiation. Many 
radiation dose-time relations have been used, without difference in outcome: 20 to 30 Gray in 
5 to 10 fractions in 1 to 2 weeks, given with a simple treatment technique.7, 12-14 
In general, survival is limited after the diagnosis of cord compression with ambulation as 
the most important pre-treatment factor for response and the most important post-treatment 
factor for survival. Patients ambulatory after treatment have a median survival time of 8 to 12 
months, compared to 1 month for non-ambulatory patients.12, 15-20 Other prognostic factors 
are the anatomic location of metastases, functional status and primary tumour histology. The 
medial survival time of patients with favourable tumour types (lymphomas, myelomas, or 
hormone-sensitive malignancies as breast and prostate) was 12 months, whereas for patients 
with unfavourable types it was 4 months.21 An associated vertebral compression fracture of 
more than 50% yielded a poor response.
Since quick and adequate treatment is important for the quality of life, any delay should 
be avoided as much as possible. However, in our institution for radiotherapy, working in close 
collaboration with 9 general hospitals, the opinion existed that these patients did have a delay 
in referral with most referrals on a Friday. Many other radiation oncologists working in other 
institutions, in the Netherlands as well as in other countries, share this feeling. However, this 
time pattern has, to our knowledge, not formerly been studied. The purpose of this study 
was to investigate the referral pattern by retrospectively analysing the first day of radiation 
treatment.
Material and methods
Based on a tumour and treatment-related registry, an analysis of referral for urgent 
radiotherapy for spinal cord compression was retrospectively performed. From January 1987 
to December 1997, 443 patients were treated urgently with a combination of steroids and 
radiotherapy. All patients were seen and started their treatment on the same day on which 
referral took place. 
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Depending on the time period, a total dose of 20 to 30 Gy was given in 5 to 8 fractions 
with the first 3 fractions without a break, thus if  necessary including the weekend. 
‘Old’ patients (n=242) are defined as patients formerly seen and treated at our 
department. We divided ‘new’ patients (n=201) into patients with a known primary tumour 
but not formerly seen in our institution (n=77) and patients in whom no primary tumour was 
known or with spinal cord compression diagnosed within the first month after diagnosis of 
their malignant disease (n=124). 
One-way Anova (Analysis of Variance) and Duncan’s Multiple Range test were performed 
on this data to investigate differences. A two-tailed t-test was used to analyse differences 
between groups. 95% confidence intervals were calculated.22  
Results
Table 1 shows the distribution of the site of the primary tumour for ‘old’ and ‘new’ 
patients. In ‘old’ patients, breast, lung and prostate are the most frequent primary tumours, 
together representing 75% of the referred patients. Unknown primary site, prostate and lung 
are most frequently seen in ‘new’ patients, accounting for a total of 64% of the referred 
patients in this category.
Table 2 - Number of  patients referred on respective days of  the week. No significant difference between patient 
categories was found. A two-tailed t-test was used to analyse differences between groups. Numbers are in absolute 
values
Monday Tuesday Wednesday Thursday Friday Saturday Sunday Total
 'Old' 27 39 36 55 68 14 3 242
 'New', known 12 14 11 11 27 2 0 77
 'New', unknown 12 21 18 23 39 8 3 124
 All 51 74 65 89 134 24 6 443
In table 2 the distribution of referral throughout the days of the week is displayed. For all 
categories of patients, significantly more referrals took place on a Friday as compared to 
other days of the week: 30% versus 12 – 20%. Only few  referrals took place during the 
weekend, respectively 5% on Saturday and only 1% on Sunday. There is no significant 
difference between any combination of the three patient categories (p=0.24 to 0.56). Figure 1 
shows the frequency distribution for all patients together. The difference between Friday and 
the other days of the week is significant (p<0.002) with even a trend of an inclining referral 
from Monday to Friday. Referral during the weekend is very rare.
Discussion
In a study of patients with spinal cord compression in a general hospital, Stark and 
colleagues note that lung cancer was responsible in 33%, breast cancer in 28%, other 
identifiable sites in 25%, and unknown primaries in 14% of  the cases.23 
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In our series, lung cancer was less common (19%), and we identified prostate cancer 
(21%) as the second most common primary tumour site, immediately behind breast cancer 
(22%). Unknown primaries represented a comparable 13%. Neurologic symptoms due to 
spinal metastases occurring as the first evidence of malignant disease was reported by Stark 
in 47% of 131 patients, in contrast to only 28% in our series of patients referred for urgent 
radiotherapy. Our lower rate can be explained by selective referral of patients without a 
known primary tumour for neurosurgery to obtain material for histological diagnosis.
Figure 1:  Percentage of patients referred on respective days plotted as mean with 95% confidence 
 intervals. * Statistically significant  difference from other days of the week (p < 0.002, 
 ANOVA test)
Since the initial neurological function status is one of the most important predictors for 
recovery after treatment, any delay in the diagnostic procedure and the initiation of 
radiotherapy might have a negative impact on the chance of recovery from the neurological 
syndrome. Diagnosis of spinal cord compression should and can be made within hours after 
the moment that a patient presents with signs and symptoms. After clinical neurological 
examination, a MRI has to be made urgently with referral for radiotherapy within 24 hours 
after the moment that the patient came for medical assistance. The first 2 to 3 fractions have 
to be given on consecutive days, thus if  necessary also on Saturday and/or Sunday.
In our series of 443 consecutive patients, significantly more referrals (almost one third) 
took place on a Friday (p<0.002), with only a very low  referral rate during the weekend. 
Theoretically, referral would have to be distributed evenly over all days of the week. Since it is 
not possible to foresee already on Friday referrals of patients with spinal cord compression 
who would present normally during the weekend, a peak on Friday indicates that most 
diagnoses and referrals are made in the second half of the week, indicating a delay in this 
process. 
!
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A number of possible reasons can be imagined for introducing such a delay: the patient 
or his family might postpone seeking medical advice; the family doctor might not be familiar 
with this disease; the specialist whom the patient is referred to might underestimate the signs 
and symptoms and not realise the negative effect of any delay; MRI-facilities are not 
everywhere and anytime easily available and finally, the radiotherapy department might not be 
prepared to treat these patients during all hours of the week. Since most of these possible 
reasons introducing a delay do not differ from one day in the week to another, an important 
aspect of the concentration of referrals on Fridays could be the effect of the weekend to 
come with patients, family and physicians trying to avoid medical problems in those days. In 
part based on this idea, many clinical departments have their ‘large clinical visits’ at the ward 
on Friday. 
The also noted lower referral rate during the weekend can not entirely be explained by a 
patient’s and doctor’s delay during the weekend since this would result in a higher referral rate 
on Monday, which is not the case. It might be interpreted as a supplementary argument that 
the process of  diagnosis and referral takes often several days.
Remarkably, no significant difference in pattern of referral was found between ‘old’ and 
‘new’ patients (p=0.28). This means that in our series neither the medical history of the 
patient nor the fact that a patient had or had not been seen before in our institution, had an 
influence on the speed of  diagnosis and referral.
Because of the negative impact of the delay of treatment on the chance of recovery from 
the neurological syndrome, measures should be taken to avoid this. Our data are discussed 
with referring physicians and have been presented at a scientific meeting of the local 
comprehensive cancer centre in order to encourage speed of diagnosis and referral. Patients 
at risk for spinal cord compression are made aware of the importance of possible 
neurological signs and symptoms to stimulate them to seek early medical advice. Registration 
of  the time pattern of  referral will be continued and reported prospectively. 
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Chapter 6
General discussion

General discussion
Trends
This thesis gives an overview  of the use of radiotherapy from 1988 to 2006 in an 
increasing and ageing population in the south of the Netherlands, a region served only by 
community hospitals and 2 large radiotherapy institutes (with no differences in geographical 
and socio-economical background of the target population) to which travel distances are on 
average 30 minutes with a maximum of one hour for 10% of the target population. We did 
not study the influence of travel time on receiving radiotherapy. Jones and colleagues 
(northern England) found that the likelihood of receiving radiotherapy was reduced with 
increasing travel time to the nearest radiotherapy facility.1 The total number of patients who 
were irradiated increased with 3.3% a year, because of the increasing number of newly 
diagnosed cancer patients.2 The proportion primarily irradiated patients remained stable, 
although a shift was seen in indications for radiotherapy for different tumour groups. There 
appeared to be an increase for rectal3 and prostate cancer patients4 and a decrease for lung5 
and gynaecological6 cancer patients; for the latter, however, an increase was seen in the period 
2003-2006, probably because of the implementation of new guidelines for endometrial and 
cervical cancer in 2004.7 About 31% of all cancer patients in the region of the 
Comprehensive Cancer Centre South and registered in the Eindhoven Cancer Registry 
received radiotherapy as part of their primary treatment. In the western part of the region 
about 29% was irradiated, in the demographically similar eastern part of the region a slightly 
higher proportion of 32% was found, mainly due to a higher proportion irradiated patients 
with breast, rectal and prostate cancer.8 This difference between the 2 regions has not been 
reduced during the latter years up till 2006.
Waiting-times for radiotherapy became longer in the Netherlands during the late 90’s, but 
never unacceptable, also because of excess-increase demand related to mass-mammography 
and opportunistic prostate screening. From 2002 a descent in waiting-times was achieved, 
according to the benchmark of the Dutch association of Radiotherapy (NVRO),9 also 
because of  increase of  equipment and personnel.
Variations in referral 
Taking age and stage at diagnosis into account, variations in referral for radiotherapy 
between regions and hospitals usually result from differences in referral behaviour of 
individual specialists. Because radiotherapy is a third line treatment, patients must be referred 
by second line specialists (or and rarely, by first line general practitioners in case of palliative 
treatment). It seems that, despite the presence of guidelines and wide efforts at 
implementation through the professional societies and regional comprehensive cancer 
centres, some specialists do not seem to be in full agreement with them, while also 
consultants from the University Hospitals might have influence. However, in medicine there 
are always rapid and slow  adapters as appeared in the implementation of a short preoperative 
radiation course with operable rectal cancer in chapter 3.2.
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Furthermore, variations can develop by differences in assessment of side effects of 
radiotherapy or differences in assessment of short- or long-term complications: omitting 
adjuvant radiotherapy might result in more local recurrences, but these recurrences might be 
easier to treat, although local recurrences might also be instrumental in the development of 
distant metastases.10 So, to a certain extent variation in application of adjuvant therapy might 
also reflect incomplete knowledge.
This same phenomenon might be seen in elderly patients with breast, rectal and prostate 
cancer: the lower radiotherapy rates for these patients were seen both in the eastern and in 
the western region; the rates are increasing in the latter years in the eastern region, especially 
for breast and rectal cancer.
Individual specialists might have their own expectations and appraisal about acute 
reactions and late complications. Variations in referral rates between them might become 
smaller if they are informed more systematically about side effects of the latest irradiation 
schedules,11-13 which might often occur only occasionally and thus not well known or only 
among radiation oncologists. They should be studied in a prospective way and regularly 
communicated by journals which are relevant for referring specialists.
In contrary to the Scandinavian and Anglo-Saxon countries where the medical oncologists 
are responsible for both systemic treatment and radiotherapy, in the Netherlands the medical 
oncologists, second-line specialists, only are responsible for systemic treatment. Adjuvant 
radiotherapy, a third-line specialism, might therefore have more competition from systemic 
treatment.
Population-based studies and estimated optimal utilisation studies
In Australia a model of radiotherapy utilisation was developed by the radiotherapy society 
between 2003 and 2005 to estimate the maximal and optimal utilisation of radiotherapy for 
the whole country. According to this model 52% of all cancer patients should receive 
radiotherapy at least once at some time during the course of their illness.14 For breast cancer 
patients (excluding ductal carcinoma in situ) the estimation was that 86% of all patients 
should at least have an indication for radiotherapy once during the course of their illness, for 
rectal cancer patients 61%.15, 16 These estimates have been based on the hierarchy of levels of 
evidence for indications for radiotherapy as used by the Australian National Health and 
Medical Research Council, and epidemiological data on the proportion of patients who 
would qualify for radiotherapy. The actual radiotherapy utilisation rates in Australia were 
much lower than the estimated rates, possibly partly because of the large distances there. A 
prospective survey of radiotherapy (curative and palliative) practice in 2001 in Sweden 
showed comparable percentages of  actual use as found with the Australian model.17
Population-based trend studies, as discussed in chapter 2.1 and 2.3, only give insight in 
radiotherapy rates for primary treatment (which can be curative or palliative).
Population-based cohort studies can give a true insight in the whole spectrum of 
radiotherapy consumption. 
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As described in chapter 3.1 and 3.2 of this thesis, the cumulative use of radiotherapy for 
patients with breast cancer in the south of the Netherlands was 67%, and for patients with 
rectal cancer 50%. The following explanations can be given for the discrepancies between real 
management, as in our studies, and the tumour-specific estimations from the Australian 
model. 
At first, we found a significantly lower radiotherapy use for elderly patients with breast 
and rectal cancer during their primary treatment (chapter 4.1), but also for secondary 
treatment for recurrences or metastases (chapter 3.1 and 3.2). Also patients with co-morbid 
diseases were irradiated less often, as we found among breast cancer patients (chapter 4.1). 
The levels of evidence in the Australian model were mostly from randomised trials, in which 
elderly patients and patients with co-morbidity often not are included.
Secondly, the adherence of guidelines differs with referring specialists so they might not 
refer all patients for radiotherapy who are eligible.
Thirdly, especially for breast cancer, the median follow-up time of our cohort may be too 
short (66 months, range 0-107); the majority of recurrences and distant relapses occur in the 
first 5 years after diagnosis, but breast cancer often behaves as a chronic disease. Although 
the life expectancy of breast cancer patients has become similar to the general female 
population 20 years after diagnosis, the risk of dying from breast cancer remains elevated.18 
Therefore patients can receive a first (palliative) radiation treatment many years after the first 
appearance of the disease. In our cohort only 28% of the patients had died on 1st January 
2005, so the cumulative use of radiotherapy may increase slowly after that time with 1% a 
year. 
Radiotherapy use versus referral
In this thesis we only studied the actual use of radiotherapy. Patients who were referred, 
but not treated, were not registered as such in the Eindhoven Cancer Registry. A study from 
Ontario showed that most of the decline in the rate of radiotherapy use with age, particularly 
for adjuvant and palliative indications, was related to a decline in referral to the cancer 
centres, not to a refusal of the radiation oncologist.19 In our population-based studies we also 
found a significant lower use of adjuvant and palliative radiotherapy for elderly patients, 
which, most plausibly, is the result of  a lower referral rate by treating specialists. 
Age and co-morbidity
Elderly patients with cancer, especially patients with breast, rectal and prostate cancer, 
received less often radiotherapy, as we saw in chapter 2, 3 and 4. 
For patients with breast20 and rectal cancer (chapter 4.2) the low  radiotherapy rates in 
elderly patients are common and often a result of omitting pre- or postoperative 
radiotherapy. 
Breast cancer patients, also elderly, with a resectable tumour can safely undergo breast- 
conserving surgery in combination with radiotherapy.21, 22 
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Elderly patients, however, tend to receive often surgery alone, without irradiation,23 which 
results in an at least 3 to 4 fold increased risk of local recurrences24 within 5 to 10 years. 
Although elderly patients more often receive a mastectomy,23 probably to avoid a long course 
of irradiation, this will not automatically prevent the need for postoperative radiotherapy.7, 25 
Post-mastectomy radiotherapy has been shown to reduce the frequency of loco-regional 
recurrences by 70%, also in elderly women and irrespective of the use of adjuvant systemic 
treatment.26-28 Moreover, in combination with systemic treatment radiotherapy seems more 
effective as well, resulting in a higher reduction of the recurrence risk, as has been suggested 
by some.27 
An alternative might be to give adjuvant hormonal treatment to the subset of patients 
with hormonal sensitive tumours.24, 29 However, the local recurrence risk seems to increase at 
longer follow  up29 and side effects and therapy compliance have to be taken into account as 
well.
A significant percentage of patients aged 80 or older received no surgery at all (chapter 
4.1), which might strongly decrease the ultimate prognosis.30 Indeed women at the age of 80 
nowadays have a median life expectancy of  8.5 years.31
In operable rectal cancer radiotherapy plays an important role in the prevention of local 
recurrences (at first postoperative, but this changed in the mid 90’s to nowadays nearly always 
preoperative32). However, preoperative radiotherapy tends to increase the risk of developing 
complications which may influence the referral in elderly patients and in patients with co-
morbidities.33, 34
For localised prostate cancer the detection rates increased after the widespread 
introduction of the PSA-test since 1994.35 It might increase even more because the ageing of 
the male population. The lack of randomised, prospective trials hampers any comparison of 
the efficacy of different treatment modalities, surgery and radiotherapy.4 However, 
encouraging results are achieved in several trials evaluating radiotherapy and adjuvant 
hormonal treatment for, also elderly, patients with locally advanced tumours.36, 37 Also, 
especially in elderly patients or in patients with co-morbid conditions, active surveillance may 
be a reasonable approach, resulting in a low  percentage of elderly patients being treated 
immediately after diagnosis.
To gain a better insight in reasons why elderly patients are less treated with radiotherapy, 
reasons for excluding (with an indication of life expectancy) should be reported 
prospectively. Moreover, prospective studies are warranted to learn more about treatment 
outcomes and complications in older patients, and in patients with serious co-morbid 
conditions.
Palliative radiotherapy 
Although radiotherapy is a third line treatment, general practitioners can refer patients 
(probably only those who have been irradiated before) directly for palliative treatment of 
metastases, which might be very convenient because of less travel movements38 and less loss 
of  time. 
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However, the survey, which we sent to all general practitioners in the region of the 
Comprehensive Cancer Centre South to evaluate knowledge of and influencing factors for 
palliative radiotherapy, showed that about half of the respondent general practitioners 
assessed their own knowledge of  palliative radiotherapy as rather modest. 
Although they considered RT effective for painful bone metastases, painful local disease, 
brain metastases and spinal cord compression, it seems, for instance, difficult for them, but 
also for second line specialist, to decide when a patient with a (threatening) spinal cord 
compression should be referred for palliative radiotherapy: for such patients any delay in 
treatment might decrease the chance of recovery but almost 30% was referred on Fridays. 
This indicates that most referrals and diagnoses are made in the second half of the week 
which suggests a delay in this process. Despite many discussions in the multidisciplinary 
oncology meetings, a repetition of the described study in later years (1998 to 2004) showed 
that the referral pattern for spinal cord compression only changed moderately.
More education seems desirable for general practitioners, but also for second line 
specialists more extensively about the effectiveness of radiotherapy in a variety of common 
palliative situations.39-42
Future perspectives
In this thesis we studied the use of radiotherapy in a region with only community 
hospitals. However, surgeons and medical oncologists from nearby academic centres 
(Rotterdam and Nijmegen) attend multidisciplinary oncological meetings at a regular basis. It 
would be interesting to investigate the referral patterns of radiotherapy in regions with an 
academic department, as academic radiation oncologists might be more persuading in selling 
the advantages of  radiotherapy. 
In the near future radiotherapy equipment and personnel planning purposes should of 
course not only be determined by the past experiences but also by applying desirable changes 
based upon up to date technology. Based upon the results of this thesis, more interest and 
knowledge in geriatric patients may lead to a better assessment of specific indications for 
radiotherapy. Also education in opportunities for palliative treatment might increase the 
awareness of  possibilities to treat patients with palliative indications. 
More sophisticated radiation equipment and the development in radiation methods might 
lead to better effectiveness and fewer complications (table 1). Developments in new 
techniques are a continuous process. Some tumours are better suited to a certain technique 
(for instance IMRT was developed for prostate cancer), but eventually more sophisticated 
techniques will be used for all types of  cancer.
Eventually it seems extremely important for radiation oncologists to communicate closer 
with referring doctors about pro’s and contras of radiotherapy, both short- and long-term, of 
course within the multidisciplinary setting.
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Table 1 - New developments in radiotherapy (RT)
New 
developments 
Breast cancer Urological 
malignancies
Rectal cancer Gynaecolo-
gical 
malignancies
Lung cancer Head/Neck 
malignancies
Primary 
central 
nervous 
system 
malignancies
Stereotactic 
RT
X 
(stage I)
X X
Image 
Guided RT 
(IGRT)
X X X X
Conformal 
RT
based on CT 
planning
X
Partial 
irradiation
X
Intensity
Modulated 
RT (IMRT)
X X X X X
4D 
Radiotherapy
X X
(vocal cords)
Conclusions
Large variation existed in the use of radiotherapy worldwide, regarding regions, hospitals, 
age and co-morbid conditions. Radiotherapy is a third-line specialism, because of which 
radiation oncologists might work relatively isolated, even though they are essential for 
adequate oncological care in up to 45% of all cancer patients. Although in our studies the 
main trends in radiotherapy use followed the same pattern in both the western and eastern 
part of the region (with their distinctive referral patterns), radiotherapy consumption in the 
eastern part was somewhat higher for all subgroups.
Especially with the ageing of the population in the near future more knowledge is 
required of the best way to treat elderly people with cancer in relation to their overall 
condition. Prospective studies on this topic are needed, taking into account the heterogeneity 
of  patients and being published also in non-radiotherapy journals.
It is obvious that it remains important to discuss all cancer patients early after diagnosis in 
multidisciplinary meetings, in which all possible treating specialists are represented.
Eventually some variations will remain because of individual differences between doctors 
and also between patients. 
166  Chapter 6
References
1. Jones AP, Haynes R, Sauerzapf V, Crawford  SM, Zhao H, Forman D. Travel time to hospital 
and treatment for breast, colon, rectum, lung, ovary and prostate cancer. Eur J Cancer 
2008;44:992-999.
2. Coebergh JW, Janssen-Heijnen ML, Louwman MW, Voogd AC. Cancer incidence, care and 
survival in the South of the Netherlands, 1955-1999. A report from the Eindhoven Cancer 
Registry (IKZ) with cross-border implications, Eindhoven, The Netherlands. 2001.
3. Kapiteijn E, Marijnen CA, Nagtegaal ID, Putter H, Steup WH, Wiggers T, et al. Preoperative 
radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J 
Med 2001;345:638-646.
4. Denis LJ. The role of active treatment in early prostate cancer. Radiother Oncol 
2000;57:251-258.
5. Janssen-Heijnen ML, Coebergh JW. The changing epidemiology of lung cancer in Europe. 
Lung Cancer 2003;41:245-258.
6. Creutzberg CL, van Putten WL, Koper PC, Lybeert ML, Jobsen JJ, Warlam-Rodenhuis CC, et 
al. Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 
endometrial carcinoma: multicentre randomised trial. PORTEC Study Group. Post Operative 
Radiation Therapy in Endometrial Carcinoma. Lancet 2000;355:1404-1411.
7. Oncoline. www.oncoline.nl. 2006.
8. Lybeert ML, Louwman M, Coebergh JW. Stable overall referral rates of primary radiotherapy 
for newly diagnosed cancer patients in the ageing population of South-Eastern Netherlands, 
1975-1998. Radiother Oncol 2004;73:101-108.
9. NVRO. www.NVRO.nl. 2008.
10. Holzel D, Engel J, Schmidt M, Sauer H. [A model for primary and secondary metastasis in 
breast cancer and the clinical consequences]. Strahlenther Onkol 2001;177:10-24.
11. Carver JR, Shapiro CL, Ng A, Jacobs L, Schwartz C, Virgo KS, et al. American Society of 
Clinical Oncology clinical evidence review on the ongoing care of adult cancer survivors: 
cardiac and pulmonary late effects. J Clin Oncol 2007;25:3991-4008.
12. van den Belt-Dusebout AW, de Wit R, Gietema JA, Horenblas S, Louwman MW, Ribot JG, et 
al. Treatment-specific risks of second malignancies and cardiovascular disease in 5-year 
survivors of  testicular cancer. J Clin Oncol 2007;25:4370-4378.
13. Borger JH, Hooning MJ, Boersma LJ, Snijders-Keilholz A, Aleman BM, Lintzen E, et al. 
Cardiotoxic effects of tangential breast irradiation in early breast cancer patients: the role of 
irradiated heart volume. Int J Radiat Oncol Biol Phys 2007;69:1131-1138.
14. Delaney G, Jacob S, Featherstone C, Barton M. The role of radiotherapy in cancer treatment: 
estimating optimal utilization from a review of evidence-based clinical guidelines. Cancer 
2005;104:1129-1137.
15. Delaney G, Barton M, Jacob S. Estimation of an optimal radiotherapy utilization rate for 
breast carcinoma: a review of  the evidence. Cancer 2003;98:1977-1986.
16. Delaney G, Barton M, Jacob S. Estimation of an optimal radiotherapy utilization rate for 
gastrointestinal carcinoma: a review of  the evidence. Cancer 2004;101:657-670.
17. Lindholm C, Cavallin-Stahl E, Ceberg J, Frodin JE, Littbrand B, Moller TR. Radiotherapy 
practices in Sweden compared to the scientific evidence. Acta Oncol 2003;42:416-429.
18. Louwman WJ, Klokman WJ, Coebergh JW. Excess mortality from breast cancer 20 years after 
diagnosis when life expectancy is normal. Br J Cancer 2001;84:700-703.
19. Tyldesley S, Zhang-Salomons J, Groome PA, Zhou S, Schulze K, Paszat LF, et al. Association 
between age and the utilization of radiotherapy in Ontario. Int J Radiat Oncol Biol Phys 
2000;47:469-480.
20. Louwman WJ, Vulto JC, Verhoeven RH, Nieuwenhuijzen GA, Coebergh JW, Voogd AC. 
Clinical epidemiology of  breast cancer in the elderly. Eur J Cancer 2007;43:2242-2252.
21. van Dongen JA, Voogd AC, Fentiman IS, Legrand C, Sylvester RJ, Tong D, et al. Long-term 
results of a randomized trial comparing breast-conserving therapy with mastectomy: 
General discussion   167
European Organization for Research and Treatment of Cancer 10801 trial. J Natl Cancer Inst 
2000;92:1143-1150.
22. Vlastos G, Mirza NQ, Meric F, Hunt KK, Kuerer HM, Ames FC, et al. Breast conservation 
therapy as a treatment option for the elderly. The M. D. Anderson experience. Cancer 
2001;92:1092-1100.
23. Siesling S, van de Poll-Franse LV, Jobsen JJ, Repelaer van Driel OJ, Voogd AC. Explanatory 
factors for variation in the use of breast conserving surgery and radiotherapy in the 
Netherlands, 1990-2001. Breast 2007;16:606-614.
24. Hughes KS, Schnaper LA, Berry D, Cirrincione C, McCormick B, Shank B, et al. 
Lumpectomy plus tamoxifen with or without irradiation in women 70 years of age or older 
with early breast cancer. N Engl J Med 2004;351:971-977.
25. Truong PT, Lee J, Kader HA, Speers CH, Olivotto IA. Locoregional recurrence risks in 
elderly breast cancer patients treated with mastectomy without adjuvant radiotherapy. Eur J 
Cancer 2005;41:1267-1277.
26. Clarke M, Collins R, Darby S, Davies C, Elphinstone P, Evans E, et al. Effects of 
radiotherapy and of differences in the extent of surgery for early breast cancer on local 
recurrence and 15-year survival: an overview of the randomised trials. Lancet 
2005;366:2087-2106.
27. Whelan TJ, Julian J, Wright J, Jadad AR, Levine ML. Does locoregional radiation therapy 
improve survival in breast cancer? A meta-analysis. J Clin Oncol 2000;18:1220-1229.
28. Favourable and unfavourable effects on long-term survival of radiotherapy for early breast 
cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative 
Group. Lancet 2000;355:1757-1770.
29. Fyles AW, McCready DR, Manchul LA, Trudeau ME, Merante P, Pintilie M, et al. Tamoxifen 
with or without breast irradiation in women 50 years of age or older with early breast cancer. 
N Engl J Med 2004;351:963-970.
30. Bouchardy C, Rapiti E, Fioretta G, Laissue P, Neyroud-Caspar I, Schafer P, et  al. 
Undertreatment strongly decreases prognosis of breast cancer in elderly women. J Clin Oncol 
2003;21:3580-3587.
31. Statline. www.statline.cbs.nl. 2006.
32. Adjuvant radiotherapy for rectal cancer: a systematic overview of 8,507 patients from 22 
randomised trials. Lancet 2001;358:1291-1304.
33. Marijnen CA, Kapiteijn E, van de Velde CJ, Martijn H, Steup WH, Wiggers T, et al. Acute 
side effects and complications after short-term preoperative radiotherapy combined with total 
mesorectal excision in primary rectal cancer: report of a multicenter randomized trial. J Clin 
Oncol 2002;20:817-825.
34. Shahir MA, Lemmens VE, van de Poll-Franse LV, Voogd AC, Martijn H, Janssen-Heijnen 
ML. Elderly patients with rectal cancer have a higher risk of treatment-related complications 
and a poorer prognosis than younger patients: A population-based study. Eur J Cancer 
2006;42:3015-3021.
35. Post PN, Kil PJ, Crommelin MA, Schapers RF, Coebergh JW. Trends in incidence and 
mortality rates for prostate cancer before and after prostate-specific antigen introduction. A 
registry-based study in southeastern Netherlands, 1971-1995. Eur J Cancer 1998;34:705-709.
36. Bolla M, Collette L, Blank L, Warde P, Dubois JB, Mirimanoff RO, et al. Long-term results 
with immediate androgen suppression and external irradiation in patients with locally 
advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet 
2002;360:103-106.
37. Pilepich MV, Winter K, Lawton CA, Krisch RE, Wolkov HB, Movsas B, et al. Androgen 
suppression adjuvant to definitive radiotherapy in prostate carcinoma--long-term results of 
phase III RTOG 85-31. Int J Radiat Oncol Biol Phys 2005;61:1285-1290.
38. Wanrooij B, Koelewijn M, Van der Linden Y. Radiotherapie. Huisarts Wet 2005;49:573-578.
39. McQuay HJ, Carroll D, Moore RA. Radiotherapy for painful bone metastases: a systematic 
review. Clin Oncol (R Coll Radiol) 1997;9:150-154.
168  Chapter 6
40. van der Linden YM, Steenland E, van Houwelingen HC, Post WJ, Oei B, Marijnen CA, et al. 
Patients with a favourable prognosis are equally palliated with single and multiple fraction 
radiotherapy: results on survival in the Dutch Bone Metastasis Study. Radiother Oncol 
2006;78:245-253.
41. Rades D, Stalpers LJ, Veninga T, Schulte R, Hoskin PJ, Obralic N, et al. Evaluation of five 
radiation schedules and prognostic factors for metastatic spinal cord compression. J Clin Oncol 
2005;23:3366-3375.
42. Lin NU, Bellon JR, Winer EP. CNS metastases in breast cancer. J Clin Oncol 
2004;22:3608-3617.
General discussion   169

Summary
This thesis describes the use of radiotherapy in the south of the Netherlands, a region 
with two large radiotherapy institutes, one covering the eastern part of the region with 
hospitals in the cities Eindhoven, Geldrop , Helmond, Veghel/Oss and Venlo, one covering 
the western part with hospitals in the cities Tilburg, Breda and ‘s Hertogenbosch, 10 general 
hospitals (as a result of merges among 20 hospitals 25 years ago) and an ageing population of 
2.4 million habitants. The Eindhoven Cancer Registry and the well kept registries of the 
radiotherapy institutes were used as the data sources.
In chapter 2 we described long-term trends and variations in the use of primary 
radiotherapy (RT) which is defined as RT given or planned within 6 months of  diagnosis.
Referral rates and time trends in the RT use in the western region for cancer patients first 
diagnosed between 1988 and 2002 were described in chapter 2.1.  The number of patients 
receiving RT within 6 months of diagnosis increased by about 3.3% annually, which was due 
mainly to earlier detection and the ageing of the population. The proportion of all incident 
cases that received primary RT remained stable at about 30%. However, only 20% of patients 
aged 75 years or older received RT. The proportion of patients who received primary RT 
increased markedly between 1988-92 and 1998-2002 for patients with prostate cancer 
(because of the growing number of older men and the widespread use of the PSA-test since 
1994), rectal cancer (because of the shift from post- to preoperative RT since 1995) and brain 
tumours. The absolute number of irradiated breast cancer patients increased 30% between 
1988 and 2002 because of the introduction of the biannual mass mammography screening, 
initially among women of 50 to 69 and since 1998 also up to age 75, and the increase in 
number of patients who received breast-conserving therapy. The percentage of irradiated 
patients with stage I endometrial cancer decreased because of participation in the Portec-trial 
(pelvic radiotherapy or no further treatment after total abdominal hysterectomy for patients 
with stage I endometrial cancer) and later because of adherence to treatment guidelines 
which were developed from the results of  this trial.
Referral for primary RT in the western region varied according to hospital size between 
1988 and 1999 (chapter 2.2). Specialists from medium-sized and small hospitals referred 
breast cancer patients significantly more often and patients with prostate cancer less often 
than specialists from large hospitals. Referral rates for patients with non-small cell lung and 
rectal cancer showed minor differences according to hospital size, referral for endometrial 
cancer was somewhat higher for patients from medium-sized hospitals. Time-trends in 
variation were shown, but differences according to hospital size only decreased over time for 
rectal cancer. Despite treatment guidelines and increasingly held multidisciplinary oncology 
meetings large variations remained in rates of  referral for radiotherapy.
The purpose of chapter 2.3 was to explore still existing variations in the use of primary 
radiotherapy in the region of  the Eindhoven Cancer Registry. 
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We calculated the proportion of all 147,588 newly diagnosed cancer patients between 
1988 and 2006 receiving primary radiotherapy, according to referral to the RT department in 
the western or eastern region, with emphasis on breast and rectal cancer.
The number of newly diagnosed patients receiving primary RT increased from 1668 in 
1988 to 2971 in 2006, the proportion remained more or less stable in the western region 
(±30%) but increased to 35% between 2003 and 2006 in the eastern region. Only 20% of 
elderly patients (≥ 75 years) received primary RT, slightly more in the eastern area.
Over time, more irradiation was administered to patients with prostate and rectal cancer, 
less to patients with lung and bladder cancer or Hodgkin’s lymphoma and recently more to 
patients with cervix or endometrial cancer. The proportion remained more or less unchanged 
for patients with most other tumour types and became slightly higher in the eastern region. 
For patients with breast or rectal cancer a large variation existed between individual hospitals 
concerning percentage irradiated patients and such patients from the eastern part of the 
region were significantly more likely to receive primary RT. 
In chapter 3 especially the use of secondary radiotherapy (SRT), which was defined as 
RT given 6 months or later after primary diagnosis or RT given after a previous course of 
radiation for the same tumour, was described in two population-based cohorts, which were 
followed until 2005.
In a cohort of 6561 patients with invasive breast cancer diagnosed between 1996-2000 
with a median follow up of 66 months, 3554 patients received only primary radiotherapy 
(PRT), 323 only SRT and 503 both. The cumulative use of RT went from 54% during the 
first 6 months after diagnosis to 67% during the follow-up until 2005. The 826 patients 
receiving SRT underwent 1846 courses 0-105 months after diagnosis; the retreat-rate was 
35%. Elderly patients received SRT significantly less often. Patients who received PRT and 
patients who underwent mastectomy including axillary node dissection as well as unresected 
patients had a higher chance to receive SRT. Despite a lower rate of mastectomy, SRT was 
administered more often to patients from the eastern region (chapter 3.1).
In a cohort of 2008 rectal cancer patients newly diagnosed between 1996-2000 46% of all 
patients received RT. Ten percent (203 patients) received at least once SRT, for recurrence or 
for metastases, either after PRT or as first RT. These patients were significantly younger and 
had a higher tumour stage. Five percent (96 patients) received SRT for a relapsed rectal 
tumour (31 after PRT on the rectal tumour, 65 as a first radiation treatment). Secondary 
pelvic irradiation was more often given to patients with a stage III tumour, and was 
significantly less often given after primary irradiation, and to patients treated in the eastern 
region, in which region patients received more often PRT for rectal cancer (chapter 3.2). 
The aim of chapter 4  was to study the influence of age and co-morbidity on receiving 
RT in primary treatment of cancer. This was possible because the Eindhoven Cancer Registry 
has collected data on co-morbid conditions since 1993. 
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Furthermore an overview is given of treatment possibilities of rectal cancer over time, 
but also of  the real management of  rectal cancer especially in relation to age.
In chapter 4.1 the influence of age and co-morbidity (such as chronic obstructive 
pulmonary diseases, cardiovascular and cerebrovascular diseases, other malignancies 
(excluding basal cell carcinoma of the skin), diabetes mellitus, hypertension, connective tissue 
disease, rheumatoid arthritis, kidney, bowel and liver diseases, dementia, tuberculosis and 
other chronic infections) was described for different tumour types, all first diagnosed between 
1995 and 2002. Patients with localised non-small cell lung cancer (NSCLC) aged 65 or older 
or with co-morbid conditions received RT alone significantly more often compared to 
younger patients or those without co-morbidity. This also applied for patients with non-
localised NSCLC aged 65-79 years compared to younger patients. RT was administered 
significantly less often to elderly (≥ 65 years) with resected rectal cancer, with breast cancer 
after conserving surgery aged ≥ 80 years and with cT1-cT3 N0 M0 prostate cancer aged ≥ 80 
years than to younger patients. Breast cancer patients undergoing breast-conserving surgery 
received significantly less often RT in the presence of co-morbidity. Older patients with 
aggressive non-Hodgkin lymphoma received RT as only treatment significantly more often 
compared to younger patients. For most tumour types age appeared to be a stronger 
predicting factor for receiving radiotherapy than co-morbidity. Under-treatment was found 
for patients with breast cancer or rectal cancer. 
To give insight in the influence of age on the treatment of rectal cancer patients we 
reviewed the literature on population-based studies describing radiotherapy or radiotherapy in 
combination with chemotherapy for resectable rectal cancer. All studies showed that 
increasing age was associated with less (neo)adjuvant treatment. Also a literature search on 
representative randomised trials on patients with resectable rectal cancer, comparing only 
surgery, post- and preoperative radiotherapy with or without chemotherapy, was done. This 
overview  showed that preoperative radiotherapy improves local control in relation to no or 
postoperative radiotherapy. Adding chemotherapy did not significantly improve survival. No 
relations were seen between age and complications. To avoid local recurrence, the best 
possible treatment, being preoperative RT, should be given to all patients with resectable 
rectal cancer, irrespective of age, except to patients who are unable to fulfil the combination 
treatment because of  patient’s condition (chapter 4.2).
The knowledge of palliative RT was discussed in chapter 5. In chapter 5.1 the results are 
described of a questionnaire, sent to all general practitioners in the region of the 
Comprehensive Cancer Centre South, to obtain insight into the knowledge of palliative RT 
among general practitioners. Four hundred and ninety-eight of 1100 questionnaires were 
analysed. Forty-six percent of the respondents had referred palliative-care patients for RT in 
the last 2 years. The knowledge about palliative RT for bone metastases and spinal cord 
compression was good, for other palliative indications it was moderate to poor. 
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General practitioners also considered their own knowledge poor, only 10% received RT 
education in the past. Factors influencing the actual referral for palliative RT were mainly 
patient-related.
Between 1987 and 1997 the speed of referral of patients with spinal cord compression 
was analysed based on a tumour and treatment related registry of the RT institute in the 
western region. All 443 patients were seen and treated on the day of referral. Significantly 
more referrals took place on Friday, 30%, compared to 12% on Monday, 17% on Tuesday, 
15% on Wednesday, 20% on Thursday, 5% on Saturday and 1% on Sunday (p<0.002). This 
difference was the same for patients who were formerly treated in the institute or not. These 
data were discussed with referring physicians and have been presented at a scientific meeting 
of the comprehensive cancer centre to encourage speed of diagnosis and referral (chapter 
5.2). 
In chapter 6 the results from this thesis and some future perspectives were discussed. To 
obtain the optimal treatment for an individual patient it remains important to discuss the case 
early after the diagnosis in multidisciplinary meetings, in which all possible treating specialists 
are represented. Furthermore, radiation oncologists, as third-line, relatively isolated working 
specialists, should also publish in journals which are relevant for referral specialists. The 
overall conclusion is that some variation in radiotherapy use will remain because of individual 
differences between doctors and between patients.
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Samenvatting
Variatie in het gebruik van radiotherapie voor kankerpatiënten.
Population-based studies in het zuiden van Nederland
Dit proefschrift beschrijft het gebruik van radiotherapie voor patiënten met kanker in 
Zuid-Nederland, een regio met een verouderende populatie van 2.4 miljoen en twee grote 
radiotherapie instituten. De radiotherapie afdeling van het Catharina Ziekenhuis te 
Eindhoven, in 1973 voortgekomen uit het in 1954 opgerichte Radiotherapeutisch Instituut, 
verzorgt het oostelijke deel van de regio, met ziekenhuizen in Eindhoven, Geldrop, Helmond, 
Veghel/Oss en Venlo. Het Dokter Bernard Verbeeten Instituut in Tilburg, opgericht in 1952 
als Radio-Therapeutisch Instituut Tilburg, is een zelfstandig instituut en verzorgt het 
westelijke deel van de regio, met ziekenhuizen in Tilburg, Den Bosch en Breda. In totaal 
bevinden zich in de regio nog 10 algemene ziekenhuizen, die ontstaan zijn door fusies van 20 
ziekenhuizen in de laatste 25 jaar. De Eindhovense kankerregistratie en de goed bijgehouden 
registraties van de radiotherapie instituten werden gebruikt als bron voor alle studies in dit 
proefschrift. Sinds 1986 worden alle kankerpatiënten in bovengenoemde regio’s geregistreerd 
door de Eindhovense kankerregistratie, voortgekomen uit de in 1955 opgerichte regionale 
kankerregistratie van het Radiotherapeutisch Instituut in Eindhoven. De kankerregistratie is 
een onderdeel van het Integraal Kankercentrum Zuid, een kennis- en kwaliteitscentrum op 
het gebied van de oncologie en de palliatieve zorg, opgericht eind 1982. 
De radiotherapeut-oncologen wonen, als consulenten, vele oncologiebesprekingen bij in 
de verschillende ziekenhuizen in de regio. Hier worden (bijna) alle nieuwe patiënten met 
kanker en de patiënten met moeilijk te behandelen recidieven of  metastasen besproken.
De radiotherapeut-oncologen hebben ook zitting in de verschillende tumorwerkgroepen 
in de regio. In deze groepen wordt (regionaal en landelijk) beleid en deelname aan studies 
besproken. Het Dokter Bernard Verbeeten Instituut neemt van oudsher op grote schaal deel 
aan EORTC en andere klinische studies, terwijl de afdeling Radiotherapie van het Catharina 
Ziekenhuis een traditie kent van (deelname aan) observationeel onderzoek sinds 25 jaar in 
verband ook van het SOOZ (Samenwerkingsorgaan Oncologie Ziekenhuizen). 
De belangrijkste vraagstellingen die in dit proefschrift aan bod komen zijn de volgende:
• Wat waren de tumorspecifieke trends in het gebruik van primaire radiotherapie?
• Welke variatie bestond er in de verwijzingspatronen, kijkend naar diagnostiserend 
ziekenhuis, leeftijd en bijkomende ziekten? 
• Welk percentage patiënten met borst- of  rectumkanker ontving secundaire 
radiotherapie?
• Bij een vermoede onderconsumptie, hoe is de kennis bij andere specialisten en 
huisartsen betreffende palliatieve radiotherapie?
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In hoofdstuk 2 werden langetermijntrends en variaties in het gebruik van primaire 
radiotherapie (RT) beschreven. Primaire RT werd gedefinieerd als RT gepland of gegeven 
binnen 6 maanden na de diagnose.
In hoofdstuk 2.1 werden trends in de tijd en verwijzingspatronen besproken voor 
kankerpatiënten met een diagnose tussen 1988 en 2002 in het deel van de regio dat bestreken 
wordt door het Dokter Bernard Verbeeten Instituut. Het aantal patiënten dat bestraald werd 
binnen 6 maanden na de diagnose kanker steeg jaarlijks met 3,3%. 
Dit was voornamelijk toe te schrijven aan eerdere ontdekking van de tumor en aan het 
ouder worden van de populatie. Het percentage bestraalde patiënten bleef stabiel en lag rond 
de 30%, maar van de patiënten ouder dan 75 jaar werd maar 20% bestraald. 
Het percentage patiënten dat primaire RT ontving, steeg opvallend tussen de periode 
1988-1992 en 1998-2002 voor patiënten met de volgende tumorsoorten:
• prostaatkanker (door het toenemende aantal oudere mannen in de populatie en als 
gevolg van het wijdverbreide gebruik van de PSA-test sinds 1994), 
• endeldarmkanker (door de verschuiving van post- naar preoperatieve RT sinds 1995),
• hersentumoren (door bestraling van patiënten ouder dan 55 jaar met een hooggradig 
astrocytoom).
Het absolute aantal patiënten met borstkanker dat bestraald werd, steeg met 30% tussen 
1988 en 2002 door de introductie van de tweejaarlijkse screening - in eerste instantie voor 
vrouwen tussen 50 en 69 jaar en sinds 1998 ook tot 75 jaar - waarbij tussen 1990 en 1995 
jaarlijks 10% meer vrouwen een borstsparende behandeling ondergingen. 
Het percentage bestraalde patiënten met een stadium I endometriumcarcinoom daalde in 
eerste instantie door de aanzienlijke participatie in de Portec-trial (bestraling op het bekken of 
geen verdere therapie na een totale abdominale hysterectomie voor patiënten met een 
stadium I endometriumcarcinoom). Een verdere daling werd gezien bij jongere vrouwen naar 
aanleiding van de resultaten van de Portec-trial; hierbij komen alleen patiënten ouder dan 60 
jaar met een endometriumcarcinoom stadium Ia en Ib graad 3 of een stadium Ic en patiënten 
jonger dan 60 jaar met een stadium Ic graad 3 in aanmerking voor postoperatieve 
radiotherapie.
In de westelijke regio varieerde de verwijzing naar primaire radiotherapie tussen 1988 en 
1999 tussen de verschillende ziekenhuizen meer dan een factor anderhalf; dit bleek met name 
afhankelijk van de grootte van de ziekenhuizen (hoofdstuk 2.2). Specialisten uit middelgrote 
en kleine ziekenhuizen verwezen significant meer patiënten met borstkanker en significant 
minder patiënten met prostaatkanker voor primaire RT dan specialisten uit de grote 
ziekenhuizen. De verwijzingspatronen voor patiënten met niet-kleincellig longcarcinoom en 
rectumcarcinoom verschilden weinig wat betreft de ziekenhuisomvang. Patiënten met 
endometriumcarcinoom werden iets vaker verwezen door specialisten uit middelgrote 
ziekenhuizen. 
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Trends in de tijd in het gebruik van primaire RT lieten alleen kleinere variaties zien bij 
rectumcarcinoom. Dus ondanks behandelingsrichtlijnen en het toenemende aantal 
multidisciplinaire oncologie bijeenkomsten bleven bovengenoemde variaties bestaan in de 
verwijzingspatronen naar radiotherapie. 
In hoofdstuk 2.3 werd het onderzoek naar trends in het primaire radiotherapie gebruik 
voortgezet tot en met 2006. Bovendien werden in deze studie alle patiënten uit zowel de 
westelijke regio (het Dokter Bernard Verbeeten Instituut), als de oostelijke regio (de afdeling 
radiotherapie van het Catharina Ziekenhuis) geïncludeerd. Dit gaf ons de mogelijkheid om 
verschillen tussen de beide regio’s te onderzoeken, uitgebreider voor borst- en rectumkanker.
Het totaal aantal primair bestraalde patiënten per jaar bleef stijgen, maar het percentage 
bestraalde patiënten bleef fluctueren tussen 30 en 32%, waarbij het in de westelijke regio 30% 
bleef, maar in de oostelijke regio steeg naar 35% in de periode 2003-2006. In beide regio’s 
werden, bij gelijke indicaties, patiënten ouder dan 75 jaar minder vaak bestraald dan jongere 
patiënten, waarbij ook hier het verschil tussen de regio west (rond 18%) en oost (23% in 
2003-2006) opvallend was.
Het percentage patiënten met rectum- en prostaatkanker dat bestraald werd, steeg verder 
in de periode 2003-2006. Het percentage bestraalde patiënten met cervix- of 
endometriumcarcinoom steeg in de laatste periode, na een eerdere daling; dit is waarschijnlijk 
toe te schrijven aan het verschijnen van nieuwe richtlijnen voor beide tumorsoorten in 2004. 
Het percentage bestraalde patiënten met long- en blaaskanker en met en Hodgkin-lymfoom 
daalde.
Tot 1995 fluctueerde het percentage bestraalde patiënten met borstkanker tussen de 57 en 
62% in zowel de regio west als oost van het IKZ. Hierna vond een divergentie plaats, waarbij 
in de westelijke regio een daling werd gezien tot 54% en in de oostelijke regio een stijging tot 
69%. Overeenkomstig deze trends in radiotherapie gebruik vonden we in de regio west een 
lager percentage patiënten dat borstsparende chirurgie, en een hoger percentage dat een 
amputatie onderging. In 2006 leken de percentages van beide chirurgische ingrepen te 
convergeren. 
Vanaf 1995 werd, eerst in de oostlijke regio, preoperatieve bestraling voor het 
rectumcarcinoom geïntroduceerd: een korte serie voor een operabel, en een lange serie voor 
een plaatselijk voortgeschreden tumor. In 2004 werd 50% van alle patiënten met 
endeldarmkanker preoperatief bestraald. Patiënten met rectumcarcinoom uit de regio oost 
werden significant vaker bestraald.
Voor beide bovengenoemde tumorsoorten bestond een grote variatie tussen de 10 
ziekenhuizen in de regio wat betreft het percentage bestraalde patiënten.
In hoofdstuk 3 werd vooral ingegaan op het gebruik van secundaire RT in twee 
cohorten met patiënten uit beide regio’s, die werden gevolgd tot 2005. Secundaire RT werd 
gedefinieerd als RT gegeven zes maanden of later na de primaire diagnose, of RT gegeven na 
een eerdere bestralingsbehandeling voor dezelfde tumor; deze wordt over het algemeen 
gegeven op recidieven en/of  metastasen.
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Het eerste cohort (hoofdstuk 3.1) bestond uit 6561 patiënten met een invasief 
mammacarcinoom, gediagnostiseerd tussen 1996 en 2000 en met een mediane follow-up van 
66 maanden. 3554 patiënten (54%) ontvingen alleen primaire RT, 323 (5%) alleen secundaire 
RT en 503 patiënten (8%) zowel primaire als secundaire RT. 
Het cumulatieve gebruik van RT steeg van 54% gedurende de eerste 6 maanden naar 67% 
gedurende de follow-up tot 2005. De 826 patiënten die secundaire RT ontvingen, kregen in 
totaal 1846 RT series 0 tot 105 maanden na de diagnose; het percentage herbehandelingen 
was 35%. 
Oudere patiënten werden beduidend minder vaak secundair bestraald. Patiënten die 
primaire RT ontvingen, patiënten die een mastectomie inclusief een okselkliertoilet 
ondergingen en patiënten die niet geopereerd werden, hadden een significant hogere kans om 
secundair bestraald te worden. Ondanks het lagere percentage patiënten dat een mastectomie 
onderging in de oostelijke regio, werden patiënten uit deze regio vaker secundair bestraald 
(14%) dan patiënten uit de westelijke regio (11.5%). Dit verschil was het grootst in de jongere 
leeftijdsgroepen. 
In het tweede cohort (hoofdstuk 3.2) werd 46% van alle 2008 patiënten met een 
rectumcarcinoom, gediagnostiseerd tussen 1996 en 2000, bestraald. Tien procent (203 
patiënten) ontving ten minste een keer secundaire RT, van wie 94 patiënten na primaire RT 
(11% van primair bestraalden). De patiënten die secundair bestraald werden, waren significant 
jonger en hadden een minder gunstige tumor stadiëring. 
Binnen een periode van drie jaar na de incidentiedatum werd vier procent (79 patiënten) 
secundair bestraald op een recidief van het rectumcarcinoom. Tweeëntwintig van deze 
patiënten waren al eerder bestraald op de rectum tumor, voor 57 patiënten was het de eerste 
bestralingsbehandeling. Binnen 5 jaar  was dit vijf procent (96 patiënten, van wie 31 patiënten 
eerder waren bestraald en 65 niet). Secundaire bestraling op het rectum werd vaker gegeven 
aan patiënten met een stadium III tumor dan een stadium II en minder vaak aan patiënten die 
primair op het rectum waren bestraald. Ook patiënten uit de oostelijke regio werden minder 
vaak secundair op het rectum bestraald. Daar werden patiënten vaker primair bestraald op het 
rectumcarcinoom. 
Het doel van hoofdstuk 4 was om de invloed van leeftijd en bijkomende ziekten bij 
diagnose op het gebruik van primaire RT te bestuderen. Dit was mogelijk omdat de 
Eindhovense Kankerregistratie sinds 1993 op verzoek van de klinici, onafhankelijk van de 
radiotherapie, gegevens heeft verzameld betreffende ernstige bijkomende ziekten.
Bovendien werd onderzocht in de literatuur hoe oudere patiënten met een 
rectumcarcinoom behandeld werden, waaraan voorafgaand een overzicht werd gegeven van 
de behandelingsmogelijkheden van het rectumcarcinoom in de loop der tijd. 
Hoofdstuk 4.1 gaat over de invloed van leeftijd en bijkomende ziekten zoals chronisch 
obstructieve longziekten, cardiovasculaire en cerebrovasculaire ziekten, andere maligniteiten 
(exclusief basaalcelcarcinoom van de huid) diabetes mellitus, hypertensie, bindweefselziekten, 
rheumatoide artritis, nier-, darm- en leverziekten, dementie, tuberculosis en andere chronische 
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infecties. Het omvat patiënten uit de regio’s west en oost met longkanker, rectumcarcinoom, 
borstkanker, prostaatkanker of non-Hodgkin-lymfoom, gediagnostiseerd tussen 1995 en 
2002. 
Patiënten met een gelokaliseerd niet-kleincellig longcarcinoom ouder dan 65 jaar of met 
bijkomende ziekten kregen vaker RT als enige behandeling ten opzichte van jongere patiënten 
of patiënten zonder bijkomende ziekten. Ditzelfde gold ook voor patiënten met een niet-
gelokaliseerd carcinoom tussen de 65 en 79 jaar. 
Significant minder vaak bestraald werden oudere patiënten met een geopereerd 
rectumcarcinoom, borstkanker patiënten van 80 jaar en ouder na borstsparende chirurgie en 
prostaatkanker patiënten van 80 jaar en ouder met een cT1-cT3 N0 M0 tumor. Patiënten met 
borstkanker en bijkomende ziekten werden na een borstsparende behandeling significant 
minder vaak bestraald. 
Bij oudere patiënten met een agressief non-Hodgkin-lymfoom was bestraling vaker de 
enige behandeling dan bij jongere patiënten (tabel 1). 
Tabel 1 - De invloed van leeftijd en co-morbiditeit op radiotherapie gebruik bij verschillende kanker soorten
Tumor soort Stadium Soort behandeling Radiotherapie bij 
ouderen (≥65 of  ≥80 
jaar of  ≥70 jaar) ten 
opzichte van jongeren 
Radiotherapie bij 
patiënten met co-
morbiditeit ten 
opzichte van patiënten 
zonder co-morbiditeit
Longkanker, 
niet-kleincellig
I en II Alleen radiotherapie Meer (≥65 jaar) Meer
Longkanker, 
niet-kleincellig
III Alleen radiotherapie Meer (≥65 jaar) Niet verschillend
Longkanker, 
kleincellig
Limited disease Alleen radiotherapie Meer (≥65 jaar) Niet verschillend
Rectumkanker I-III Radiotherapie voor/na 
chirurgie
Minder (≥65 jaar) Niet verschillend
Borstkanker Radiotherapie na 
borstsparende chirurgie
Minder (≥80 jaar) Minder
Prostaatkanker CT1-cT3 N0 M0 Alleen radiotherapie Minder (≥80 jaar) Niet verschillend
Non-Hodgkin- 
lymfoom
Agressief Alleen radiotherapie Meer (≥70 jaar) Meer
Voor de meeste tumorgroepen bleek leeftijd een sterkere voorspellende factor voor 
primaire radiotherapie dan de genoemde bijkomende ziekten. Vooral oudere patiënten met 
borstkanker of rectumcarcinoom werden veel minder vaak bestraald dan jongere patiënten, 
iets dat ook in de literatuur beschreven wordt. 
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Om inzicht te krijgen in de invloed van leeftijd op de behandeling van rectumcarcinoom, 
bestudeerden we de literatuur betreffende ‘population-based’ studies van het gebruik van RT 
of van RT in combinatie met chemotherapie voor het operabel rectumcarcinoom (hoofdstuk 
4.2). Uit alle studies bleek dat hogere leeftijd geassocieerd was met minder (neo)adjuvante 
behandeling. 
Bovendien bestudeerden we grondig de literatuur betreffende representatieve 
gerandomiseerde studies die chirurgie als enige behandeling, postoperatieve en preoperatieve 
RT (met of zonder chemotherapie) vergeleken. Preoperatieve RT bleek de lokale controle te 
verbeteren ten opzichte van geen of  postoperatieve RT. 
Toevoeging van chemotherapie gaf geen significante verbetering van de overleving. Er 
werd geen relatie gevonden tussen leeftijd en het optreden van complicaties na RT. 
Om lokaal recidief te vermijden, moet evenwel de best mogelijke behandeling gegeven 
worden aan patiënten met een operabel rectumcarcinoom. Alle patiënten zouden dus 
preoperatief bestraald moeten worden, onafhankelijk van de leeftijd, behalve patiënten die 
hiertoe niet in staat zijn door hun (slechte) conditie. Om echter het risico van een dubbele 
belasting (radiotherapie en meteen daarna chirurgie) bij ouderen te voorkomen, zou 
uitgestelde chirurgie na voorbestraling een mogelijkheid zijn, iets dat nu in studieverband 
onderzocht wordt. 
In hoofdstuk 5 werden aspecten van palliatieve RT besproken. In hoofdstuk 5.1 staan de 
resultaten van een in samenwerking met de afdeling palliatieve zorg ondernomen enquête 
onder alle huisartsen in de regio van het Integraal Kankercentrum Zuid, met als doel inzicht 
te verkrijgen in de kennis van palliatieve RT. Vierhonderdnegenentachtig van de 1100 
verstuurde enquêtes werden geanalyseerd. Van de respondenten zei 47% betrokken te zijn 
geweest bij verwijzing van patiënten voor palliatieve RT in de afgelopen 2 jaar. De 
behandeling middels RT van pijnklachten bij botmetastasen en dreigende dwarslaesie was 
ruimschoots bekend, in tegenstelling tot andere indicaties zoals hersenmetastasen, 
luchtwegobstructies, hematurie of hemoptisis. Kennis over de verdere (on)mogelijkheden van 
RT en de bijwerkingen ervan werden door 80% van de huisartsen zelf als onvoldoende tot 
matig geschat. Bij de besluitvorming tot verwijzing speelden, volgens de huisartsen, vooral de 
wens van de patiënt en de leeftijd een belangrijke rol, iets dat mede een gevolg kan zijn van 
een ondervertegenwoordiging van scholing in (palliatieve) RT in de basisopleiding en daarna, 
zoals men aangaf. Ook in Canada, de Verenigde Staten en Japan geven huisartsen en 
specialisten aan dat hun kennis betreffende palliatieve radiotherapie niet optimaal is, iets dat 
voor een deel te wijten is aan onvoldoende scholing. Dit kan tot gevolg hebben dat RT 
onthouden wordt aan patiënten die er veel baat bij kunnen hebben.
Tussen 1987 en 1997 werd de snelheid van verwijzing naar RT onderzocht bij patiënten 
met een (dreigende) dwarslaesie door tumoringroei in het ruggenmerg, met behulp van de 
tumor- en therapieregistratie in de database van het RT instituut in het westelijke deel van de 
regio. Alle 443 patiënten met een (dreigende) dwarslaesie werden gezien en behandeld op de 
dag van verwijzing. 
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Er vonden significant meer verwijzingen plaats op vrijdag, namelijk 30%, vergeleken met 
12% op maandag, 17% op dinsdag, 15% op woensdag, 20% op donderdag, 5% op zaterdag 
en 1% op zondag (P=<0.002). Het maakte geen verschil of patiënten al in het instituut 
bekend waren of  niet. 
Deze bevindingen werden bediscussieerd met de verwijzende specialisten op een 
wetenschappelijke bijeenkomst in de regio om hen aan te sporen tot spoed bij diagnose en 
verwijzing, maar anno 2008 lijkt het patroon vrijwel onveranderd (hoofdstuk 5.2).
Hoofdstuk 6 bevat een algemene bespreking van de resultaten. ‘Population-based’ studies 
geven in beginsel een reëel inzicht in het gebruik van radiotherapie en variatie daarin in plaats 
en tijd: uit de trendstudies bleek dat het percentage patiënten dat radiotherapie in het kader 
van de primaire behandeling ontving, stabiel bleef tussen 1988 en 2006, maar dat er 
verschillen waren tussen de westelijke en oostelijke regio van het Integraal Kankercentrum 
Zuid; uit de cohort studies, waarmee tevens het gebruik van radiotherapie in het kader van 
recidief of metastase bestudeerd kan worden (secundaire radiotherapie), bleek dit verschil 
ook. Tevens bleek dat ouderen minder vaak bestraald werden en dat de kennis betreffende 
toepassing van palliatieve radiotherapie verbeterd zou kunnen worden. Ook worden in 
hoofdstuk 6 enkele toekomstige ontwikkelingen besproken. 
We kunnen concluderen dat het van groot belang blijft dat patiënten zo vroeg mogelijk na 
de diagnose besproken worden in multidisciplinaire oncologie besprekingen. Het ligt voor de 
hand dat radiotherapeut-oncologen, als 3e-lijns, relatief geïsoleerd werkende specialisten, 
vooral ook publiceren in tijdschriften die relevant zijn voor verwijzende 2e-lijns specialisten. 
Uiteindelijk zal er enige variatie blijven bestaan door individuele verschillen tussen artsen en 
tussen patiënten.
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